



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/00	A2	(11) International Publication Number: WO 99/58559 (43) International Publication Date: 18 November 1999 (18.11.99)
(21) International Application Number: PCT/US99/10793 (22) International Filing Date: 14 May 1999 (14.05.99) (30) Priority Data: 09/081,385 14 May 1998 (14.05.98) US (71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GATANAGA, Tetsuya [JP/US]; 77 Wellesley, Irvine, CA 92612 (US). GRANGER, Gale, A. [US/US]; 31562 Santa Rosa, Laguna Beach, CA 92651 (US). (74) Agents: CAMPBELL, Cathryn et al.; Campbell and Flores, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: FACTORS AFFECTING TUMOR NECROSIS FACTOR RECEPTOR RELEASING ENZYME ACTIVITY (57) Abstract The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are method for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

FACTORS AFFECTING TUMOR NECROSIS FACTOR RECEPTOR RELEASING ENZYME ACTIVITY

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the priority benefit of U.S. application 09/081,385,
5 filed May 14, 1998, pending. For purposes of prosecution in the U.S., the priority
application is hereby incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

This invention relates generally to the field of signal transduction between
10 cells, via cytokines and their receptors. More specifically, it relates to enzymatic
activity that cleaves and releases the receptor for TNF found on the cell surface,
and the consequent biological effects. Certain embodiments of this invention are
compositions that affect such enzymatic activity, and may be included in
medicaments for disease treatment.

15

BACKGROUND OF THE INVENTION

Cytokines play a central role in the communication between cells.
Secretion of a cytokine from one cell in response to a stimulus can trigger an
adjacent cell to undergo an appropriate biological response — such as
20 stimulation, differentiation, or apoptosis. It is hypothesized that important
biological events can be influenced not only by affecting cytokine release from
the first cell, but also by binding to receptors on the second cell, which mediates
the subsequent response. The invention described in this patent application
provides new compounds for affecting signal transduction from tumor necrosis
25 factor.

The cytokine known as tumor necrosis factor (TNF or TNF- α) is
structurally related to lymphotoxin (LT or TNF- β). They have about 40 percent
amino acid sequence homology (Old, *Nature* 330:602-603, 1987). These
cytokines are released by macrophages, monocytes and natural killer cells and

play a role in inflammatory and immunological events. The two cytokines cause a broad spectrum of effects both in vitro and in vivo, including: (i) vascular thrombosis and tumor necrosis; (ii) inflammation; (iii) activation of macrophages and neutrophils; (iv) leukocytosis; (v) apoptosis; and (vi) shock. TNF has been
5 associated with a variety of disease states including various forms of cancer, arthritis, psoriasis, endotoxic shock, sepsis, autoimmune diseases, infections, obesity, and cachexia. TNF appears to play a role in the three factors contributing to body weight control: intake, expenditure, and storage of energy (Rothwell, *Int. J. Obesity* 17:S98-S101, 1993). In septicemia, increased
10 endotoxin concentrations appear to raise TNF levels (Beutler et al. *Science* 229:869-871, 1985).

Attempts have been made to alter the course of a disease by treating the patient with TNF inhibitors, with varying degrees of success. For example, the TNF inhibitor dexamabolin provided protection against TNF mediated effects
15 following traumatic brain injury (Shohami et al. *J. Neuroimmun.* 72:169-77, 1997). Some improvement in Crohn's disease was afforded by treatment with anti-TNF antibodies (Neurath et al., *Eur. J. Immun.* 27:1743-50, 1997).

Human TNF and LT mediate their biological activities by binding specifically to two distinct glycoprotein plasma membrane receptors (55 kDa and
20 75 kDa in size, known as p55 and p75 TNF-R, respectively). The two receptors share 28 percent amino acid sequence homology in their extracellular domains, which are composed of four repeating cysteine-rich regions (Tartaglia and Goeddel, *Immunol. Today* 13:151-153, 1992). However, the receptors lack significant sequence homology in their intracellular domains, and mediate
25 different intracellular responses to receptor activation. In accordance with the different activities of TNF and LT, most human cells express low levels of both TNF receptors: about 2,000 to 10,000 receptors per cell (Brockhaus et al., *Proc. Natl. Acad. Sci. USA* 87:3127-3131, 1990).

Expression of TNF receptors on both lymphoid and non-lymphoid cells
30 can be influenced experimentally by many different agents, such as bacterial lipopolysaccharide (LPS), phorbol myristate acetate (PMA; a protein kinase C

activator), interleukin-1 (IL-1), interferon-gamma (IFN- γ) and IL-2 (Gatanaga et al. *Cell Immunol.* 138:1-10, 1991; Yui et al. *Placenta* 15:819-835, 1994). It has been shown that complexes of human TNF bound to its receptor are internalized from the cell membrane, and then the receptor is either degraded or recycled (Armitage, *Curr. Opin. Immunol.* 6:407-413, 1994). It has been proposed that TNF receptor activity can be modulated using peptides that bind intracellularly to the receptor, or which bind to the ligand binding site, or that affect receptor shedding. See for example patent publications WO 95/31544, WO 95/33051, WO 96/01642, and EP 568 925.

TNF binding proteins (TNF-BP) have been identified at elevated levels in the serum and urine of febrile patients, patients with renal failure, and cancer patients, and even certain healthy individuals. Human brain and ovarian tumors produced high serum levels of TNF-BP. These molecules have been purified, characterized, and cloned (Gatanaga et al., *Lymphokine Res.* 9:225-229, 1990a; Gatanaga et al., *Proc. Natl. Acad. Sci. USA* 87:8781-8784, 1990b). Human TNF-BP consists of 30 kDa and 40 kDa proteins which are identical to the N-terminal extracellular domains of p55 and p75 TNF receptors, respectively (US Patent No. 5,395,760; EP 418,014). Such proteins have been suggested for use in treating endotoxic shock. Mohler et al. *J. Immunol.* 151:1548-1561, 1993

There are several mechanisms possible for the production of secreted proteins resembling membrane bound receptors. One involves translation from alternatively spliced mRNAs lacking transmembrane and cytoplasmic regions. Another involves proteolytic cleavage of the intact membrane receptors, followed by shedding of the cleaved receptor from the cell. The soluble form of p55 and p75 TNF-R do not appear to be generated from mRNA splicing, since only full length receptor mRNA has been detected in human cells *in vitro* (Gatanaga et al., 1991). Carboxyl-terminal sequencing and mutation studies on human p55 TNF-R indicates that a cleavage site may exist between residues Asn 172 and Val 173 (Gullberg et al. *Eur. J. Cell. Biol.* 58:307-312, 1992).

There are reports that a specific metalloprotease inhibitor, TNF- α protease inhibitor (TAPI) blocks the shedding of soluble p75 and p55 TNF-R (Crowe et al.

J. Exp. Med. 181:1205-1210, 1995; Mullberg et al. *J. Immunol.* 155:5198-5205, 1995). The processing of pro-TNF on the cell membrane to release the TNF ligand appears to be dependent on a matrix metalloprotease like enzyme (Gearing et al. *Nature* 370:555-557, 1994). This is a family of structurally related
5 matrix-degrading enzymes that play a major role in tissue remodeling and repair associated with development and inflammation (Birkedal-Hansen et al. *Crit. Rev. Oral Biol. Med.* 4:197-250, 1993). The enzymes have Zn^{2+} in their catalytic domains, and Ca^{2+} stabilizes their tertiary structure significantly.

In European patent application EP 657536A1, Wallach et al. suggest that
10 it would be possible to obtain an enzyme that cleaves the 55,000 kDa TNF receptor by finding a mutated form of the receptor that is not cleaved by the enzyme, but still binds to it. The only proposed source for the enzyme is a detergent extract of membranes for cells that appear to have the protease activity. If it were possible to obtain an enzyme according to this scheme, then
15 the enzyme would presumably comprise a membrane spanning region. The patent application does not describe any protease that was actually obtained.

In a previous patent application in the present series (International Patent Publication WO 9820140), methods are described for obtaining an isolated enzyme that cleaves both the p55 and p75 TNF-R from cell surfaces. A
20 convenient source is the culture medium of cells that have been stimulated with phorbol myristate acetate (PMA). The enzyme activity was given the name TRRE (TNF receptor releasing enzyme). In other studies, TRRE was released immediately upon PMA stimulation, indicating that it is presynthesized in an inactive form to be rapidly converted to the active form upon stimulation.
25 Evidence for direct cleavage of TNF-R is that the shedding begins very quickly (~5 min) with maximal shedding within 30 min. TRRE is specific for the TNF-R, and does not cleave IL-1 receptors, CD30, ICAM-1 or CD11b. TRRE activity is enhanced by adding Ca^{++} or Zn^{++} , and inhibited by EDTA and phenantroline.

Given the involvement of TNF in a variety of pathological conditions, it is
30 desirable to obtain a variety of factors that would allow receptor shedding to be

modulated, thereby controlling the signal transduction from TNF at a disease site.

SUMMARY OF THE INVENTION

5 This disclosure provides new compounds that promote enzymatic cleavage and release of TNF receptors from the cell surface. Nine new DNA clones have been selected after repeat screening in an assay that tests the ability to enhance receptor release. The polynucleotide sequences of this invention and the proteins encoded by them have potential as diagnostic aids,
10 and therapeutic compounds that can be used to adjust TNF signal transduction in a beneficial way.

One embodiment of the invention is an isolated polynucleotide comprising a nucleotide sequence with the following properties: a) the sequence is expressed at the mRNA level in Jurkat T cells; b) when COS-1 cells expressing
15 TNF-receptor are genetically transformed to express the sequence, the cells have increased enzymatic activity for cleaving and releasing the receptor. If a polynucleotide sequence is expressed in Jurkat cells, then it can be found in the Jurkat cell expression library deposited with the ATCC (Accession No. TIB-152). It is recognized that the polynucleotide can be obtained from other cell lines, or
20 produced by recombinant techniques.

Included are polynucleotides in which the nucleotide sequence is contained in any of SEQ. ID NOS:1-10. Also embodied are polynucleotides comprising at least 30 and preferably more consecutive nucleotides in said nucleotide sequence, or at least 50 consecutive nucleotides that are homologous
25 to said sequence at a significant level, preferably at the 90% level or more. Also included antisense and ribozyme polynucleotides that inhibit the expression of a TRRE modulator.

Another embodiment of the invention is isolated polypeptides comprising an amino acid sequence encoded by a polynucleotide of this invention. Non-
30 limiting examples are sequences shown in SEQ. ID NOS: 147-158. Fragments

and fusion proteins are included in this invention, and preferably comprise at least 10 consecutive residues encoded by a polynucleotide of this invention, or at least 15 consecutive amino acids that are homologous at a significant level, preferably at least 80%. Preferred polypeptides promote cleavage and release
5 of TNF receptors from the cell surface, especially COS-1 cells genetically transformed to express TNF receptor. The polypeptides may or may not have a membrane spanning domain, and may optionally be produced by a process that involves secretion from a cell. Included are species homologs with the desired activity, and artificial mutants with additional beneficial properties.

10 Another embodiment of this invention is an antibody specific for a polypeptide of this invention. Preferred are antibodies that bind a TRRE modulator protein, but not other substances found in human tissue samples in comparable amounts.

Another embodiment of the invention is an assay method of determining
15 altered TRRE activity in a cell or tissue sample, using a polynucleotide or antibody of this invention to detect the presence or absence of the corresponding TRRE modulator. The assay method can optionally be used for the diagnosis or evaluation of a clinical condition relating to abnormal TNF levels or TNF signal transduction.

20 Another embodiment of the invention is a method for increasing or decreasing signal transduction from a cytokine into a cell (including but not limited to TNF), comprising contacting the cell with a polynucleotide, polypeptide, or antibody of this invention.

A further embodiment of the invention is a method for screening
25 polynucleotides for an ability to modulate TRRE activity. The method involves providing cells that express both TRRE and the TNF-receptor; genetically altering the cells with the polynucleotides to be screened; cloning the cells; and identifying clones with the desired activity.

Yet another embodiment of the invention is a method for screening
30 substances for an ability to affect TRRE activity. This typically involves incubating cells expressing TNF receptor with a TRRE modulator of this

invention in the presence or absence of the test substance; and measuring the effect on shedding of the TNF receptor .

The products of this invention can be used in the preparation of a medicament for treatment of the human or animal body. The medicament
5 contains a clinically effective amount for treatment of a disease such as heart failure, cachexia, inflammation, endotoxic shock, arthritis, multiple sclerosis, sepsis, and cancer. These compositions can be used for administration to a subject suspected of having or being at risk for the disease, optionally in combination with other forms of treatment appropriate for their condition.

10

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of plasmid pCDTR2. This plasmid expresses p75 TNF-R, the ~75 kDa form of the TNF receptor. PCMV stands for cytomegalovirus; BGHpA stands for bovine growth hormone polyadenylation
15 signal.

Figure 2 is a line depicting the levels of p75 TNF-R detected on COS-1 cells genetically altered to express the receptor. Results from the transformed cells, designated C75R (●, upward swooping line) is compared with that from the parental COS-1 cells (■, baseline). The receptor number was calculated by
20 Scatchard analysis (inset).

Figure 3 is a survival graph, showing that TRRE decreases mortality in mice challenged with lipopolysaccharide (LPS) to induce septic peritonitis. (♦) LPS alone; (■) LPS plus control buffer; (●) LPS plus TRRE (2,000 U); (▲) LPS plus TRRE (4,000 U).

25 **Figure 4** is a half-tone reproduction of a bar graph, showing the effect of 9 new clones on TRRE activity on C75R cells (COS-1 cells transfected to express the TNF-receptor. Each of the 9 clones increases TRRE activity by over 2-fold.

Figure 5 is a survival graph, showing the ability of 4 new expressed to save mice challenged with LPS. (♦) saline; (■) BSA; (Δ) Mey-3 (100 μg); (X) Mey-3 (10 μg); (*) Mey-5 (10 μg); (●) Mey-8 (10 μg).
30

DETAILED DESCRIPTION OF THE INVENTION

It has been discovered that certain cells involved in the TNF transduction pathway express enzymatic activity that causes TNF receptors to be shed from the cell surface. Enzymatic activity for cleaving and releasing TNF receptors has been given the designation TRRE. Phorbol myristate acetate induces release of TRRE from cells into the culture medium. An exemplary TRRE protein had been purified from the supernatant of TNF-1 cells (Example 2). The protease bears certain hallmarks of the metalloprotease family, and is released rapidly from the cell upon activation.

In order to elucidate the nature of this protein, functional cloning was performed. Jurkat cells were selected as being a good source of TRRE. The cDNA from a Jurkat library was expressed, and cell supernatant was tested for an ability to release TNF receptors from cell surfaces. Cloning and testing of the expression product was conducted through several cycles, and nine clones were obtained that more than doubled TRRE activity in the assay (Figure 4). At the DNA level, all 9 clones had different sequences.

Protein expression products from the clones have been tested in a lipopolysaccharide animal model for sepsis. Protein from three different clones successfully rescued animals from a lethal dose of LPS (Figure 5). This points to an important role for these molecules in the management of pathological conditions mediated by TNF.

The number of new TRRE promoting clones obtained from the expression library was surprising. The substrate specificity of the TRRE isolated in Example 2 distinguishes the 75 kDa and 55 kDa TNF receptors from other cytokine receptors and cell surface proteins. There was little reason beforehand to suspect that cells might have nine different proteases for the TNF receptor. It is possible that one of the clones encodes the TRRE isolated in Example 2, or a related protein. It is possible that some of the other clones have proteolytic activity to cleave TNF receptors at the same site, or at another site that causes release of the soluble form from the cell. It is a hypothesis of this disclosure that some of the clones may not have proteolytic activity themselves, but play a role in promoting TRRE activity in a secondary fashion.

This possibility is consistent with the observations made, because there is an endogenous level of TRRE activity in the cells used in the assay. The cleavage assay involves monitoring TNF receptor release from C75 cells, which are COS-1 cells genetically altered to express p75 TNF-R. The standard assay is conducted by contacting the transformed cells with a fluid believed to contain TRRE. The level of endogenous TRRE activity is evident from the rate of spontaneous release of the receptor even when no exogenous TRRE is added (about 200 units). Accordingly, accessory proteins that promote TRRE activity would increase the activity measured in the assay. Many mechanisms of promotion are possible, including proteins that activate a zymogen form of TRRE, proteins that free TRRE from other cell surface components, or proteins that stimulate secretion of TRRE from inside the cell. It is not necessary to understand the mechanism in order to use the products of this invention in most of the embodiments described.

It is anticipated that several of the clones will have activity not just for promoting TNF receptor cleavage, but also having an effect on other surface proteins. To the extent that cleavage sequences or accessory proteins are shared between different receptors, certain clones would promote phenotypic change (such as receptor release) for the family of related substrates.

This disclosure provides polypeptides that promote TRRE activity, polynucleotides that encode such polypeptides, and antibodies that bind such peptides. The binding of TNF to its receptor mediates a number of biological effects. Cleavage of the TNF-receptor by TRRE diminishes signal transduction by TRRE. Potentiators of TRRE activity have the same effect. Thus, the products of this invention can be used to modulate signal transduction by cytokines, which is of considerable importance in the management of disease conditions that are affected by cytokine action. The products of this invention can also be used in diagnostic methods, to determine when signal transduction is being inappropriately affected by abnormal TRRE activity. The assay systems described in this disclosure provide a method for screening additional compounds that can influence TRRE activity, and thus the signal transduction from TNF.

Based on the summary of the invention, and guided by the illustrations in the example section, one skilled in the art will readily know what techniques to employ in the practice of the invention. The following detailed description is provided for the additional convenience of the reader.

Definitions and basic techniques

As used in this disclosure, "TRRE activity" refers to the ability of a composition to cleave and release TNF receptors from the surface of cells expressing them. A preferred assay is cleavage from transfected COS-1 cells, as described in Example 1. However, TRRE activity can be measured on any cells that bear TNF receptors of the 55 kDa or 75 kDa size. Other features of the TRRE enzyme obtained from PMA induction of THP-1 cells (exemplified in Example 2) need not be a property of the TRRE activity measured in the assay.

Unit activity of TRRE is defined as 1 pg of soluble p75 TNF-R released from cell surface in a standard assay, after correction for spontaneous release. The measurement of TRRE activity is explained further in Example 1.

A "TRRE modulator" is a compound that has the property of either increasing or decreasing TRRE activity for processing TNF on the surface of

cells. Those that increase TRRE activity may be referred to as TRRE promoters, and those that decrease TRRE activity may be referred to as TRRE inhibitors. TRRE promoters include compounds that have proteolytic activity for TNF-R, and compounds that augment the activity of TNF-R proteases. The nine
5 polynucleotide clones described in Example 5, and their protein products, are exemplary TRRE promoters. Inhibitors of TRRE activity can be obtained using the screening assays described below.

The term "polynucleotide" refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof.
10 Polynucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, (mRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, nucleic acid probes, and primers. A polynucleotide may comprise
15 modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The term polynucleotide refers interchangeably to double-and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention described herein that is a polynucleotide
20 encompasses both the double-stranded form, and each of two complementary single-stranded forms known or predicted to make up the double-stranded form

"Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. Hybridization reactions can be performed
25 under conditions of different "stringency". Relevant conditions include temperature, ionic strength, and the presence of additional solutes in the reaction mixture such as formamide. Conditions of increasing stringency are 30°C. in 10X SSC (0.15M NaCl, 15 mM citrate buffer); 40°C. in 6X SSC; 50°C. in 6X SSC 60°C. in 6X SSC, or at about 40°C. in 0.5X SSC, or at about 30°C. in 6.X.
30 SSC containing 50% formamide. SDS and a source of fragmented DNA (such as salmon sperm) are typically also present during hybridization. Higher

stringency requires higher minimum complementarity between hybridizing elements for a stable hybridization complex to form. See "Molecular Cloning: A Laboratory Manual", Second Edition (Sambrook, Fritsch & Maniatis, 1989).

It is understood that purine and pyrimidine nitrogenous bases with similar structures can be functionally equivalent in terms of Watson-Crick base-pairing; and the inter-substitution of like nitrogenous bases, particularly uracil and thymine, or the modification of nitrogenous bases, such as by methylation, does not constitute a material substitution.

The percentage of sequence identity for polynucleotides or polypeptides is calculated by aligning the sequences being compared, and then counting the number of shared residues at each aligned position. No penalty is imposed for the presence of insertions or deletions, but are permitted only where required to accommodate an obviously increased number of amino acid residues in one of the sequences being aligned. When one of the sequences being compared is indicated as being "consecutive", then no gaps are permitted in that sequence during the comparison. The percentage identity is given in terms of residues in the test sequence that are identical to residues in the comparison or reference sequence.

As used herein, "expression" of a polynucleotide refers to the production of an RNA transcript. Subsequent translation into protein or other effector compounds may also occur, but is not required unless specified.

"Genetic alteration" refers to a process wherein a genetic element is introduced into a cell other than by mitosis or meiosis. The element may be heterologous to the cell, or it may be an additional copy or improved version of an element already present in the cell. Genetic alternation may be effected, for example, by transducing a cell with a recombinant plasmid or other polynucleotide through any process known in the art, such as electroporation, calcium phosphate precipitation, or contacting with a polynucleotide-liposome complex. Genetic alteration may also be effected, for example, by transduction or infection with a DNA or RNA virus or viral vector. It is preferable that the

genetic alteration is inheritable by progeny of the cell, but this is not generally required unless specified.

The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.

A "fusion polypeptide" is a polypeptide comprising regions in a different position in the sequence than occurs in nature. The regions can normally exist in separate proteins and are brought together in the fusion polypeptide; they can normally exist in the same protein but are placed in a new arrangement in the fusion polypeptide; or they can be synthetically arranged. A "functionally equivalent fragment" of a polypeptide varies from the native sequence by addition, deletion, or substitution of amino acid residues, or any combination thereof, while preserving a functional property of the fragment relevant to the context in which it is being used. Fusion peptides and functionally equivalent fragments are included in the definition of polypeptides used in this disclosure.

It is understood that the folding and the biological function of proteins can accommodate insertions, deletions, and substitutions in the amino acid sequence. Some amino acid substitutions are more easily tolerated. For example, substitution of an amino acid with hydrophobic side chains, aromatic side chains, polar side chains, side chains with a positive or negative charge, or side chains comprising two or fewer carbon atoms, by another amino acid with a side chain of like properties can occur without disturbing the essential identity of the two sequences. Methods for determining homologous regions and scoring the degree of homology are described in Altschul et al. *Bull. Math. Bio.* 48:603-616, 1986; and Henikoff et al. *Proc. Natl. Acad. Sci. USA* 89:10915-10919, 1992. Substitutions that preserve the functionality of the polypeptide, or confer a new

and beneficial property (such as enhanced activity, stability, or decreased immunogenicity) are especially preferred.

An "antibody" (interchangeably used in plural form) is an immunoglobulin molecule capable of specific binding to a target, such as a polypeptide, through
5 at least one antigen recognition site, located in the variable region of the immunoglobulin molecule. As used herein, the term encompasses not only intact antibodies, but also antibody equivalents that include at least one antigen combining site of the desired specificity. These include but are not limited to enzymatic or recombinantly produced fragments antibody, fusion proteins,
10 humanized antibodies, single chain variable regions, diabodies, and antibody chains that undergo antigen-induced assembly.

An "isolated" polynucleotide, polypeptide, protein, antibody, or other substance refers to a preparation of the substance devoid of at least some of the other components that may also be present where the substance or a similar
15 substance naturally occurs or is initially obtained from. Thus, for example, an isolated substance may be prepared by using a purification technique to enrich it from a source mixture. Enrichment can be measured on an absolute basis, such as weight per volume of solution, or it can be measured in relation to a second, potentially interfering substance present in the source mixture. Increasing
20 enrichments of the embodiments of this invention are increasingly more preferred. Thus, for example, a 2-fold enrichment is preferred, 10-fold enrichment is more preferred, 100-fold enrichment is more preferred, 1000-fold enrichment is even more preferred. A substance can also be provided in an isolated state by a process of artificial assembly, such as by chemical synthesis
25 or recombinant expression.

A "host cell" is a cell which has been genetically altered, or is capable of being transformed, by administration of an exogenous polynucleotide.

The term "clinical sample" encompasses a variety of sample types obtained from a subject and useful in an in vitro procedure, such as a diagnostic
30 test. The definition encompasses solid tissue samples obtained as a surgical removal, a pathology specimen, or a biopsy specimen, cells obtained from a

clinical subject or their progeny obtained from culture, liquid samples such as blood, serum, plasma, spinal fluid, and urine, and any fractions or extracts of such samples that contain a potential indication of the disease.

Unless otherwise indicated, the practice of the invention will employ
5 conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, within the skill of the art. Such techniques are explained in the standard literature, such as: "Molecular Cloning: A Laboratory Manual", Second Edition (Sambrook, Fritsch & Maniatis, 1989), "Oligonucleotide Synthesis" (M. J. Gait, ed., 1984), "Animal Cell Culture" (R. I. Freshney, ed., 1987); the series
10 "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology" (D. M. Weir & C. C. Blackwell, Eds.), "Gene Transfer Vectors for Mammalian Cells" (J. M. Miller & M. P. Calos, eds., 1987), "Current Protocols in Molecular Biology" (F. M. Ausubel et al., eds., 1987); and "Current Protocols in Immunology" (J. E. Coligan et al., eds., 1991). The reader may also choose to
15 refer to a previous patent application relating to TRRE, International Patent Application WO 98020140.

For purposes of prosecution in the U.S., and in other jurisdictions where allowed, all patents, patent applications, articles and publications indicated anywhere in this disclosure are hereby incorporated herein by reference in their
20 entirety.

Polynucleotides

Polynucleotides of this invention can be prepared by any suitable technique in the art. Using the data provided in this disclosure, sequences of
25 less than ~50 base pairs are conveniently prepared by chemical synthesis, either through a commercial service or by a known synthetic method, such as the triester method or the phosphite method. A preferred method is solid phase synthesis using mononucleoside phosphoramidite coupling units (Hirose et al., *Tetra. Lett.* 19:2449-2452, 1978; U.S. Patent No. 4,415,732).

30 For use in antisense therapy, polynucleotides can be prepared by chemistry that produce more stable in pharmaceutical preparations. Non-limiting

examples include thiol-derivatized nucleosides (U.S. Patent 5,578,718), and oligonucleotides with modified backbones (U.S. Patent Nos. 5,541,307 and 5,378,825).

Polynucleotides of this invention can also be obtained by PCR
5 amplification of a template with the desired sequence. Oligonucleotide primers spanning the desired sequence are annealed to the template, elongated by a DNA polymerase, and then melted at higher temperature so that the template and elongated oligonucleotides dissociate. The cycle is repeated until the
10 desired amount of amplified polynucleotide is obtained (U.S. Patent Nos. 4,683,195 and 4,683,202). Suitable templates include the Jurkat T cell library and other human or animal expression libraries that contain TRRE modulator encoding sequences. The Jurkat T cell library is available from the American Type Culture Collection, 10801 University Blvd., Manassas VA 20110, U.S.A. (ATCC #TIB-152). Mutations and other adaptations can be performed during
15 amplification by designing suitable primers, or can be incorporated afterwards by genetic splicing.

Production scale amounts of large polynucleotides are most conveniently obtained by inserting the desired sequence into a suitable cloning vector and reproducing the clone. Techniques for nucleotide cloning are given in Sambrook,
20 Fritsch & Maniatis (supra) and in U.S. Patent No. 5,552,524. Exemplary cloning and expression methods are illustrated in Example 6.

Preferred polynucleotide sequences are 50%, 70%, 80% , 90%, or 100% identical to one of the sequences exemplified in this disclosure; in order of increasing preference. The length of consecutive residues in the identical or
25 homologous sequence compared with the exemplary sequence can be about 15, 30, 50, 75, 100, 200 or 500 residues in order of increasing preference, up to the length of the entire clone. Nucleotide changes that cause a conservative substitution or retain the function of the encoded polypeptide (in terms of hybridization properties or what is encoded) are especially preferred
30 substitutions.

The polynucleotides of this can be used to measure altered TRRE activity in a cell or tissue sample. This involves contacting the sample with the polynucleotide under conditions that permit the polynucleotide to hybridize specifically with nucleic acid that encodes a modulator of TRRE activity, if present in the sample, and determining polynucleotide that has hybridized as a result of step a). Specificity of the test can be provided in one of several ways. One method involves the use of a specific probe — a polynucleotide of this invention with a sequence long enough and of sufficient identity to the sequence being detected, so that it binds the target and not other nucleic acid that might be present in the sample. The probe is typically labeled (either directly or through a secondary reagent) so that it can be subsequently detected. Suitable labels include ^{32}P and ^{33}P , chemiluminescent and fluorescent reagents. After the hybridization reaction, unreacted probe is washed away so that the amount of hybridized probe can be determined. Signal can be amplified using branched probes (U.S. Patent No. 5,124,246). In another method, the polynucleotide is a primer for a PCR reaction. Specificity is provided by the ability of the paired probes to amplify the sequence of interest. After a suitable number of PCR cycles, the amount of amplification product present correlates with the amount of target sequence originally present in the sample.

Such tests are useful both in research, and in the diagnosis or assessment of a disease condition. For example, TNF activity plays a role in eliminating tumor cells (Example 4), and a cancer may evade the elimination process by activating TRRE activity in the diseased tissue. Hence, under some conditions, high expression of TRRE modulators may correlate with progression of cancer. Diagnostic tests are also of use in monitoring therapy, such as when gene therapy is performed to increase TRRE activity.

Polynucleotides of this invention can also be used for production of polypeptides and the preparation of medicaments, as explained below.

Polypeptides

Short polypeptides of this invention can be prepared by solid-phase chemical synthesis. The principles of solid phase chemical synthesis can be found in Dugas & Penney, Bioorganic Chemistry, Springer-Verlag NY pp 54-92 (1981), and U.S. Patent No. 4,493,795. Automated solid-phase peptide synthesis can be performed using devices such as a PE-Applied Biosystems 430A peptide synthesizer (commercially available from Applied Biosystems, Foster City CA).

Longer polypeptides are conveniently obtained by expression cloning. A polynucleotide encoding the desired polypeptide is operably linked to control elements for transcription and translation, and then transfected into a suitable host cell. Expression may be effected in procaryotes such as E. coli (ATCC Accession No. 31446 or 27325), eukaryotic microorganisms such as the yeast *Saccharomyces cerevisiae*, or higher eukaryotes, such as insect or mammalian cells. A number of expression systems are described in U.S. Patent No. 5,552,524. Expression cloning is available from such commercial services as Lark Technologies, Houston TX. The production of protein from 4 exemplary clones of this invention in insect cells is illustrated in Example 6. The protein is purified from the producing host cell by standard methods in protein chemistry, such as affinity chromatography and HPLC. Expression products are optionally produced with a sequence tag to facilitate affinity purification, which can subsequently be removed.

Preferred sequences are 40%, 60%, 80%, 90%, or 100% identical to one of the sequences exemplified in this disclosure; in order of increasing preference. The length of the identical or homologous sequence compared with the native human polynucleotide can be about 7, 10, 15, 20, 30, 50 or 100 residues in order of increasing preference, up to the length of the entire encoding region.

Polypeptides can be tested for an ability to modulate TRRE in a TNF-R cleavage assay. The polypeptide is contacted with the receptor (preferably expressed on the surface of a cell, such as a C75 cell), and the ability of the polypeptide to increase or decrease receptor cleavage and release is

determined. Cleavage of TNF-R by exemplary polypeptides of this invention is illustrated in Example 7.

Polypeptides of this invention can be used as immunogens for raising antibody. Large proteins will raise a cocktail of antibodies, while short peptide
5 fragments will raise antibodies against small region of the intact protein. Antibody clones can be mapped for protein binding site by producing short overlapping peptides of about 10 amino acids in length. Overlapping peptides can be prepared on a nylon membrane support by standard F-Moc chemistry, using a SPOTS™ kit from Genosys according to manufacturer's directions.

10 Polypeptides of this invention can also be used to affect TNF signal transduction, as explained below.

Antibodies

Polyclonal antibodies can be prepared by injecting a vertebrate with a
15 polypeptide of this invention in an immunogenic form. Immunogenicity of a polypeptide can be enhanced by linking to a carrier such as KLH, or combining with an adjuvant, such as Freund's adjuvant. Typically, a priming injection is followed by a booster injection is after about 4 weeks, and antiserum is harvested a week later. Unwanted activity cross-reacting with other antigens, if
20 present, can be removed, for example, by running the preparation over adsorbants made of those antigens attached to a solid phase, and collecting the unbound fraction. If desired, the specific antibody activity can be further purified by a combination of techniques, which may include protein, A chromatography, ammonium sulfate precipitation, ion exchange chromatography, HPLC, and
25 immunoaffinity chromatography using the immunizing polypeptide coupled to a solid support. Antibody fragments and other derivatives can be prepared by standard immunochemical methods, such as subjecting the antibody to cleavage with enzymes such as papain or pepsin.

Production of monoclonal antibodies is described in such standard
30 references as Harrow & Lane (1988), U.S. Patent Nos. 4,491,632, 4,472,500 and 4,444,887, and *Methods in Enzymology* 73B:3 (1981). Briefly, a mammal is

immunized, and antibody-producing cells (usually splenocytes) are harvested. Cells are immortalized by fusion with a non-producing myeloma, transfecting with Epstein Barr Virus, or transforming with oncogenic DNA. The treated cells are cloned and cultured, and the clones are selected that produce antibody of the
5 desired specificity.

Other methods of obtaining specific antibody molecules (optimally in the form of single-chain variable regions) involve contacting a library of immunocompetent cells or viral particles with the target antigen, and growing out positively selected clones. Immunocompetent phage can be constructed to
10 express immunoglobulin variable region segments on their surface. See Marks et al., *New Eng. J. Med.* 335:730, 1996, International Patent Applications WO 9413804, WO 9201047, WO 90 02809, and McGuinness et al., *Nature Biotechnol.* 14:1449, 1996.

The antibodies of this invention are can be used in immunoassays for
15 TRRE modulators. General techniques of immunoassay can be found in "The Immunoassay Handbook", Stockton Press NY, 1994; and "Methods of Immunological Analysis", Weinheim: VCH Verlags gesellschaft mbH, 1993). The antibody is combined with a test sample under conditions where the antibody will bind specifically to any modulator that might be present, but not any other
20 proteins liable to be in the sample. The complex formed can be measured in situ (U.S. Patent Nos. 4,208,479 and 4,708,929), or by physically separating it from unreacted reagents (U.S. Patent No. 3,646,346). Separation assays typically involve labeled TRRE reagent (competition assay), or labeled antibody (sandwich assay) to facilitate detection and quantitation of the complex. Suitable
25 labels are radioisotopes such as ¹²⁵I, enzymes such as β -galactosidase, and fluorescent labels such as fluorescein. Antibodies of this invention can also be used to detect TRRE modulators in fixed tissue sections by immunohistology. The antibody is contacted with the tissue, unreacted antibody is washed away, and then bound antibody is detected — typically using a labeled anti-
30 immunoglobulin reagent. Immunohistology will show not only whether the modulator is present, but where it is located in the tissue.

Detection of TRRE modulators is of interest for research purposes, and for clinical use. As indicated earlier, high expression of TRRE modulators may correlate with progression of cancer. Diagnostic tests are also of use in monitoring TRRE modulators that are administered in the course of therapy.

5 Antibodies of this invention can also be used for preparation of medicaments. Antibodies with therapeutic potential include those that affect TRRE activity — either by promoting clearance of a TRRE modulator, or by blocking its physiological action. Antibodies can be screened for desirable activity according to assays described in the next section.

10

Screening assays

This invention provides a number of screening methods for selecting and developing products that modulate TRRE, and thus affect TNF signal transduction.

15 One screening method is for polynucleotides that have an ability to modulate TRRE activity. To do this screening, cells are obtained that express both TRRE and the TNF receptor. Suitable cell lines can be constructed from any cell that expresses a level of functional TRRE activity. These cells are identifiable by testing culture supernatant for an ability to release membrane-
20 bound TNF-R. The level of TRRE expression should be moderate, so that an increase in activity can be detected. The cells can then be genetically altered to express either p55 or p75 TNF-R, illustrated in Example 1. Exemplary is the C75R line: COS-1 cells genetically altered to express the 75 kDa form of the TNF-R. Release of TNF-R from the cell can be measured either by testing
25 residual binding of labeled TNF ligand to the cell, or by immunoassay of the supernatant for released receptor (Example 1).

30 The screening assay is conducted by contacting the cells expressing TRRE and TNF-R with the polynucleotides to be screened. The effect of the polynucleotide on the enzymatic release of TNF-R from the cell is determined, and polynucleotides with desirable activity (either promoting or inhibiting TRRE activity) are selected. In a variation of this method, cells expressing TRRE

activity but not TNF-R (such as untransfected COS-1 cells) are contacted with the test polynucleotide. Then the culture medium is collected, and used to assay for TRRE activity using a second cell expressing TNF-R (such as C75 cells).

This type of screening assay is useful for the selection of polynucleotides from an expression library believed to contain encoding sequences for TRRE modulators. The Jurkat cell expression library (ATCC Accession No. TIB-152) is exemplary. Other cells from which suitable libraries can be constructed are those known to express high levels of TRRE, especially after PMA stimulation, such as THP-1, U-937, HL-60, ME-180, MRC-5, Raji, K-562, and normal human monocytes. The screening involves expressing DNA from the library in the selected cell line being used for screening. Wells with the desired activity are selected, and the DNA is recovered, optionally after replication or cloning of the cells. Repeat cycles of functional screening and selection can lead to identification of new polynucleotide clones that promote or inhibit TRRE activity. This is illustrated below in Example 5. Further experiments can be performed on the selected polynucleotides to determine it modulates TRRE activity inside the cell, or through the action of a protein product. A long open reading frame suggests a role for a protein product, and examination of the amino acid sequence for a signal peptide and a membrane spanning region can help determine whether the protein is secreted from the cell or expressed in the surface membrane.

This type of screening is also useful for further development of the polynucleotides of this invention. For example, expression constructs can be developed that encode functional peptide fragments, fusion proteins, and other variants. The minimum size of polynucleotide sequence that still encodes TRRE modulation activity can be determined by removing part of the sequence and then using the screening assay to determine whether the activity is still present. Mutated and extended sequences can be tested in the same way.

This type of screening assay is also useful for developing compounds that affect TRRE activity by interfering with mRNA that encode a TRRE modulator. Of particular interest are ribozymes and antisense oligonucleotides. Ribozymes

are endoribonucleases that catalyze cleavage of RNA at a specific site. They comprise a polynucleotide sequence that is complementary to the cleavage site on the target, and additional sequence that provide the tertiary structure to effect the cleavage. Construction of ribozymes is described in U.S. Patent Nos. 5 4,987,071 and 5,591,610. Antisense oligonucleotides that bind mRNA comprise a short sequence complementary to the mRNA (typically 8-25 bases in length). Preferred chemistry for constructing antisense oligonucleotides is outlined in an earlier section. Specificity is provided both by the complementary sequence, and by features of the chemical structure. Antisense molecules that inhibit 10 expression of cell surface receptors are described in U.S. Patent Nos. 5,135,917 and 5,789,573. Screening involves contacting the cell expressing TRRE activity and TNF-R with the compound and determining the effect on receptor release. Ribozymes and antisense molecules effective in altering expression of a TRRE promoter would decrease TNF-R release. Ribozymes and antisense molecules 15 effective in altering expression of a TRRE inhibitor would increase TNF-R release.

Another screening method described in this disclosure is for testing the ability of polypeptides to modulate TRRE activity (Example 7). Cells expressing both TNF-R and a moderate level of TRRE activity are contacted with the test 20 polypeptides, and the rate of receptor release is compared with the rate of spontaneous release. An increased rate of release indicates that the polypeptide is a TRRE promoter, while a decreased rate indicates that the polypeptide is a TRRE inhibitor. This assay can be used to test the activity of new polypeptides, and develop variants of polypeptides already known to modulate TRRE. The 25 minimum size of polypeptide sequence that still encodes TRRE modulation activity can be determined by making a smaller fragment of the polypeptide and then using the screening assay to determine whether the activity is still present. Mutated and extended sequences can be tested in the same way.

Another screening method embodied in this invention is a method for 30 screening substances that interfere with the action of a TRRE modulator at the protein level. The method involves incubating cells expressing TNF receptor

(such as C75R cells) with a polypeptide of this invention having TNF promoting activity. There are two options for supplying the TRRE modulator in this assay. In one option, the polypeptide is added to the medium of the cells as a reagent, along with the substance to be tested. In another option, the cells are genetically
5 altered to express the TRRE modulator at a high level, and the assay requires only that the test substance be contacted with the cells. This option allows for high throughput screening of a number of test compounds.

Either way, the rate of receptor release is compared in the presence and absence of the test substance, to identify compounds that enhance or diminish
10 TRRE activity. Parallel experiments should be conducted in which the activity of the substance on receptor shedding is tested in the absence of added polypeptide (using cells that don't express the polypeptide). This will determine whether the activity of the test substance occurs via an effect on the TRRE promoter being added, or through some other mechanism.

15 This type of screening assay is useful for identifying antibodies that affect the activity of a TRRE modulator. Antibodies are raised against a TRRE modulator as described in the previous section. If the antibody decreases TRRE activity in the screening assay, then it has therapeutic potential to lower TRRE activity in vivo. Screening of monoclonal antibodies using this assay can also
20 help identify binding or catalytic sites in the polypeptide.

This type of screening assay is also useful for high throughput screening of small molecule compounds that have the ability to affect the level of TNF receptors on a cell, by way of its influence on a TRRE modulator. Small molecule compounds that have the desired activity are often preferred for
25 pharmaceutical compositions, because they are often more stable and less expensive to produce.

Medicaments and their use

As described earlier, a utility of certain products embodied in this invention
30 is to affect signal transduction from cytokines (particularly TNF). Products that promote TRRE activity have the effect of decreasing TNF receptors on the

surface of cells, which would decrease signal transduction from TNF. Conversely, products that inhibit TRRE activity prevent cleavage of TNF receptors, increasing signal transduction.

5 The ability to affect TNF signal transduction is of considerable interest in the management of clinical conditions in which TNF signaling contributes to the pathology of the condition. Such conditions include:

- 10 • Heart failure. IL-1 β and TNF are believed to be central mediators for perpetuating the inflammatory process, recruiting and activating inflammatory cells. The inflammation depress cardiac function in congestive heart failure, transplant rejection, myocarditis, sepsis, and burn shock.
- Cachexia. The general weight loss and wasting occurring in the course of chronic diseases, such as cancer. TNF is believed to affect appetite, energy expenditure, and metabolic rate.
- 15 • Crohn's disease. The inflammatory process mediated by TNF leads to thickening of the intestinal wall, ensuing from lymphedema and lymphocytic infiltration.
- Endotoxic shock. The shock induced by release of endotoxins from gram-negative bacteria, such as E. coli, involves TNF-mediated inflammation
- 20 • Arthritis. TNF promotes expression of nitric oxide synthetase, believed to be involved in disease pathogenesis.

Other conditions of interest are multiple sclerosis, sepsis, inflammation brought on by microbe infection, and diseases that have an autoimmune etiology, such as Type I Diabetes.

25 Polypeptides of this invention that promote TRRE activity can be administered with the objective of decreasing or normalizing TNF signal transduction. For example, in congestive heart failure or Crohn's disease, the polypeptide is given at regular intervals to lessen the inflammatory sequelae.

30 The treatment is optionally in combination with other agents that affect TNF

signal transduction (such as antibodies to TNF or receptor antagonists) or that lessen the extent of inflammation in other ways.

Polynucleotides of this invention can also be used to promote TRRE activity by gene therapy. The encoding sequence is operably linked to control elements for transcription and translation in human cells. It is then provided in a form that will promote entry and expression of the encoding sequence in cells at the disease site. Forms suitable for local injection include naked DNA, polynucleotides packaged with cationic lipids, and polynucleotides in the form of viral vectors (such as adenovirus and AAV constructs). Methods of gene therapy known to the practitioner skilled in the art will include those outlined in U.S. Patent Nos. 5,399,346, 5,827,703, and 5,866,696.

The ability to affect TNF signal transduction is also of interest where TNF is thought to play a beneficial role in resolving the disease. In particular, TNF plays a beneficial role in the necrotizing of solid tumors. Accordingly, products of this invention can be administered to cancer patients to inhibit TRRE activity, thereby increasing TNF signal transduction and improve the beneficial effect.

Embodiments of the invention that inhibit TRRE activity include antisense polynucleotides. A method of conferring long-standing inhibitory activity is to administer antisense gene therapy. A genetic construct is designed that will express RNA inside the cell which in turn will decrease the transcription of the target gene (U.S. Patent No. 5,759,829). In humans, a more frequent form of antisense therapy is to administer the effector antisense molecule directly, in the form of a short stable polynucleotide fragment that is complementary to a segment of the target mRNA (U.S. Patent Nos. 5,135,917 and 5,789,573) — in this case, the transcript that encodes the TRRE modulator. Another embodiment of the invention that inhibits TRRE are ribozymes, constructed as described in an earlier section. The function of ribozymes in inhibiting mRNA translation is described in U.S. Patent Nos. 4,987,071 and 5,591,610.

Once a product of this invention is found to have suitable TRRE modulation activity in the in vitro assays described in this disclosure, it is preferable to also test its effectiveness in an animal model of a TNF mediated

disease process. Example 3 describes an LPS model for sepsis that can be used to test promoters of TRRE activity. Example 4 describes a tumor necrosis model, in which TRRE inhibitors could be tested for an ability to enhance necrotizing activity. Those skilled in the art will know of other animal models suitable for testing effects on TNF signal transduction or inflammation. Other illustrations are the cardiac ischemia reperfusion models of Weyrich et al. (*J. Clin. Invest.* 91:2620, 1993) and Garcia-Criado et al. (*J. Am. Coll. Surg.* 181:327, 1995); the pulmonary ischemia reperfusion model of Steinberg et al. (*J. Heart Lung Transplant.* 13:306, 1994), the lung inflammation model of International Patent Application WO 9635418; the bacterial peritonitis model of Sharar et al. (*J. Immunol.* 151:4982, 1993), the colitis model of Meenan et al. (*Scand. J. Gastroenterol.* 31:786, 1996), and the diabetes model of von Herrath et al. (*J. Clin. Invest.* 98:1324, 1996). Models for septic shock are described in Mack et al. *J. Surg. Res.* 69:399, 1997; and Seljelid et al. *Scand. J. Immunol.* 45:683-7.

For use as an active ingredient in a pharmaceutical preparation, a polypeptide, polynucleotide, or antibody of this invention is generally purified away from other reactive or potentially immunogenic components present in the mixture in which they are prepared. Typically, each active ingredient is provided in at least about 90% homogeneity, and more preferably 95% or 99% homogeneity, as determined by functional assay, chromatography, or SDS polyacrylamide gel electrophoresis. The active ingredient is then compounded into a medicament in accordance with generally accepted procedures for the preparation of pharmaceutical preparations, such as described in *Remington's Pharmaceutical Sciences 18th Edition* (1990), E.W. Martin ed., Mack Publishing Co., PA. Steps in the compounding of the medicament depend in part on the intended use and mode of administration, and may include sterilizing, mixing with appropriate non-toxic and non-interfering excipients and carriers, dividing into dose units, and enclosing in a delivery device. The medicament will typically be packaged with information about its intended use.

Mode of administration will depend on the nature of the condition being treated. For conditions that are expected to require moderate dosing and that are at well perfused sites (such as cardiac failure), systemic administration is acceptable. For example, the medicament may be formulated for intravenous
5 administration, intramuscular injection, or absorption sublingually or intranasally. Where it is possible to administer the active ingredient locally, this is usually preferred. Local administration will both enhance the concentration of the active ingredient at the disease site, and minimize effects on TNF receptors on other tissues not involved in the disease process. Conditions that lend themselves to
10 administration directly at the disease site include cancer and rheumatoid arthritis. Solid tumors can be injected directly when close to the skin, or when they can be reached by an endoscopic procedure. Active ingredients can also be administered to a tumor site during surgical resection, being implanted in a gelatinous matrix or in a suitable membrane such as Gliadel® (Guilford
15 Sciences). Where direct administration is not possible, the administration may be given through an arteriole leading to the disease site. Alternatively, the pharmaceutical composition may be formulated to enhance accumulation of the active ingredient at the disease site. For example, the active ingredient can be encapsulated in a liposome or other matrix structure that displays an antibody or
20 ligand capable of binding a cell surface protein on the target cell. Suitable targeting agents include antibodies against cancer antigens, ligands for tissue-specific receptors (e.g., serotonin for pulmonary targeting). For compositions that decrease TNF signal transduction, an appropriate targeting molecule may be the TNF ligand, since the target tissue may likely display an unusually high
25 density of the TNF receptor.

Effective amounts of the compositions of the present invention are those that alter TRRE activity by at least about 10%, typically by at least about 25%, more preferably by about 50% or 75%. Where near complete ablation of TRRE activity is desirable, preferred compositions decrease TRRE activity by at least
30 90%. Where increase of TRRE activity is desirable, preferred compositions increase TRRE activity by at least 2-fold. A minimum effective amount of the

active compound will depend on the disease being treated, which of the TRRE modulators is selected for use, and whether the administration will be systemic or local. For systemic administration, an effective amount of activity will generally be an amount of the TRRE modulator that can cause a change in the enzyme
5 activity by 100 to 50,000 Units — typically about 10,000 Units. The mass amount of protein, nucleic acid, or antibody is chosen accordingly, based on the specific activity of the active compound in Units per gram.

The following examples provided as a further guide to the practitioner, and are not intended to limit the invention in any way.

10

EXAMPLES

Example 1: Assay system for TRRE activity.

This Example illustrates an assay system that measures TRRE activity on the human TNF-R in its native conformation in the cell surface membrane

15 Membrane-associated TNF-R was chosen as the substrate, as having microenvironment similar to that of the substrate for TRRE in vivo. Membrane-associated TNF-R also requires more specific activity, which would differentiate less-specific proteases. Cells expressing an elevated level of the p75 form of TNF-R were constructed by cDNA transfection into monkey COS-1 cells which
20 express little TNF-R of either the 75 kDa or 55 kDa size.

The procedure for constructing these cells was as follows: cDNA of human p75 TNF-R was cloned from a λ gt10 cDNA library derived from human monocytic U-937 cells (Clontech Laboratories, Palo Alto, CA). The first 300 bp on both 5' and 3' ends of the cloned fragment was sequenced and compared to the
25 reported cDNA sequence of human p75 TNF-R. The cloned sequence was a 2.3 kb fragment covering positions 58-2380 of the reported p75 TNF-R sequence, which encompasses the full length of the p75 TNF-R-coding sequence from positions 90-1475. The 2.3 kb p75 TNF-R cDNA was then subcloned into the multiple cloning site of the pCDNA3 eukaryotic expression vector. The

orientation of the p75 TNF-R cDNA was verified by restriction endonuclease mapping.

Figure 1 illustrates the final 7.7 kb construct, pCDTR2. It carries the neomycin-resistance gene for the selection of transfected cells in G418, and the expression of the p75 TNF-R is driven by the cytomegalovirus promoter. The pCDTR2 was then transfected into monkey kidney COS-1 cells (ATCC CRL-1650) using the calcium phosphate-DNA precipitation method. The selected clone in G418 medium was identified and subcultured. This clone was given the designation **C75R**.

To determine the level of p75 TNF-R expression on C75R cells, 2×10^5 cells/well were plated into a 24-well culture plate and incubated for 12 to 16 hours in 5% CO₂ at 37°C. They were then incubated with 2-30 ng ¹²⁵I human recombinant TNF (radiolabeled using the chloramine T method) in the presence or absence of 100-fold excess of unlabeled human TNF at 4°C for 2 h. After three washes with ice-cold PBS, cells were lysed with 0.1N NaOH and bound radioactivity was determined in a Pharmacia Clinigamma counter (Uppsala, Sweden).

Figure 2 shows the results obtained. C75R had a very high level of specific binding of radiolabeled ¹²⁵I-TNF, while parental COS-1 cells did not. The number of TNF-R expressed on C75R was determined to be 60,000-70,000 receptors per cell by Scatchard analysis (**Figure 2**, inset). The K_d value calculated was 5.6×10^{-10} M. This K_d value was in close agreement to the values previously reported for native p75 TNF-R.

TRRE was obtained by PHA stimulation of THP-1 cells (WO 9802140). THP-1 cells (ATCC 45503) growing in logarithmic phase were collected and resuspended to 1×10^6 cells/ml of RPMI-1640 supplemented with 1% FCS and incubated with 10^{-6} M PMA for 30 min in 5% CO₂ at 37 °C. The cells were collected and washed once with serum-free medium to remove PMA and resuspended in the same volume of RPMI-1640 with 1% FCS. After 2 hours incubation in 5% CO₂ at 37°C, the cell suspension was collected, centrifuged, and the cell-free supernatant was collected as the source of TRRE.

In order to measure the effect of TRRE on membrane-bound TNF-R in the COS-1 cell constructs, the following experiment was performed. C75R cells were seeded at a density of 2×10^5 cells/well in a 24-well cell culture plate and incubated for 12 to 16 hours at 37°C in 5% CO₂. The medium in the wells was
5 aspirated, replaced with fresh medium alone or with TRRE medium, and incubated for 30 min at 37°C. The medium was then replaced with fresh medium containing 30 ng/ml ¹²⁵I-labeled TNF. After 2 hours at 4°C, the cells were lysed with 0.1 N NaOH and the level of bound radioactivity was measured. The level of specific binding of C75R by ¹²⁵I-TNF was significantly decreased after
10 incubation with TRRE. The radioactive count was 1,393 cpm on the cells incubated with TRRE compared to 10,567 cpm on the cells not treated with TRRE, a loss of 87% of binding capacity.

In order to determine the size of the p75 TNF-R cleared from C75R by TRRE, the following experiment was performed. 15×10^6 C75R cells were
15 seeded in a 150 mm cell culture plate and incubated at 37°C in 5% CO₂ for 12 to 16 hours. TRRE medium was incubated with C75R cells in the 150 mm plate for 30 min and the resulting supernatant was collected and centrifuged. The concentrated sample was applied to 10% acrylamide SDS-PAGE and electrophoretically transferred to a polyvinylidene difluoride membrane
20 (Immobilon). Immunostaining resulted in a single band of 40 kDa, similar to the size found in biological fluids. Thus, transfected COS-1 cells expressed high levels of human p75 TNF-R in a form similar to native TNF-R.

The following assay method was adopted for routine measurement of TRRE activity. C75R cells and COS-1 cells were seeded into 24-well culture
25 plates at a density of 2.5×10^5 cells/ml/well and incubated overnight (for 12 to 16 hours) in 5% CO₂ at 37°C. After aspirating the medium in the well, 300 µl of TRRE medium was incubated in each well of both the C75R and COS-1 plates for 30 min in 5% CO₂ at 37°C (corresponding to A and C mentioned below, respectively). Simultaneously, C75R cells in 24-well plates were also incubated
30 with 300 µl of fresh medium or buffer. The supernatants were collected,

centrifuged, and then assayed for the concentration of soluble p75 TNF-R by ELISA.

ELISA assay for released TNF-R (WO 9802140) was performed as follows: Polyclonal antibodies to human p75 TNF-R were generated by immunization of New Zealand white female rabbits (Yamamoto et al. *Cell. Immunol.* 38:403-416, 1978). The IgG fraction of the immunized rabbit serum was purified using a protein G (Pharmacia Fine Chemicals, Uppsala, Sweden) affinity column (Ey et al. (1978) *Immunochemistry* 15:429-436, 1978). The IgG fraction was then labeled with horseradish peroxidase (Sigma Chemical Co., St. Louis, MO) (Tijssen and Kurstok, *Anal. Biochem.* 136:451-457, 1984). In the first step of the assay, 5 µg of unlabeled IgG in 100 µl of 0.05 M carbonate buffer (pH 9.6) was bound to a 96-well ELISA microplate (Corning, Corning, NY) by overnight incubation at 4°C. Individual wells were washed three times with 300 µl of 0.2% Tween-20 in phosphate buffered saline (PBS). The 100 µl of samples and recombinant receptor standards were added to each well and incubated at 37°C for 1 to 2 hours. The wells were then washed in the same manner, 100 µl of horseradish peroxidase-labeled IgG added and incubated for 1 hour at 37 °C. The wells were washed once more and the color was developed for 20 minutes (min) at room temperature with the substrates ABTS (Pierce, Rockford, IL) and 30% H₂O₂ (Fisher Scientific, Fair Lawn, NJ). Color development was measured at 405 nm.

When C75R cells were incubated with TRRE medium, soluble p75 TNF-R was released into the supernatant which was measurable by ELISA. The amount of receptors released corresponded to the amount of TRRE added. There was also a level of spontaneous TNF-R release in C75R cells incubated with just medium alone. It is hypothesized that this is due to an endogenous source of proteolytic enzyme, a homolog of the human TRRE of monkey origin.

The following calculations were performed. A = (amount of soluble p75 TNF-R in a C75R plate treated with the TRRE containing sample); i.e. the total amount of sTNF-R in a C75R plate. B = (amount of soluble p75 TNF-R spontaneously released in a C75R plate treated with only medium or buffer

containing the same reagent as the corresponding samples but without exogenous TRRE); i.e. the spontaneous release of sTNF-R from C75R cells. C = (amount of soluble p75 TNF-R in a COS-1 plate treated with the TRRE sample or the background level of soluble p75 TNF-R released by THP-1.); i.e. the degraded value of transferred (pre-existing) sTNF-R in the TRRE sample during 30 min incubation in a COS-1 plate. This corresponds to the background level of sTNF-R degraded in a C75R plate. The net release of soluble p75 TNF-R produced only by TRRE activity existing in the initial sample is calculated as follows: (Net release of soluble p75 TNF-R only by TRRE) = A - B - C.

10 **Unit activity** of TRRE was defined as follows: 1 pg of soluble p75 TNF-R net release (A-B-C) in the course of the assay is one unit (U) of TRRE activity.

Using this assay, the time course of receptor shedding by TRRE was measured in the following experiment. TRRE-medium was incubated with C75R and COS-1 cells for varying lengths of time. The supernatants were then collected and assayed for the level of soluble p75 TNF-R by ELISA and the net TRRE activity was calculated. Detectable levels of soluble receptor were released by TRRE within 5 min and increased up to 30 min. Longer incubation times showed that the level of TRRE remained relatively constant after 30 min, presumably from the depletion of substrates. Therefore, 30 min was determined to be the optimal incubation time.

The induction patterns of TRRE and known MMPs by PMA stimulation are quite different. In order to induce MMPs, monocytic U-937 cells, fibrosarcoma HT-1080 cells, or peritoneal exudate macrophages (PEM) usually have to be stimulated for one to three days with LPS or PMA. On the other hand, as compared with this prolonged induction, TRRE is released very quickly in culture supernatant following 30 min of PMA-stimulation. The hypothesis that TRRE and sTNF-R form a complex *in vitro* was confirmed by the experiment that 25% TRRE activity was recovered from soluble p75 TNF-R affinity column. This means that free TRRE has the ability to bind to its catalytic product, sTNF-R. The remaining 75% which did not combine to the affinity column may already be

bound to sTNF-R or may not have enough affinity to bind to sTNF-R even though it is in a free form.

Example 2: Characterization of TRRE obtained from THP-1 cells.

5 TRRE obtained by PHA stimulation of THP-1 cells was partially purified from the culture medium (WO 9802140). First, protein from the medium was concentrated by 100% saturated ammonium sulfate precipitation at 4°C. The precipitate was pelleted by centrifugation at 10,000 x g for 30 min and resuspended in PBS in approximately twice the volume of the pellet. This
10 solution was then dialyzed at 4°C against 10 mM Tris-HCl, 60 mM NaCl, pH 7.0. This sample was loaded on an anion-exchange chromatography, Diethylaminoethyl (DEAE)-Sephadex A-25 column (Pharmacia Biotech) (2.5 x 10 cm) previously equilibrated with 50 mM Tris-HCl, 60 mM NaCl, pH 8.0. TRRE was then eluted with an ionic strength linear gradient of 60 to 250 mM
15 NaCl, 50 mM Tris-HCl, pH 8.0. Each fraction was measured for absorbance at 280 nm and assayed for TRRE activity. The DEAE fraction with the highest specific activity (the highest value of TRRE units/A280) was pooled and used in the characterizations of TRRE described in this example.

In the next experiment, the substrate specificity of the enzyme was
20 elucidated using immunohistochemical techniques. Fluorescein isothiocyanate (FITC)-conjugated anti-CD54, FITC-conjugated goat anti-rabbit and mouse antibodies, mouse monoclonal anti-CD30, anti-CD11b and anti-IL-1R (Serotec, Washington D.C.) were used. Rabbit polyclonal anti-p55 and p75 TNF-R were obtained according to Yamamoto et al. (1978) *Cell Immunol.* 38:403-416. THP-
25 1 cells were treated for 30 min with 1,000 and/or 5,000 U/ml of TRRE eluted from the DEAE-Sephadex column, and then transferred to 12 x 75 mm polystyrene tubes (Fischer Scientific, Pittsburgh, PA) at 1×10^5 cells/100 μ l/tube. The cells were then pelleted by centrifugation at 350 x g for 5 min at 4°C and stained directly with 10 μ l FITC-conjugated anti-CD54 (diluted in cold PBS/0.5% sodium
30 aside), indirectly with FITC-conjugated anti-mouse antibody after treatment of

mouse monoclonal anti-CD11b, IL-1R and CD30 and also indirectly with FITC-conjugated anti-rabbit antibody after treatment of rabbit polyclonal anti-p55 and p75 TNF-R.

THP-1 cells stained with each of the antibodies without treatment of TRRE
5 were used as negative controls. The tubes were incubated for 45 min at 4°C, agitated every 15 min, washed twice with PBS/2% FCS, repelleted and then resuspended in 200µl of 1% paraformaldehyde. These labeled THP-1 cells were analyzed using a fluorescence activated cell sorter (FACS) (Becton-Dickinson, San Jose, CA) with a 15 mW argon laser with an excitation of 488 nm.
10 Fluorescent signals were gated on the basis of forward and right angle light scattering to eliminate dead cells and aggregates from analysis. Gated signals (10⁴) were detected at 585 BP filter and analyzed using Lysis II software. Values were expressed as percentage of positive cells, which was calculated by dividing mean channel fluorescence intensity (MFI) of stained THP-1 cells
15 treated with TRRE by the MFI of the cells without TRRE treatment (negative control cells).

To test the *in vitro* TNF cytolytic assay by TRRE treatment the L929 cytolytic assay was performed according to the method described by Gatanaga et al. (1990b). Briefly, L929 cells, an adherent murine fibroblast cell line, were
20 plated (70,000 cells/0.1ml/well in a 96-well plate) overnight. Monolayered L929 cells were pretreated for 30 min with 100, 500 or 2,500 U/ml of partially-purified TRRE and then exposed to serial dilutions of recombinant human TNF for 1 hour. After washing the plate with RPMI-1640 with 10% FCS to remove the TRRE and TNF, the cells were incubated for 18 hours in RPMI-1640 with 10%
25 FCS containing 1 µg/ml actinomycin D at 37°C in 5% CO₂. Culture supernatants were then aspirated and 50 µl of 1% crystal violet solution was added to each well. The plates were incubated for 15 min at room temperature. After the plates were washed with tap water and air-dried, the cells stained with crystal violet were lysed by 100 µl per well of 100 mM HCl in methanol. The absorbance at

550 nm was measured using an EAR 400 AT plate reader (SLT-Labinstruments, Salzburg, Austria).

To investigate whether TRRE also truncates the ~55 kDa size of TNF-R, partially-purified TRRE was applied to THP-1 cells which express low levels of both p55 and p75 TNF-R (approximately 1,500 receptors/cell by Scatchard analysis). TRRE eluate from the DEAE-Sephadex column was added to THP-1 cells (5×10^6 cells/ml) at a final TRRE concentration of 1,000 U/ml for 30 min. The concentration of soluble p55 and p75 TNF-R in that supernatant was measured by soluble p55 and p75 TNF-R ELISA. TRRE was found to truncate both human p55 and p75 TNF-R on THP-1 cells and released 2,382 and 1,662 pg/ml soluble p55 and p75 TNF-R, respectively.

Therefore, TRRE obtained by PHA stimulation of THP-1 cells is capable of enzymatically cleaving and releasing human p75 TNF-R on C75R cells, and both human p55 and p75 TNF-R on THP-1 cells.

Partial inhibition of TRRE activity was obtained by chelating agents such as 1,10-phenanthroline, EDTA and EGTA (% TRRE activity remaining were 41%, 67% and 73%, respectively, at 2 mM concentration). On the other hand, serine protease inhibitors such as PMSF, AEBSF and 3,4-DCI, and serine and cysteine protease inhibitors such as TLCK and TPCK had no effect on the inhibition of TRRE. TRRE was slightly activated in the presence of Mn^{2+} , Ca^{2+} , Mg^{2+} , and Co^{2+} (% TRRE activities remaining were 157%, 151%, 127%, and 123%, respectively), whereas partial inhibition occurred in the presence of Zn^{2+} and Cu^{2+} (% TRRE activities remaining were 23% and 47%, respectively) (WO 9802140).

TRRE fractions from the most active DEAE fraction (60 mM to 250 mM NaCl) can be purified further. In one method (WO 9802140), the fractions were concentrated to 500 μ L with a Centriprep-10 filter (10,000 MW cut-off membrane) (Amicon). This concentrated sample was applied to 6% PAGE under non-denaturing native conditions. The gel was sliced horizontally into 5 mm strips and each was eluted into 1 ml PBS. The eluates were then tested according to the assay (Example 1) for TRRE activity.

Example 3: TRRE activity alleviates septic shock

The following protocol was used to test the effects of TRRE in preventing mortality in a model for septic shock. Mice were injected with lethal or sublethal levels of LPS, and then with a control buffer or TRRE. Samples of peripheral blood were then collected at intervals to establish if TRRE blocked TNF-induced production of other cytokines in the bloodstream. Animals were assessed for the ability of TRRE to block the clinical effects of shock, and then euthanized and tissues examined by histopathological methods.

Details were as follows: adult Balb/c mice, were placed in a restraining device and injected intravenously via the tail vein with a 0.1 ml solution containing 10 ng to 10 mg of LPS in phosphate buffer saline (PBS). These levels of LPS induce mild to lethal levels of shock in this strain of mice. Shock results from changes in vascular permeability, fluid loss, and dehydration, and is often accompanied by symptoms including lethargy, a hunched, stationary position, rumped fur, cessation of eating, cyanosis, and, in serious cases, death within 12 to 24 hours. Control mice received an injection of PBS. Different amounts (2,000 or 4,000 U) of purified human TRRE were injected IV in a 0.1 ml volume within an hour prior to or after LPS injection. Serum (0.1 ml) was collected with a 27 gauge needle and 1 ml syringe IV from the tail vein at 30, 60 and 90 minutes after LPS injection. This serum was heparinized and stored frozen at -20°C. Samples from multiple experiments were tested by ELISA for the presence of sTNF-R, TNF, IL-8 and IL-6. Animals were monitored over the next 12 hours for the clinical effects of shock. Selected animals were euthanized at periods from 3 to 12 hours after treatment, autopsied and various organs and tissues fixed in formalin, imbedded in paraffin, sectioned and stained by hematoxylin-eosin (H and E). Tissue sections were subjected to histopathologic and immunopathologic examination.

Figure 3 shows the results obtained. (♦) LPS alone; (■) LPS plus control buffer; (●) LPS plus TRRE (2,000 U); (▲) LPS plus TRRE (4,000 U).

Mice injected with LPS alone or LPS and a control buffer died shortly after injection. 50% of the test animals were dead after 8 hours (LPS) or 9 hours (LPS plus control buffer), and 100% of the animals were dead at 15 hours. In contrast, animals treated with TRRE obtained as described in Example 1 did much better.

5 When injections of LPS were accompanied by injections of a 2,000 U of TRRE, death was delayed and death rates were lower. Only 40% of the animals were dead at 24 hours. When 4,000 U of TRRE was injected along with LPS, all of the animals had survived at 24 hours. Thus, TRRE is able to counteract the mortality induced by LPS in test animals.

10

Example 4: TRRE activity decreases tumor necrotizing activity

The following protocol was followed to test the effects of TRRE on tumor necrosis in test animals in which tumors were produced, and in which TNF was subsequently injected.

15 On Day 0, cutaneous Meth A tumors were produced on the abdominal wall of fifteen BALB/c mice by intradermal injection of 2×10^5 Meth A tumor cells. On Day 7, the mice were divided into three groups of five mice each and treated as follows:

- Group 1: Injected intravenously with TNF (1 μ g/mouse).
- 20 • Group 2: Injected intravenously with TNF (1 μ g/mouse) and injected intratumorally with TRRE obtained as in Example 1 (400 units/mouse, 6, 12 hours after TNF injection).
- Group 3: Injected intravenously with TNF (1 μ g/mouse) and injected intratumorally with control medium (6, 12 hours after TNF injection).

25 On Day 8, tumor necrosis was measured with the following results: Group 1: 100% of necrosis (5/5); Group 2: 20% (1/5); Group 3: 80% (4/5). Injections of TRRE greatly reduced the ability of TNF to induce necrosis in Meth A tumors in BALB/c mice.

Since adding TRRE activity ablates the beneficial necrotizing activity of TNF, blocking endogenous TRRE activity would promote the beneficial effects of TNF.

5 **Example 5: Nine new polynucleotide clones that affect TRRE activity**

A number of cells have been found to express high levels of TRRE activity, especially after PMA stimulation. These include the cell lines designated THP-1, U-937, HL-60, ME-180, MRC-5, Raji, K-562. Jurkat cells have a high TRRE activity (850 TRRE U/mL at 10^{-2} PMA). In this experiment, the expression
10 library of the Jurkat T cell (ATCC #TIB-152) was obtained and used to obtain 9 polynucleotide clones that augment TRRE activity.

Selection of expression sequences in the library was done by repeated cycles of transfection into COS-1 cells, followed by assaying of the supernatant as in Example 1 for the presence of activity cleaving and releasing the TNF
15 receptor. Standard techniques were used in the genetic manipulation. Briefly, the DNA of 10^6 Jurkat cells was extracted using an InVitrogen plasmid extraction kit according to manufacturer's directions. cDNA was inserted in the ZAP Express™/EcoRI vector (cat. no. 938201, Stratagene, La Jolla CA. The library was divided into 48 groups of DNA and transformed into COS-1 cells using the
20 CaCl transfection method. Once the cells were grown out, the TRRE assay was performed, and five positive groups were selected. DNA from each of these five groups was obtained, and transfected into *E. coli*, with 15 plates per group. DNA was prepared from these cells and then transfected into COS-1 cells once more. The cells were grown out, and TRRE activity was tested again. Two positive
25 groups were selected and transfected into *E. coli*, yielding 98 colonies. DNA was prepared from 96 of these colonies and transfected into COS-1 cells. The TRRE activity was performed again, and nine clones were found to substantially increase TRRE activity in the assay. These clones were designated 2-8, 2-9, 2-14, 2-15, P2-2, P2-10, P2-13, P2-14, and P2-15.

30 **Figure 4** is a bar graph showing the TRRE activity observed when the 9 clones were tested with C75 cells in the standard assay (Example 1).

These nine clones were then sequenced according to the following procedure:

1. Plasmid DNA was prepared using a modified alkaline lysis procedure.
2. DNA sequencing was performed using DyeDeoxy termination reactions (ABI). Base-specific fluorescent dyes were used as labels.
3. Sequencing reactions were analyzed on 5.75% Long Ranger™ gels by an ABI 373A-S or on 5.0% Long Ranger™ gels by an ABI 377 automated sequencer.
4. Subsequent data analysis was performed using Sequencher™ 3.0 software.

Standard primers T7X, T3X, -40, -48 Reverse, and BK Reverse (BKR) were used in sequencing reactions. For each clone, several additional internal sequencing primers (listed below) were synthesized.

NCBI BLAST (Basic Local Alignment Search Tool) sequence analysis (Altschul et al. (1990) *J. Mol. Biol.* 215:403-410) was performed to determine if other sequences were significantly similar to these sequences. Both the DNA sequences of the clones and the corresponding ORFs (if any) were compared to sequences available in databases.

The following clones were obtained and sequenced:

TABLE 1: DNA sequences affecting TRRE activity					
Clone	Sequence Designation	SEQ ID NO:	Approx Length (bp)	Expressi on Designati on	Related sequences (potential homology)
2-9	AIM2	1	4,047		—
2-8	AIM3T3 (partial sequence)	2	739		<i>M. musculus</i> 45S pre-rRNA gene
	AIM3T7 (partial sequence)	3	233		
2-14	AIM4	4	2,998	Mey3	human arfaptin 2 and others (see below)
2-15	AIM5	5	4,152		—
P2-2	AIM6	6	3,117	Mey5	—
P2-10	AIM7	7	3,306	Mey6	Human Insulin-like Growth factor II Receptor
P1-13	AIM8	8	4,218		—
P2-14	AIM9	9	1,187	Mey8	—
P2-15	AIM10	10	3,306		E1b-55kDa-associated protein

Clone 2-9 (AIM2): The internal primers used for sequencing are shown in SEQ. ID NOS:11-38. The sequence of AIM2 is presented in SEQ ID NO:1. The complementary strand of the AIM2 sequence is SEQ ID NO:147. The longest open reading frame (ORF) in the AIM2 sequence is 474 AA long and represented in SEQ ID NO:148.

Clone 2-8 (AIM3): Two partial sequences of length 739 and 233 were obtained and designated AIM3T3 and AIM3T7. The internal primers used for sequencing are shown in SEQ. ID NOS:39-46. The sequences of AIM3T3 and

AIM3T7 are presented in SEQ ID NOs:2 and 3, respectively. The BLAST search revealed that the AIM3T3 sequence may be homologous to the mouse (*M. musculus*) 28S ribosomal RNA (Hassouna et al. *Nucleic Acids Res.* 12:3563-3583, 1984) and the *M. musculus* 45S pre-rRNA genes (Accession No. X82564.

- 5 The complementary sequence of the AIM3T3 sequence showed 99% similarity over 408 bp beginning with nt 221 of SEQ ID NO:2 to the former and 97% similarity over the same span to the latter.

Clone 2-14 (AIM4). The internal primers used for sequencing are shown in SEQ. ID NOS:14-65. The sequence of AIM4 is presented in SEQ ID NO:4. The
10 complementary strand of the AIM4 sequence is SEQ ID NO:149. The longest ORF in the AIM4 sequence is 236 AA long and represented in SEQ ID NO:150. AIM4 has significant alignments to human sequences arfaptin 2, ADE2H1 mRNA showing homologies to SAICAR synthetase, polypyrimidine tract binding protein (heterogeneous nuclear ribonucleoprotein I) mRNA, several PTB genes for
15 polypyrimidine tract binding proteins, mRNA for por1 protein. Human arfaptin 2 is a putative target protein of ADP-ribosylation factor that interacts with RAC1 by binding directly to it. RAC1 is involved in membrane ruffling. Arfaptin 2 has possible transmembrane segments, potential CK2 phosphorylation sites, PKC phosphorylation site and RGD cell attachment sequence.

- 20 *Clone 2-15 (AIM5)*: The internal primers used for sequencing are shown in SEQ. ID NOS:66-80. The sequence of AIM5 is presented in SEQ ID NO:5. The BLAST search revealed that the AIM5 sequence displays some similarity to Human Initiation Factor 5A (eIF-5A) Koettnitz et al. (1995) *Gene* 159:283-284, 1995 and Human Initiation Factor 4D (eIF 4D) Smit-McBride et al. (1989) *J. Biol.*
25 *Chem.* 264:1578-1583, 1989.

Clone P2-2 (AIM6): The internal primers used for sequencing are shown in SEQ. ID NOS:81-93. The sequence of AIM6 is presented in SEQ ID NO:6. The longest ORF in the AIM6 sequence is 1038 AA long and represented in SEQ ID NO:151.

- 30 *Clone P2-10 (AIM7)*: The internal primers used for sequencing are shown in SEQ. ID NOS:94-106. The sequence of AIM7 is presented as SEQ ID NO:7.

The longest ORF in the AIM7 sequence is 849 AA long and represented in SEQ ID NO:152. The BLAST search revealed that this clone may be related to the Human Insulin-like Growth Factor II Receptor (Morgan et al. *Nature* 329:301-307, 1987 or the Human Cation-Independent Mannose 6-Phosphate Receptor mRNA (Oshima et al. *J. Biol. Chem.* 263:2553-2562, 1988). The AIM7 sequence showed roughly 99% identity to both sequences over 2520 nucleotides beginning with nt 12 of SEQ ID NO:7 and 99% similarity to the latter over the same span.

Clone P2-13 (AIM8): The internal primers used for sequencing are shown in SEQ. ID NOS:107-118. The sequence of AIM8 is presented as SEQ ID NO:8.

10 The longest ORF in the AIM8 sequence is 852 AA long and represented in SEQ ID NO:153.

Clone P2-14 (AIM9): The internal primers used for sequencing are shown in SEQ. ID NOS:119-124. The sequence of AIM9 is presented as SEQ ID NO:9. The longest ORF was about 149 amino acids in length.

15 *Clone P2-15 (AIM10)*: The internal primers used for sequencing are shown in SEQ. ID NOS:125-146. The sequence of AIM10 is presented as SEQ ID NO:10. The longest ORF in the AIM10 sequence is 693 AA long and represented in SEQ ID NO:154. Sequence 10 on BLASTN search of non-redundant databases at NCBI aligns with Human mRNA for E1b-55kDa-associated protein, locus HSA7509 (Accession AJ007509, NID g3319955).

20

Clonal DNA may be directly injected into test animals in order to test the ability of these nucleic acids to induce TRRE activity, counteract septic shock and/or affect tumor necrosis, as is described in detail in Examples 3 and 4. Alternatively, proteins or RNA can be generated from the clonal DNA for similar testing.

25

Example 6: Expression of newly obtained clones

Example 5 describes 9 new clones which enhance TRRE activity in a cell surface assay system. The clones were obtained in the pBK-CMB Phagmid vector.

30

The following work was done on contract through the commercial laboratory Lark Technologies, Houston, TX. The clones were removed from shuttle vectors and inserted into expression vectors in the following manner. Recombinant plasmid (pBK-CMV containing insert) was digested with
5 appropriate restriction enzyme(s) such as Spe I, Xba I, EcoR I or others, as appropriate. The Baculovirus Transfer Vector (pAcGHLT-A Baculovirus Transfer Vector, PharMingen, San Diego, CA, Cat. No. 21460P) was also cut with appropriate restriction enzyme(s) within or near the multiple cloning site to receive the insert removed from the shuttle vector.

10 The fragment of interest being subcloned was isolated from the digest using Low-Melting agarose electrophoresis and purified from the gel using a Qiaquick Gel Extraction Kit following Lark SOP MB 020602. If necessary, the receiving vector was treated with alkaline phosphatase according to Lark SOP MB 090201. The fragment was ligated into the chosen site of the vector
15 pAcGHLT-A. The recombinant plasmid was transformed into *E. coli* XL1 Blue MRF' cells and the transformed bacterial cells were selected on LB agar plates containing ampicillin (100µg/ml). Ampicillin resistant colonies were picked and grown on LB broth containing ampicillin for plasmid preparation.

Plasmid DNA was prepared using Alkaline Minilysate Procedure (Lark
20 SOP MB 010802 and digested with appropriate restriction enzyme(s). Selected subclones were confirmed to be of the correct size. Subclones were digested with other appropriate restriction enzyme(s) to ascertain correct orientation of the insert by confirming presence of fragments of proper size(s). A subclone was grown in 100 ml of LB broth containing ampicillin (100µg/ml) and the plasmid
25 DNA prepared using Qiagen Midi Plasmid Preparation Kit (Lark SOP MB 011001). The DNA concentration was determined by measuring the absorbance at 260 nm and the DNA sample was verified to be originated from correct subclone by restriction digestion.

Thus were produced the expression constructs for Mey3, Mey5, Mey6,
30 Mey8 now with the coding sequence of interest fused to GST gene with polyhistitidine tag, protein kinase A site and thrombin cleavage site. The GST

gene and now the fusion protein are under the polyhedrin promotor. PharMingen (San Diego, CA) incorporated the vector with insert into functional baculovirus particles by co-inserting the transfer vector (pAcGHLT) into susceptible insect cell line S along with linearized virus DNA (PharMingen, San Diego, CA, BaculoGold viral DNA, Cat. No. 21100D). The functional virus particles were grown again on the insect cells to generate a high titer stock. Protein production was then done by infecting a large culture of cells in Tini cell. The cells were harvested when the protein yield reached a maximum and before the virus killed the cells. Fusion proteins were collected on a glutathione-agarose column, washed and released with glutathionine.

Proteins collected from the affinity column were quantified by measuring OD₂₈₀ and were assayed on gels using SDS-PAGE and Western blotting with labeled anti-GST (PharMingen, San Diego, CA, mAbGST Cat. No. 21441A) to confirm that all the bands present included the GST portion.

Four of the ten sequences have been cloned, expressed in baculovirus infected insect cells, and then purified.

TABLE 2: Expressed protein from Jurkat library clones		
Name	Sequence in insert	Amount of protein (mg/mL)
Mey3	AIM4	4.7, 5.0
Mey5	AIM6	1.36, 1.50
Mey6	AIM7	0.33
Mey8	AIM9	1.53

Gels indicated the presence of the GST protein in addition to larger proteins that were also positive with the anti-GST antibody in Western analyses. Mey3 repeatedly exhibited the presence of proteins around 32kDa, 56kDa, bands around 60-70kDa and another larger than 70kDa. Mey5 consistently had proteins migrating as approximately 34kDa, 38kDa, 58kDa, around 60-70kDa, and others larger than 70kDa. Mey6 had protein bands around 34kDa, 56kDa,

58kDa, and bands around 60-70kDa. Mey8 had protein bands around 36kDa, 58kDa and bands around 60-70kDa. All of the indicated bands were positive for GST. The bands may represent the desired fusion protein or degradation/cleavage product generated during growth and purification.

5

Example 7: Assay of expression products for effect on TNF-R cleaving activity

The following method was used to measure TRRE activity of Mey 3, 5, 6 and 8. C75R cells and COS-1 cells were seeded into 24-well culture plates at a density of 2.5×10^5 cells/ml/well and incubated overnight (for 12 to 16 hours) in 5% CO₂ at 37°C. After aspirating the medium in the well, 300µl of 1 µg of Mey 3, 5 and 8 were incubated in each well of both the C75R and COS-1 plates for 30 min in 5% CO₂ at 37°C (corresponding to A and C mentioned below, respectively). Simultaneously, C75R cells in 24-well plates were also incubated with 300µl of fresh medium or buffer (corresponding to B mentioned below). The supernatants were collected, centrifuged, and then assayed for the concentration of soluble p75 TNF-R by ELISA as described in Example 1.

The following results were obtained:

TABLE 3: Enzymatic activity of expressed clones	
Clone No.	TNF-receptor releasing activity U/mg
Mey-3	341
Mey-5	671
Mey-6	452
Mey-8	191

20

Example 8: Effectiveness of expression products in treating septic shock

The protocol outlined in Example 3 was used to test the effects of the expression products from the new clones in preventing mortality in the septic shock model.

- 5 Different amounts of recombinant Mey 3, 5, and 8 (10 – 100 ug/mouse) were injected i.v. in a 0.05 ml volume within an hour prior to or after injection of a lethal dose of LPS. Serum (0.1ml) was collected using a 27 gauge needle and 1 ml syringe from the tail vein at 30, 60 and 90 minutes after LPS injection. This serum was heparinized and stored frozen at -20°C. Samples from multiple
10 experiments were tested by ELISA for the presence of solubilized TNR-R, the TNR ligand, IL-8, and IL-6. Animals were monitored over the next 12 hours for the clinical effects of shock. Selected animals were euthanized from 3 to 12 hours after treatment, autopsied and various organs and tissues fixed in formalin, imbedded in paraffin, sectioned and stained by hematoxylin-eosin (H and E).
15 Tissue sections were subjected to histopathologic and immunopathologic examination.

Figure 5 shows the results obtained. (♦) saline; (■) BSA; (Δ) Mey-3 (100 µg); (X) Mey-3 (10 µg); (*) Mey-5 (10 µg); (●) Mey-8 (10 µg).

- Mice injected with LPS alone or LPS, a control buffer or control protein
20 (BSA) died rapidly. All of the animals in this group were dead at 24 hours. In contrast, when injections of LPS were accompanied by injections of a 10 – 100 ug of Mey 3, 5 and 8, death was delayed and death rates were lower. None of the animal were dead at 24 hours that had been treated with Mey 3 and Mey 5. Only 66 % of the animals were dead at 24 hours that had been treated with Mey
25 8. Thus, Mey 3, 5 and 8 were able to counteract the mortality induced by LPS in test animals.

CLAIMS

What is claimed as the invention is:

1. An isolated polynucleotide comprising a nucleotide sequence with the following properties:
 - a) the sequence is expressed at the mRNA level in Jurkat T cells;
 - b) when COS-1 cells expressing TNF receptor are genetically altered to express the sequence, the cells have increased enzymatic activity for cleaving and releasing the receptor.
2. The polynucleotide of claim 1, wherein the nucleotide sequence is contained in a sequence selected from the group consisting of
 - a) SEQ. ID NO:1;
 - b) SEQ. ID NO:2 or SEQ. ID NO:3;
 - c) SEQ. ID NO:4;
 - d) SEQ. ID NO:5;
 - e) SEQ. ID NO:6;
 - f) SEQ. ID NO:7;
 - g) SEQ. ID NO:8;
 - h) SEQ. ID NO:9; and
 - i) SEQ. ID NO:10.
3. An isolated polynucleotide comprising at least 30 consecutive nucleotides in said nucleotide sequence of a polynucleotide according to any of claims 1-3.
4. An isolated polynucleotide comprising a linear sequence of at least 50 consecutive nucleotides at least 90% identical to a sequence contained in said nucleotide sequence of the polynucleotide of claim 1.

5. An isolated polynucleotide of at least 50 nucleotides capable of hybridizing specifically to said nucleotide sequence of a polynucleotide according to any of claims 1-3 at 68°C in 0.5 M phosphate buffer pH 7, 7% SDS, and 100 µg/mL salmon sperm DNA, followed by washing in a buffer containing 3X SSC.
6. An antisense polynucleotide or ribozyme comprising at least 10 consecutive nucleotides in said nucleotide sequence of a polynucleotide according to claim 1 or 2, which inhibits the expression of a TRRE modulator.
7. An isolated polypeptide comprising an amino acid sequence encoded by a polynucleotide according to any of claims 1-5.
8. The polypeptide of claim 7, selected from the group consisting of SEQ. ID NOS: 147-158.
9. An isolated polypeptide, comprising at least 10 consecutive residues in said amino acid sequence of a polypeptide according to claim 7 or 8.
10. An isolated polypeptide, comprising at least 15 consecutive amino acids which are at least 80% identical to a sequence contained in said amino acid sequence of the polypeptide according to claim 7 or 8.
11. The polypeptide of claim 7-11, which when incubated with COS-1 cells expressing TNF receptor, promotes enzymatic cleavage and release of the receptor.
12. The polypeptide of claims 7-11, which either:
 - a) lacks a membrane spanning sequence; or

- b) is produced by a process comprising recombinant expression in a host cell followed by purification of the polypeptide from medium in which the cell is cultured.
13. A method of producing the polypeptide according to any of claims 7 to 11, comprising the steps of:
- a) culturing host cells genetically altered to express the polynucleotide according to claim 3; and subsequently
 - b) purifying the polypeptide from the cells.
14. The method according to claim 13, comprising harvesting culture medium following step a); and purifying the polypeptide from the culture medium by a process comprising affinity chromatography.
15. An isolated polynucleotide encoding the polypeptide of claim 8 or 9.
16. An isolated antibody specific for a polypeptide according any of claims 7-11.
17. A method for producing the antibody according to claim 16, comprising immunizing a mammal or contacting an immunocompetent cell or particle with a polypeptide according to claim 9 or 10.
18. An assay method of determining altered TRRE activity in a cell or tissue sample, comprising the steps of:
- a) contacting the sample with the polynucleotide of claim 4 or 5 under conditions that permit the polynucleotide to hybridize specifically with nucleic acid that encodes a modulator of TRRE activity, if present in the sample; and
 - b) determining polynucleotide that has hybridized as a result of step a), as a measure of altered TRRE activity in the sample.

19. An assay method for determining altered expression of a modulator of TRRE activity in a cell or tissue sample, comprising the steps of:
- a) contacting the sample with the antibody of claim 16 under conditions that permit the antibody to bind the modulator if present in the sample, thereby forming an antibody-antigen complex; and
 - b) determining complex formed in step a), as a measure of the modulator.
20. A method for assessing a disease condition associated with altered TRRE activity in a subject, comprising determining altered TRRE activity in the sample from the subject according to claim 18, or determining altered expression of a TRRE modulator according to claim 19, and then correlating the extent of alteration with the disease condition.
21. A method for decreasing signal transduction from a cytokine into a cell, comprising contacting the cell with a polypeptide according to any of claims 7-8 and 11-12, or with a polynucleotide according to any of claims 1-3 and 15.
22. A method for increasing signal transduction from a cytokine into a cell, comprising contacting the cell with a polynucleotide according to claim 6, or with an antibody according to claim 16.
23. The method according to claim 21 or claim 22, wherein the cytokine is TNF.
24. A method for screening polynucleotides for an ability to modulate TRRE activity, comprising the steps of:
- a) providing cells that express both TRRE and the TNF-receptor;
 - b) genetically altering the cells with the polynucleotides to be screened;
 - c) cloning the cells genetically altered in step b); and

d) identifying clones that enzymatically release the receptor at an altered rate.

25. A method for screening substances for an ability to affect TRRE activity, comprising the steps of:

- a) incubating cells expressing TNF receptor with a polypeptide according to claim 9 in the presence of the substance;
- b) incubating cells expressing TNF receptor with a polypeptide according to claim 9 in the absence of the substance;
- c) measuring any TNF receptor released from the cells in steps a) and b); and
- d) correlating an increase or decrease of the receptor released in step a) relative to that in step b) with an ability of the substance to enhance or diminish TRRE activity.

26. Use of a polypeptide according to any of claims 7-8 or 11-12, in the preparation of a medicament for treatment of the human or animal body by surgery or therapy.

27. Use of a polynucleotide according to any of claims 1-3, 6, or 15 in the preparation of a medicament for treatment of the human or animal body by surgery or therapy.

28. Use of an antibody according to claim 16, in the preparation of a medicament for treatment of the human or animal body by surgery or therapy.

29. Use of a polypeptide according to any of claims 7-8 and 11-12, a polynucleotide according to any of claims 1-3 and 15 or an antibody according to claim 16, in the preparation of a medicament for treatment of a

disease selected from the group consisting of heart failure, cachexia, inflammation, endotoxic shock, arthritis, multiple sclerosis, and sepsis.

30. A method of treating cancer in a subject, comprising increasing signal transduction from TNF into cells at the site of the cancer in the subject according to claim 22 or 23.

31. A method of treating a disease selected from the group consisting of heart failure, cachexia, inflammation, endotoxic shock, arthritis, multiple sclerosis, and sepsis, comprising decreasing signal transduction from TNF into cells at the site of the disease in the subject according to claim 21 or 23.

32. The method of claim 31, comprising administering to the subject an effective amount of the polypeptide of any of claims 7-8 or 11-12.

1/5




Fig. 1

2/5




Fig. 2

3/5





Fig. 3

4/5

Fig. 4



5/5




Fig. 5

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Gatanaga, T.
Granger, G.A.(ii) TITLE OF INVENTION: Factors Altering Tumor Necrosis
Factor Receptor Releasing Enzyme Activity

(iii) NUMBER OF SEQUENCES: 154

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: MORRISON & FOERSTER
(B) STREET: 755 PAGE MILL ROAD
(C) CITY: Palo Alto
(D) STATE: CA
(E) COUNTRY: USA
(F) ZIP: 94304-1018

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: Windows
(D) SOFTWARE: FastSEQ for Windows Version 2.0b

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: USSN 09/081,385
(B) FILING DATE: 014-NOV-1998

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME:
(B) REGISTRATION NUMBER:
(C) REFERENCE/DOCKET NUMBER: 22000-20577.21

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 650-813-5600
(B) TELEFAX: 650-494-0792
(C) TELEX: 706141

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4047 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAGCTTTTTC	CTTTCCTTCC	CCGGGAAAGG	CCGGGGCCAG	AGACCCGCAC	TCGGACCAGG	60
CGGGGGCTGC	GGGGCCAGAG	TGGGCTGGGG	AGGGCTGGGA	GGGCGTCTGG	GGCCGGCTCC	120
TCCAGGCTGG	GGGCCGCCAG	CTCCGGGAAG	GCAGTCCTGG	CCTGCGGATG	GGGCCGCGCG	180
TGGGGCCCGG	CGGGGCGGCC	TCGGGAGGCG	TCCAGGCTGC	GGGAGCGGGA	GGAGCGGCCG	240
TGCGGGCGCC	AGCGCCGTGG	GTGGAGGTTC	CCGTCCCTCC	TGAGGGGCGA	CCAGTGCGTT	300
TGGGACCCGG	GAGCAGAGCC	CGCGCCTCCC	CAGCGCCCTC	CCCGGGGGTC	TCACCGGGTC	360
ACCCGAGAGC	GGAGGCCCCG	GCTCCGCAGA	AACCCGGGGC	GGCCGCGGGG	AAGCAGCGCC	420
CTCAGGCGTC	GGAGGAGCCC	CCAGAAGGAC	CTCGCGCTT	CCCGCCGGGC	TCCGACCGCC	480
TGGGTTCCGT	GCGGGACGGC	CCAGGCCGCC	AGGACCCCCA	AGCGCAGCTC	AGTCTGCGGG	540
GCACGACCCA	GAGGCCAGCA	GCAGAGGACG	GGGCCGGGGC	CGGGAGAGGG	CGGGGAGGGC	600
GCTCCTGGGA	GGTCAAGGCC	AGGGCTAGAC	TTTCAGGGTC	ATGGCCTGGC	CCCTCATCCC	660
CAGGGAGGTG	AGGGGGCTCT	GTGAGCAGAG	GGGGCCCCGG	TGGAGAAGGC	GCTGCTAGCC	720

```

AGGGGCGGGG CAGGAGCCCA GGTGGGACT TAAGGGTGGC TGAAGGGACC CTCAGGCTGC 780
AGGGATAGGG AGGGAAGCTA GGGGTGTGGC TTGGGGAGGT GCTGGGGGAC CGCGGGCGCC 840
CTTTATTCTG AAGCCGAATG TGCTGCCGGA GTCCCCAGTG ACCTAGAAAT CCATTTC AAG 900
ATTTTCAGGA GTTTCAGGTG GAGACAAAGG CCAGGCCAGG GTGAAAATGT GGCAGTGACA 960
GAGTATGGGG TGAGAACCAC GGAGAGAGGA AGTCCCCGAG GCGGATGATG GGACAGAGAG 1020
CGGGGACCAG AATTTTTTAA AACGCATCTG AGATGCGTTT GGCAGACTCA TAGTTGTTTT 1080
CCTTTACGG AGAAAGTGTG GGCAGAAGCC AGCTCTAAAG CCCAGGCTGC CCAGCCTGCA 1140
CTGGCAGAGC TGACGGAAGG CCAGGGCAGA GCCTTCCCTC CCTGTACAG ACATGAGCCC 1200
TGGAGATCTG GAATGAGGCA GATGTGCCCA GGGAAAGCTG ATCCGCCCCG ACCCAGGGCC 1260
CCCCGGGTGC CCCTTTGAGC GTGGAATCGT TGCCAGGTCA TGGCTCCCTG CTATCGAACA 1320
CCGGACACGG GTCGTGTGCT GCACCTGGCA GTTGACAGGAC CGACACCCAC AATGCCTTAA 1380
GAGGTGATGA CTGCCTTCCA GGGGCTGGC TGGCTGACAC TTTGCATGGC TCCTGGAGAA 1440
GAGGGATTGA GTGGAGTCCA CGGGTCATGG CCACGTCCTG GGTGCTGCCT CTGAGGCAGG 1500
GCCCCGCTGG GGTGAGAAGG GGCTGGAGAC AGGTTCTGCG CAGTTCAGCC TCTAACCGGT 1560
GGTCTTCATG CCTAGGAACC CACTGGGGGC TTATGAACT GCAGGTGGCT GAGTCCTTGC 1620
CATGGGGTCT CTCCTTCAGG AGGTCTGGGT GGGGCCGAG ACTGTACCCC ACAAAAGGCT 1680
CCAGGTGAGG CGGATGTGGC CTGGCGTGT GTGGCTCTGG ACCTAGTCTT TGGGCTTGGG 1740
CTGGCGCCCA GGGCCTGGGC TTGAGACAGC TGTGACGAG GCAAGCCATT TACCCCGTTT 1800
GTGGGGACAT TACATCTTCC TAGCTTGGAA CACACAGGCA GCCAGGGTTG TTATCCACAT 1860
TCCTCTCCA TGTCTTCTC TTGAGAACTT TTACCAGGTA TGTACAGGAG TGGGCTCCAC 1920
CAGGGAGACT CAAGTGGAAA GCCCTCATCC TTGCTCTCCA GGAGACAGGA AAACCTATGG 1980
TTACAATTCC AGGGACAAGA GCGATGCATG TGAGGTGTGG CAAATCTCAC TGTTC AACTG 2040
GAGAAATCAG AGACAGCTTC CTGGAGGCGAG TGACACCTGG ACAGGCTTCT CCACAGGAGG 2100
AAGCGAGTGA GAGAAGCCAA CTGGGATGGA CCCATCATGT AGGGGGAACA GTGCGCGCAG 2160
AACCAACAAC CACCCCCACC CTAGGCCAG AGCTCACGGA GAGAGCTGGG CCTCTCGGG 2220
TGACTACATA GTTCCCTGCT GGATCTTAGG TCTGTCTCTT GGGCAGCTCT GCTGAGACCT 2280
CTATGCCTGT TCCAGGCTGC ACCAAGGTTT TGTGACTATT GGTCTGGGGT TGTTTTGCAG 2340
CAACTGAAGT GTTCTGTTGT AAAACAGGCA CTGATTTGCG TGAAGGAAT GCTGTTTGT 2400
CTTGCTGCGA CAAACATTGA GCAGCATTTA GTGGCGGTT TATATCTTGT GGAGTAATGG 2460
GTGTTTTTGA AGTCTGTCTT GGGTACTGCA CATTAAAAGG AATATCATT TCTGAAACAT 2520
TGCTATTTTC CACACCAGAA ATCATATCCT CTGCTGGTC CATGTCTGAA GACCTTACAC 2580
GAGAAAGTCT TAATGTAAGT TTAGTAGAGT CCTTGGATGG AGAACTAAT ATATCATACA 2640
TTGCCGCTT CTCACTCTGC TCTTTTTCAT CCTTGCCTAA TTTCAATTTT TCTGCTTCT 2700
TTTGTCTTCT TTCTGGAGAA TCTAGCAAGA TATCTGGTGG AACATCTCGA GGTGATGAAC 2760
AAGGTAGAGA CTGAGATTGT AGGATTAAAG GTGGTCTTGA GCCTTTAGGA GTTCTTCAC 2820
TTCCAGCAGG GGAGCATACT GGCTGTGGAG ATCTCAAGGG AAAAGATGCA GCATTCTCA 2880
TTGTTGAAGA ATCTCCATCG TCACTACTTA GCCTGTGCAC CATGTGTAGG TAGTCTCAC 2940
TTGAACCATG TTAGGATTA TCAGCATGAT GATTAGCTGA ATTGCCAGAC AACGGACAG 3000
AACTTTTATT ATCATGTATG TTTCTCAAAC CACCTGCAAC AATGGGACTT GATACCGATG 3060
CTTGTGTCAT CTGTGGATGT GTTGTGTAAC TTGAAGGATG GGAATATGGC ATGTATCTCG 3120
CAGGGCTTTG TGGGGCGTAT GGACTAGGCA CTGGGCTATT TTGCTGTGGC ATAAATCTGT 3180
TCCCAGAGCT TGTCTGTGGT GGCACAAACC GGCTGGAGGG GCTATGTGAG ATAGTGGTTT 3240
GTTGATAATT GGAAGATGCA GGACTACTGT GCATGGAATT CTGAGAAAGT TTATACTGAG 3300
ACATCATCAT TCCACTTTGT ACATATCTGT TCTGCATGCT TTTCTCCCTG AAAACATTAG 3360
GACTCCTTGC CAGGACGGCC TGCAACAAGA CTGGTATGTC ACCTTCTGGG TCATCACTGC 3420
CAAGGTTATC TTTCAACTCT ATGTGATCTG TTGATACCTG GTTGGGCTA TGGACAAGCT 3480
GTGAAACCAA ATTGTATCC CTACAAGCCA AAAGGCAGTT CACCTCTTCT GCTATTCTGT 3540
CATTAAAGAG AAGGCTCTTT GTAGTTGTAG CAGGTAAGG AGATGGAAGA GGCAGCTGGT 3600
TCAGGAGGTC TGTGAGACTA GCAATCCCCG CAAGAGTAGT AATGGGGACA TGGGGCATAT 3660
CCCCATTCAT CCTGAATTC TGGAAATGGT TTGCTTATAA AAGTACTTAG TTCAGGTGCC 3720
AGCTGTCAAT ACTTCCCAT TCCCAAACAC TGGGCGAATC GGCCTCTGAA TCCAAGGGGA 3780
GGCCGAGGCC GCTGTGGCGA GAGACTATAA TCCGGGCGCG GAGGGGGGGC GGCTACGGCT 3840
CCTCTTCCGT CTCCTCAGTG CGGGGAACAT GTAGAGCCGG GGGGAGACCA GCCGAGAAGA 3900
CAAAATGTTG CTTCTTCTC CTCCTCCTCC TCCTTCTCCC ACATAGAAAC ACTCACAAC 3960
ACCCGACCAC GGGCCCGAGC TACCGGGGGG GCATCGCCGC GGGCCCGGGA ACCAATTCTC 4020
CTGTCGGCGG GGGCGTCTT TGGATCC 4047

```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 739 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

GGATCCAAAG GTCAAATCC CCACCTGGCA CTGTCCCCGG AGCGGGTGGC GCCCGGCCGG 60
CGCGCGGCCG GGCCTTGGC GCCAGAAGCG AGAGCCCTC GGGGCTCGCC CCCCAGCCTC 120
ACCGGGTCAG TGA AAAAAGC ATCAGAGTAG TGGTATTTCA CCGGCGGCCG GCAGGGCCGG 180
CGGACCCCGC CCGGGCCCC TCGGGGGGAC ACCGGGGGGG CGCGGGGGGC CTCCCACTTA 240

```

TTCTACACCT	CTCATGTCTC	TTCACCGTGC	CAGACTAGAG	TCAAGCTCAA	CAGGGTCTTC	300
TTTCCCCGCT	GATTCCGCCA	AGCCCCGTTC	CTTGGCTGTG	GTTTCGCTGG	ATAGTAGGTA	360
GGGACAGTGG	GAATCTCGTT	CATCCATTCA	TGCGCGTCAC	TAATTAGATG	ACGAGGCATT	420
TGGCTACCTT	AAGAGAGTCA	TAGTTACTCC	CGCCGTTTAC	CCGCGCTTCA	TTGAATTTCT	480
TCACTTTGAC	ATTGAGAGCA	CTGGGCAGAA	ATCACATCGC	GTCACACCCC	GCCGCGGGCC	540
TTGCGATGTC	TTTGTTTTAA	TAAACAGTC	GGATTCCCCT	GGTCCGCACC	AGTTCTAAGT	600
CGGCTGCTAG	GCGCCGGCCG	AAGCGAGGCG	CCGCGCGGAA	CCGCGGCCCC	CGGGGCGGAC	660
CCGCGGGGGG	GACCGGGCCG	CGGCCCTCC	GCCGCTGCC	GCCGCGCCG	CCGCGCGCG	720
CCGAAGAAGA	AGGGGGAAA					739

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 233 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CAAGAGTGGC	GGCCGCAGCA	GGCCCCCGG	GTGCCCGGGC	CCCCCTCGAG	GGGGACAGTG	60
CCCCCGCCGC	GGGGGCCCCG	CGGCGGGCCG	CCGCGGCCCC	CTGCCGCCCC	GACCCTTCTC	120
CCCCCGCCGC	CGCCCCACG	CGGCGCTCCC	CCGGGGAGGG	GGGAGGACGG	GGAGCGGGGG	180
AGAGAGAGAG	AGAGAGAGGG	CGCGGGGTGG	CTCGTGCCGA	ATTCAAAAAG	CTT	233

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2998 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GGATCCAAAG	AATTCGGCAC	GAGGTAGTCA	CGGCTCTTGT	CATTGTTGTA	CTTGACGTTG	60
AGGCTGGTGA	GCTTGGAAAA	GTGATGCGC	AGCGTGCAGC	AGGCGTTGTA	GATGTTCTGC	120
CCGTCCAGCG	ACAGCTTGGC	GTGCTGGGCG	CTCACGGGGT	CCGCATACTG	CAGCAGGGCC	180
TGGAAGTGGT	TGTTCTTGGT	GAAGGTGATG	ATCTTCAACA	CTGTGCCGAA	CTTGGAGAAA	240
ATCTGGTGCA	GCACATCCAG	GGTCACAGGG	TAGAAGAGGT	TCTCCACGAT	GATCCTGAGC	300
ACGGGGCTCT	GCCCGGCCAT	CGCCATCCCT	GCATCCACGG	CCGCGGCCGA	GGCAGCCAAAG	360
GCCAGGTTCC	CCGACTGGAC	CGAGTTTACC	GCCTGCAGGG	CCGCTGGGC	CCGCGCCTGG	420
TTGGGAGAGC	TGTCGGTCTT	CAGCTCCTTG	TGGTTGGAGA	ACTGGATGTA	GATGGGCTGG	480
CCGCGCAGCA	CAGGGGTAC	CGAGGTGTAG	TAGTTCACCA	TGGTATTGGC	AGCCTCCTCC	540
GTGTTTCATCT	CGATGAAGGC	CTGGTTTTTC	CCCTTCAGCA	TCAGGAGGTT	GGTGACCTTC	600
CCAAAGGGCA	GCCCCAGGGA	GATGACTTCC	CCCTCCGTGA	CGTCGATGGG	GAGCTTCCGG	660
ATGTGGATCA	CTCTAGAGGG	GACGCTGCA	CTTCGGCTGT	CACCTTTGAA	CTTCTTGCTG	720
TCATTTCCGT	TTGCTGCAGA	AGCCGAGTTG	CTGCTCATGA	TAAACGGTCC	GTAGTGACA	780
CAAGTAGAGA	AAAGCTCGTC	AGATCCCCCG	TTTGTACCAA	CGGCTATATC	TGGGACAATG	840
CCGTCCATGG	CACACAGAGC	AGACCCGCGG	GGGACGGAGT	GGAGGCGCCG	GAATCCTGGA	900
GCTAGAGCTG	CAGATTGAGT	TGCTGCGTGA	GACGAAGCGC	AAGTATGAGA	GTGCTCTGCA	960
GCTGGGCCGG	GCACTGACAG	CCCACCTCTA	CAGCCTGCTG	CAGACCCAGC	ATGCACTGGG	1020
TGATGCCTTT	GCTGACCTCA	GCCAGAAGTC	CCCAGAGCTT	CAGGAGGAAT	TTGGCTACAA	1080
TGCAGAGACA	CAGAACTAC	TATGCAAGAA	TGGGAAACG	CTGCTAGGAG	CCGTGAACCT	1140
CTTTGTCTCT	AGCATCAACA	CATTGGTCAC	CAAGACCATG	GAAGACACGC	TCATGACTGT	1200
GAAACAGTAT	GAGGCTGCCA	GGCTGGAATA	TGATGCCTAC	CGAACAGACT	TAGAGGAGCT	1260
GAGTCTAGGC	CCCCGGGATG	CAGGGACACG	TGGTCGACTT	GAGAGTGCCC	AGGCCACTTT	1320
CCAGGCCCAT	CGGGACAAGT	ATGAGAAGCT	GCGGGGAGAT	GTGGCCATCA	AGCTCAAGTT	1380
CTTGGAGAAA	AACAAGATCA	AGGTGATGCA	CAAGCAGCTG	CTGCTCTTCC	ACAATGCTGT	1440
GTCCGCCTAC	TTTGCTGGGA	ACCAGAAACA	GCTGGAGCAG	ACCCTGCAGC	AGTTCAACAT	1500
CAAGCTGCGG	CCTCCAGGAG	CTGAGAAACC	CTCCTGGCTA	GAGGAGCAGT	GAGCTGCTCC	1560
CAGGCCAACT	TGGCTATCAA	GAAAGACATT	GGGAAGGGCA	GCCCCAGGGT	GTGGGAGATT	1620
GGACATGGTA	CATCCTTTGT	CACCTTGCCCT	CTGGCTTGGG	CTCCTTTTTC	TGGCTGGGGC	1680
CTGACACCAG	TTTTGCCAC	ATTGCTATGG	TGGGAAGAGG	GCCTGGAGGC	CCAGAAGTTG	1740
CTGCCCTGTC	TATCTTCTTG	GCCACAGGGC	TTCAATCCCA	GATCTTTTCC	TTCCACTTCA	1800
CAGCCAACGG	CTATGACAAA	ACCACTCCCT	GGCCAATGGC	ATCACTCTTC	AGGCTGGGGT	1860
GTGCTCCCTG	ACCAATGACA	GAGCCTGAAA	ATGCCCTGTC	AGCCAATGGC	AGCTCTTCTC	1920
GGACTCCCTT	GGGCAATGA	TGTTGCGTCT	AATACCCTTT	GTCTCTCTCT	TATGCGTGCC	1980
CATTGCAGAG	AAGGGGACTG	GGACCAAGG	GGTGGGGATA	ATGGGGAGCC	CCATTGCTGG	2040

CCTTGCATCT	GAATAGGCCT	ACCCTCACCA	TTTATTCAT	AATACATTTT	ATTTGTGTTT	2100
TCTAATTAA	AATTACCTTT	TCATCTTGCT	TGATTTTCCT	TCAGCTAAAT	TAGAAATTTG	2160
TAGTTTTTCC	CCTAAAAAAT	TCAATGGCAT	TCTTTCTTAT	AAATTACATT	CTCTGATTTT	2220
CTTGTCAGCC	TGCTTCAAGG	AAATCCATGT	GTTCAAAATG	CTTGCTCGCA	GTTTGCTCCA	2280
TACCAATGG	TTGCTTAACC	CAATATCTG	AGCAGCAAT	TGAGCTGATC	CTTCTGGAGA	2340
AAGTACGGTT	GAACAGCCAA	GACCACTGGG	TAGTCGAAGA	GAAGACCACA	CATCCTGAAC	2400
TCCCCAGTCT	GGTGTGAGGG	GAGGACAGCT	GATAACTGGA	TATGCAGTGT	TCCCAGACAT	2460
CACTGGTCCC	AAACCATTAC	TTCTGCCTGC	CACTGCCACA	AATACAGTAG	GAATGCCATC	2520
CCCTTCATAC	TCAGCTTTAA	TCCTCAGAGT	TTTCTCTGGT	CCTTTATGCG	CAGATGTTAC	2580
TCGAAGTTCA	CATGGAATGC	CAAAATTTCC	ACAGGCCTTC	TTGATTTTTT	CACAGTGACC	2640
AAGATCAGAA	GTAGAGCCCA	TCAACACTAC	AACCCCTGCAC	TGACTTTCTG	ATTTCAAAG	2700
CAACTCTACT	CTCTCTGCAA	CCCACTCAAA	GTTTTCTTT	ACCATTTGGA	GCCCTTCAGG	2760
AGTTACTTCT	TTGAGGTCCC	GATAAGACTG	TTTGTCTTTC	TGTTGGCTTC	GATCTCCTGA	2820
TGGCCAGAGT	TCACAGGAAT	CATTGTCAAT	AACATCAGCA	AGAAACAATTT	CTTTGGTGGT	2880
TACATCAACA	CCAAATTCAA	TCTTCATATC	AACCACTGTA	CAATTCTGGG	GCAACCAGGA	2940
TTTCTCCAGT	ATTTCAAATA	TAGCCTGTGT	AGCATCTCGT	GCCGAATTCA	AAAAGCTT	2998

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4152 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AAGCTTTTTG	TGAAAACCTT	AGGATATGTC	CCCTCCCTCA	CCACACCCAA	CCCCCGCCCC	60
CTGCCCCAGG	ACATGACGAT	GCCTCACACA	CACACACACA	CACACATACA	CACAAGGCCG	120
TGAGCTGCAC	GCAGGAACAT	GGGCTGCACT	CACGACAACA	TTGAAAAAAT	ATACATTATA	180
TATGTACACC	CGGGGCCCCC	ACGTCCCTTC	CCGTCCCCGC	AGCCTGGCCA	CACCAGGTCA	240
CGGAGGAGGG	GCCGGGGCTG	CAGGACCTCA	GGACTGCAAG	GGCAGGAAGG	GAACACAGGAC	300
AAGAAAGGAA	GGAAGTTGGA	AAGGAGGGAG	AAATGGGGTC	CCCAGACTGA	AATGGAAATG	360
AGGTGGGGCG	ATCATAAGAG	AAGCAGGGAC	GATGGTCCAG	CTGAGGGAGC	CCTGCAGAGG	420
GGGAAAGCTT	TCCCATGGAC	AGGAGAGAGA	AGGGAAGGGG	AGAGGAGAGG	GTTTCCTTCA	480
ATCCCAACCC	CAGCCCCAGC	CCCAGCCCCA	GCCATTGCAA	TCGTCACCTT	CTCCCCAACA	540
CAGTGAGTGC	TAAGGGGGCA	GCTGCCATTG	GGGGTGAAGA	GGCAGCTGAA	GTCCAGCCCA	600
CTTTCCAACC	CAGCCAGCCC	CAGTGCAAGG	GGCACACCAG	GAGCATGACA	GCCCAGAAAT	660
GAGGGATGGG	GGGCCGGGGG	AGGGGCAGGG	CGGACTCCAG	AGGGCCCCGT	GGGGTTTTGA	720
AATGAAAGAG	GGACTGGTTC	TGAAGCCTCT	CTCCCTCTTG	GTCTCTGTGT	TCCCAGAAAG	780
TCCTTCTCCC	ATGTCTGGAG	TGTCTGTTTC	ACCAGGGCAG	AATTCCCCCT	CTGCGTGGGG	840
AGAGGTGTAG	GCCTTAGTAG	CGGTGTGGGG	GGGTCTCGAT	GATGCGTCTC	TCGTCGCTGC	900
TGGGGGAATC	GGCCACCTCC	GAGTCACTGC	TGTCCTCATC	CTCCTGCTGG	CCCCCAACAG	960
CCCCCGTCAC	ACAGGACTGC	CGATTCTGGT	AGGACTCCAT	GGGGTTTACA	ATGATGGTGA	1020
GAGCTGAGTC	ATCCCAAGAG	AGGTCTGGGT	CCTTGGGGTC	ACTGGAGGCC	CCTGGAGGCC	1080
CGCCGGCCCC	TGAGACGCGG	CGGTGAAGGG	AATGGATGCG	CACCAGGCCC	AGGACGACCA	1140
TGAGCACCCAG	GAAGCCCACG	CACACCACAA	TGATGAGGGT	TGCGGCGCTG	GGTATCATGG	1200
AGTTTCTGTG	GGAGCTGGCT	AGGCTGTGTC	CAGCCATCTC	AGGCGGGGGC	TGGTGACCA	1260
GGTGCAGGAA	CTGCTGGGAG	CTGAGCACGT	GGCTGGGGTG	GGCAACCCGG	TTCATGCTGT	1320
GCAGGACATT	GACCTCCACG	ATGAATTCA	TGCTGGAGTA	ACGGCCATTC	ATTTCCGAGC	1380
AGGAAAGCCG	GAACCTTCTG	GTGTAGAGGG	CAGCTCCGTG	TGCGAGCCGA	TAACGAGCCT	1440
GCCTCAGGAT	CTCTTCATAC	ACAGTGATGC	TCTCCACCCC	AGCAATAGTG	AGGTAGGCAG	1500
ATGTGTTGGT	GAGCTCCAGC	CCCCGCTGCT	GCAGAGAGGT	TGTGTCCAGG	AGCAGGCTTT	1560
CCCGCTCGGG	ATCCAGGTCA	TCCCCACCA	GAGAAATTTT	ACAGCCATCC	AGGTTGTGCA	1620
CAATCTCATC	CGACATGCGT	GTGTCTGTCA	CTGTGCCCTG	CCAACCTCTA	TCCTTTTTGG	1680
CCTCCACCTG	GTGAGAAATG	GAGCAGGTGA	TTTGAAGATC	AGGGAACAAA	GGGACGCCGT	1740
TGGTTCCTTC	AAAGTCCACA	GCTGGGCGGG	CAAAATGAGC	AGTGCCACTC	AGCAGGATCT	1800
GGGGGGCGTC	AGGCTGAAGG	ACGACCACGT	AGCCCTCCAC	TTCAGGGATG	GAGACGCAAG	1860
ACTCTTCGCT	GAAGCACTTG	ACAGCAGTGG	TGAGGCGCAG	GGGCCTGACG	CCGGGCGTGG	1920
CAAGAGCCAG	AGTGTTCATG	TAAGCCACAT	GCTGCAGGGC	ATGGTTGAAG	GTCTCCACAT	1980
CATCCCCCTC	CAGGGTGAGC	AGGGACTGTG	AGGGGTTTAC	GTGGACCTTC	ATGCCTTTGC	2040
CCAGGCTCTC	GAAATCCCTA	TAGTCCAGCC	CCTCCCGACA	TGCATAGAGG	CACTCGATGA	2100
CCTCGCGGCT	CTCCAGGCGA	CCTGAGCGCA	CGTGAAACC	AGCCAGGTAG	CCATGGAAGT	2160
AGTGGTGGAT	CGACAAAGGG	TCTCCTTGGG	TGGTGTCTGT	ACTGTTGTCT	CCCTTTTCCT	2220
TCTCTTTGTT	CTTCTCTCTA	GTCCAGCAGG	CCCCAATCAT	GAGAGCAGGC	TCCCTTCGGG	2280
GTGGGTGGAT	GAGGCCATTG	TCATGGATGA	GGGCAGGGTC	GAAGGAGATG	CCGTGCGTAT	2340
AGAGTGTGAC	TGTGGGGAAC	TCGAGGTTCA	GAGCGTAGTG	GTGCCACTCA	TCATCACAGA	2400
CCTGCTCCAG	CTTCCAGAGG	AACCTTCACT	GGCGGGCACT	CTCAAGCAGG	GGCCAGTAGA	2460
GGAAGGCAAT	CCTACAGCCG	TGGACAGTCA	GCGAGTAGTG	AGAGAAGCCG	TCCTCATTTCT	2520
GGACAGTGTT	ACATACGATG	GTTTCTCTCT	CCTTCTTGCC	CTTGTGGGGA	GTTACGCCAT	2580
GCTTCATCCA	GAAGGACAGG	GTGAAGTGGT	CACTGAGGCT	GTCCTGGGGC	CCAGAGCCCA	2640

GCCCACTGGG	GCCACCCAGG	GGCACCTGCA	CAGCCTGGGT	GCCATTGAAC	CAGTAGATCA	2700
GGCTGCTGTC	CTGGCTGTAG	TGCACCGAGA	GTCTGTCTGT	CCAGTTGGCA	TTGGGGCCAG	2760
GCATGGGGCAA	CAGATCCACT	TCCCCAGTGG	CAGCACCACA	GAGTTTCCGC	AGCGCCCGCT	2820
CTGAGTAGTT	GTACCGGTCA	CAGCCCTTGG	CCACATGGCT	GGTCTGCAGC	TCTATGGTGG	2880
CCTGAATGTT	CCAGAGTGGT	TCATCACAGG	TCTCCAGGCG	GATACCAGGG	AACAAAGCCA	2940
AGCTCCACGC	ACCTGGTGCA	TATTCGATCC	TTTTGTTCCA	GCCTTGCCAG	CTGGGTTTAC	3000
AGGTGGGCTT	CACCTGAATC	TCCACCTCAG	CATCATCTGC	TGCCCGCTTC	TTCCACAGT	3060
CATAAGCTGT	CACGTAAAC	TTATAGAGCC	TCTCACCCT	GTACTGCAGC	TTCTCTGTGT	3120
TCTCAATGTT	CCCGTCATTG	TCAATGAGGA	AAGGGGTGTT	GGGTGTGAGA	ATCTCATAGT	3180
AGCAGATCTG	GCTGTACTGG	GGGGAGCAGT	CACCGTCAAT	GGCTTCCACC	CGCAGGATGC	3240
GATCGTACAG	CTTCCCCTCT	GTACACGCGG	CACGATACAG	CCGTTCCACA	AACACTGGGG	3300
CAAACTCGTT	CACATCGTTG	ACCCGCACAT	GCACAGTGGC	CTTGTGGGAC	TTCTTGGTGT	3360
TGGCCCCGTC	GGGGCCCTCG	CCACAGTCAT	AGGCCTGGAT	GGTGAAGGTG	TGTTCCCTCT	3420
GGGCCCTCGCA	GTCCACAGGC	TCCTTGGCCC	GGATCAGCCC	CTCTCCTGTC	GCCTTGTCAA	3480
GGATCACAGC	CTCAAAGGGC	ACCCAGAGCC	CATGGAGCCG	GAAGCCGAG	ATCTCACCTG	3540
CATAGCGCAG	CGGGGCATCC	TTGTCCAAGG	CAAAGAGTGG	TGGATTCACT	AGGACCGTGT	3600
TGTCATTTCT	CATGACGATG	CCCTGGTACT	CTGCCTCAAT	CCATGGCTTG	TGCTTGTGG	3660
CTTTGTTACA	GGAGCAGGAC	GCGAGCAGAG	AGGCCAGCAG	AAGGGGCAGC	AGCAGGAGGG	3720
TCATGGTGGC	GCGTGGGGCA	GGGCAGGGCC	AGGCGTTTGC	CTCCCTGGG	AGCCTCCAGC	3780
CTGCGGATTC	CACCTTGGCG	GAGGGATACA	GGGGGGGAAA	ACCAAAATAA	AACGTCAAAT	3840
AAATTGTGTA	GGAGGAGTCC	AGCTTAGGAC	CGGGCCAGAG	CCAGGCCAGG	CTCGGGGAGG	3900
GGGCCCTGTC	AGGTTTCAGAG	GATCACTGCT	GCCACCACCG	CCACCTGGG	AGCCAGTTAT	3960
TTTGCCATGG	CTTTGATTGC	AACAGCTGCC	TCCTCTGTCA	TGGCAGACAG	CACCGTGATC	4020
AGGATCTCTT	CTCCACAGTC	GTACTTCTGC	TCAATCTCCT	TGCCAAGGTC	TCCCTCAGGG	4080
AGACGAAGGT	CCTCTCGTAC	CTCCCCGCTG	TCCTGGAGCA	GTGATAGGTA	CCCATCCTGG	4140
ATCTTTGGAT	CC					4152

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3117 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GGATCCAAAG	ATTCGGCAGC	AGTGGCCACA	TCATGAACCT	CCAGGCCAG	CCCAAGGCTC	60
AGAACAAGCG	GAAGCGTTGC	CTCTTTGGGG	GCCAGGAACC	AGCTCCCAAG	GAGCAGCCCC	120
CTCCCCTGCA	GCCCCCCCAG	CAGTCCATCA	GAGTGAAGGA	GGAGCAGTAC	CTCGGGCAGC	180
AGGGTCCAGG	AGGGGCAGTC	TCCACCTCTC	AGCCTGTGGA	ACTGCCCCCT	CCTAGCAGCC	240
TGGCCCTGCT	GAAGTCTGTG	GTGTATGGGC	CTGAGCGGAC	CTCAGCAGCC	ATGCTGTCCC	300
AGCAGGTGGC	CTCAGTAAAG	TGGCCCAACT	CTGTGATGGC	TCCAGGGCGG	GGCCCGGAGC	360
GTGGAGGAGG	TGGGGGTGTC	AGTGACAGCA	GCTGGCAGCA	GCAGCCAGGC	CAGCCTCCAC	420
CCCATTCAAC	ATGGAAGTGC	CACAGTCTGT	CCCTCTACAG	TGCAACCAAG	GGGAGCCCGC	480
ATCCTGGAGT	GGGAGTCCCG	ACTTACTATA	ACCACCCTGA	GGCACTGAAG	CGGGAGAAAG	540
CGGGGGGGCC	ACAGCTGGAC	CGCTATGTGC	GACCAATGAT	GCCACAGAG	GTGCAGCTGG	600
AGGTAGGGCG	GCCCCAGGCA	CCCCTGAATT	CTTCCACGC	AGCCAAGAAA	CCCCCAAACC	660
AGTCACTGCC	CCTGCAACCC	TTCCAGCTGG	CATTGCGCCA	CCAGGTGAAC	CGGCAGGTCT	720
TCCGGCAGGG	CCCACCGCCC	CCAACCCCGG	TGGCTGCCTT	CCCTCCACAG	AAGCAGCAGC	780
AGCAGCAGCA	ACCACAGCAG	CAGCAGCAGC	AGCAGCAGGC	AGCCCTACCC	CAGATGCCGC	840
TCTTTGAGAA	CTTCTATTCC	ATGCCACAGC	AACCCCTCGCA	GCAACCCAG	GACTTTGGCC	900
TGCAGCCAGC	TGGGCCACTG	GGACAGTCCC	ACCTGGCTCA	CCACAGCATG	GCACCTACC	960
CCTTCCCCCC	CAACCCAGAT	ATGAACCCAG	AACTGCGCAA	GGCCCTTCTG	CAGGACTCAG	1020
CCCCGCGAGC	AGCGCTACCT	CAGGTCCAGA	TCCCCTTCCC	CGCGCGCTCC	CGCCGCTCT	1080
CTAAGGAGGG	TATCCTGCCT	CCCAGCGCCC	TGGATGGGGC	TGGCACCCAG	CCTGGGCAGG	1140
AGGCCACTGG	CAACCTGTTT	CTACATCACT	GGCCCCGTGA	GCAGCCGCCA	CCTGGCTCCC	1200
TGGGGCAGCC	CCATCCTGAA	GCTCTGGGAT	TCCCGCTGGA	GCTGAGGGAG	TCGCAGCTAC	1260
TGCTGTATGG	GGAGAGACTA	GCACCAATG	GCGGGAGCG	AGAGGCTCCT	GCCATGGGCA	1320
GCGAGGAGGG	CATGAGGGCA	GTGAGCACAG	GGGACTGTGG	GCAGGTGCTA	CGGGGCGGAG	1380
TGATCCAGAG	CACGCGACGG	AGGCGCCGGG	CATCCAGGA	GGCCAATTTC	CTGACCCTGG	1440
CCCAGAAAGC	TGTGGAGCTG	GCCTCACTGC	AGAATGCAAA	GGATGGCAGT	GGTTCTGAAG	1500
AGAAAGCGAA	AAGTGTATTG	GCCTCAACTA	CCAAGTGTGG	GGTGGAGTTT	TCTGAGCCTT	1560
CCTTAGCCAC	CAAGCGAGCA	CGAGAAGACA	GTGGGATGGT	ACCCCTCATC	ATCCCACTGT	1620
CTGTGCTCTG	GCGAAGTGTG	GACCCAACTG	AGGCAGCCCA	GGCTGGAGGT	CTTGATGAGG	1680
ACGGGAAGGG	TCTTGAACAG	AACCTGTCTG	AGCACAAGCC	ATCAGTCATC	GTACCCGCA	1740
GGCGGTCCAC	CCGAATCCCC	GGGACAGATG	CTCAAGCTCA	GGCGGAGGAC	ATGAATGTCA	1800
AGTTGGAGGG	GGAGCCTTCC	GTGCGGAAAC	CAAAGCAGCG	GCCCAGGCC	GAGCCCTCA	1860
TCATCCCCAC	CAAGGCGGGG	ACTTTCATCG	CCCCTCCCGT	CTACTCCAAC	ATCACCCTAT	1920
ACCAGAGCCA	CCTGCGCTCT	CCCGTGGGCC	TAGCTGACCA	CCCCTCTGAG	CGGAGCTTTG	1980
AGTACCTCC	CTACACGCCG	CCCCCATCC	TCAGCCCTGT	GCGGGAAGGC	TCTGGCCTCT	2040

ACTTCAATGC	CATCATATCA	ACCAGCACCA	TCCCTGCCCC	TCCTCCCATC	ACGCCTAAGA	2100
GTGCCCATCG	CACGCTGCTC	CGGACTAACA	GTGCTGAAGT	AACCCCGCCT	GTCTCTCTG	2160
TGATGGGGGA	GGCCACCCCA	GTGAGCATCG	AGCCACGGAT	CAACGTGGGC	TCCCGGTTCC	2220
AGGCAGAAAT	CCCTTGATG	AGGGACCGTG	CCCTGGCAGC	TGCAGATCCC	CACAAGGCTG	2280
ACTTGGTGTG	GCAGCCATGG	GAGGACCTAG	AGAGCAGCCG	GGAGAAGCAG	AGGCAAGTGG	2340
AAGACCTGCT	GACAGCCGCC	TGCTCCAGCA	TTTTCCCTGG	TGCTGGCACC	AACCAGGAGC	2400
TGGCCCTGCA	CTGTCTGCAC	GAATCCAGAG	GAGACATCCT	GGAAACGCTG	AATAAGCTGC	2460
TGCTGAAGAA	GCCCCGCGG	CCCCACAACC	ATCCGCTGGC	AACCTATCAC	TACACAGGCT	2520
CTGACCAGTG	GAAGATGGCC	GAGAGGAAGC	TGTTCAACAA	AGGCATTGCC	ATCTACAAGA	2580
AGGATTTCTT	CCTGGTGAG	AAGCTGATCC	AGACCAAGAC	CGTGGCCCG	TGCGTGGAGT	2640
TCTACTACAC	CTACAAGAAG	CAGGTGAAAA	TCGGCCGCAA	TGGGACTCTA	ACCTTTGGGG	2700
ATGTGGATAC	GAGCGATGAG	AAGTCGGCCC	AGGAAGAGGT	TGAAGTGGAT	ATTAAGACTT	2760
CCCAAAGGTT	CCCAAGGGTG	CCTCTTCCCA	GAAGAGAGTC	CCCAAGTGAA	GAGAGGCTGG	2820
AGCCCAAGAG	GGAGGTGAAG	GAGCCAGGA	AGGAGGGGGA	GGAGGAGGTG	CCAGAGATCC	2880
AAGAGAAGGA	GGAGCAGGAA	GAGGGGCGAG	AGCGCAGCAG	GCGGGCAGCG	GCAGTCAAAG	2940
CCACGCAGAC	ACTACAGGCC	AATGAGTCGG	CCAGTGACAT	CCTCATCCTC	CGGAGCCACG	3000
AGTCCAACGC	CCCTGGGTCT	GCCGGTGGCC	AGGCCTCGGA	GAAGCCAAGG	GAAGGGACAG	3060
GGAAATCAGC	AAGGGCACTA	CCTTTTTCAG	AAAAAAAAAA	AAAAAACAA	AAAGCTT	3117

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3306 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GAATTCGGCA	CGAGGTCAGT	TTCCTGTGGA	ACACAGAGGC	TGCCTGTCCC	ATTCAGACAA	60
CGACGGATAC	AGACCAGGCT	TGCTCTATAA	GGGATCCCAA	CAGTGGATTT	GTGTTTAATC	120
TTAATCCGCT	AAACAGTTCG	CAAGGATATA	ACGTCTCTGG	CATTGGGAAG	ATTTTTATGT	180
TTAATGTCTG	CGGCACAATG	CCTGTCTGTG	GGACCATCCT	GGGAAACCT	GCTTCTGGCT	240
GTGAGGCAGA	AACCCAAACT	GAAGAGCTCA	AGAATTGGAA	GCCAGCAAGG	CCAGTCGGAA	300
TTGAGAAAG	CCTCCAGCTG	TCCACAGAGG	GCTTCATCAC	TCTGACCTAC	AAAGGGCCTC	360
TCTCTGCCAA	AGGTACCGCT	GATGCTTTTA	TCGTCCGCTT	TGTTTGCAAT	GATGATGTTT	420
ACTCAGGGCC	CCTCAAAATC	CTGCATCAAG	ATATCGACTC	TGGGCAAGGG	ATCCGAAACA	480
CTTACTTTGA	GTTTGAACC	GCGTTGGCCT	GTGTTCTTTC	TCCAGTGGAC	TGCCAAGTCA	540
CCGACCTGGC	TGGAAATGAG	TACGACCTGA	CTGGCCTAAG	CACAGTCAGG	AAACCTTGGA	600
CGGCTGTTGA	CACCTCTGTC	GATGGGAGAA	AGAGGACTTT	CTATTTGAGC	GTTTGCAATC	660
CTCTCCCTTA	CATTCTGGGA	TGCCAGGGCA	GCGCAGTGGG	GTCTTGCTTA	GTGTCAGAAG	720
GCAATAGCTG	GAATCTGGGT	GTGGTGAGAA	TGAGTCCCA	AGCCGCGGCG	AATGGATCTT	780
TGAGCATCAT	GTATGTCAAC	GGTGACAAGT	GTGGGAACCA	GCGCTTCTCC	ACCAGGATCA	840
CGTTTGAGTG	TGCTCAGATA	TCGGGCTCAC	CAGCATTTCA	GCTTCAGGAT	GGTTGTGAGT	900
ACGTGTTTAT	CTGGAGAACT	GTGGAAGCCT	GTCCCGTTGT	CAGAGTGGAA	GGGGACAACCT	960
GTGAGGTGAA	AGACCCAAGG	CATGGCAACT	TGTATGACCT	GAAGCCCTTG	GGCCTCAACG	1020
ACACCATCGT	GAGCGCTGGC	GAATACACTT	ATTACTTCCG	GGTCTGTGGG	AAGCTTTCTT	1080
CAGACGCTCG	CCCCACAAGT	GACAAGTCCA	AGGTGGTCTC	CTCATGTCAG	GAAAAGCGGG	1140
AACCCGAGGG	ATTTCAACAA	GTGGCAGGTC	TCCTGACTCA	GAAGCTAACT	TATGAAAATG	1200
GCTTGTTAAA	AATGAACCTC	ACGGGGGGGG	ACACTTGCCA	TAAGGTTTAT	CAGCGCTCCA	1260
CAGCCATCTT	CTTCTACTGT	GACCGCGGCA	CCCAGCGGCC	AGTATTCTTA	AAGGAGACTT	1320
CAGATTGTTC	CTACTTGTTT	GAGTGGCGAA	GCGAGTATGC	CTGCCCACCT	TTGATCTGTA	1380
CTGAATGTTC	ATTCAAAGAT	GGGGCTGGCA	ACTCCTTCGA	CCTCTCGTCC	CTGTCAAGGT	1440
ACAGTGACAA	CTGGGAAGCC	ATCACTGGGA	CGGGGGACCC	GGAGCACTAC	CTCATCAATG	1500
TCTGCAAGTC	TCTGGCCCCG	CAGGCTGGCA	CTGAGCCGTG	CCCTCCAGAA	GCAGCCGCGT	1560
GTCTGCTGGG	TGGTCCAAG	CCCGTGAACC	TCGGCAGGGT	AAGGGACGGA	CCTCAGTGGA	1620
GAGATGGCAT	AATTGTCCTG	AAATACGTTG	ATGGCGACTT	ATGTCCAGAT	GGGATTCGGA	1680
AAAAGTCAAC	CACCATCCGA	TTCACCTGCA	GCGAGAGCCA	AGTGAACCTC	AGGCCCATGT	1740
TCATCAGCCG	CGTGGAGGAC	TGTGAGTACA	CCTTTGCTTG	GCCCAAGGCC	ACAGCCTGTC	1800
CCATGAAGAG	CAACGAGCAT	GATGACTGCC	AGGTCACCAA	CCCAAGCACA	GGACACCTGT	1860
TTGATCTGAG	CTCCTTAAGT	GGCAGGGCGG	GATTCACAGC	TGCTTACAGC	GAGAAGGGGT	1920
TGTTTACAT	GAGCATCTGT	GGGGAGAATG	AAAAGTCCCC	TCCTGGCGTG	GGGGCCTGCT	1980
TTGGACAGAC	CAGGATTAGC	GTGGGCAAGG	CCAACAAGAG	GCTGAGATAC	GTGGACCAGG	2040
TCCTGCAGCT	GGTGTACAAG	GATGGGTCCC	CTTGTCCCTC	CAAATCCGGC	CTGAGCTATA	2100
AGAGTGTGAT	CAGTTTCGTG	TGCAGGCCCTG	AGGCCGGGCC	AACCAATAGG	CCCATGCTCA	2160
TCTCCCTGGA	CAAGCAGACA	TGCACTCTCT	TCTTCTCCTG	GCACACGCCG	CTGGCCTGCG	2220
AGCAAGCGAC	CGAATGTTCC	GTGAGGAATG	GAAGCTCTAT	TGTTGACTTG	TCTCCCTTAA	2280
TTTCATCGAC	TGGTGGTTAT	GAGGCTTATG	ATGAGAGTGA	GGATGATGCC	TCCGATACCA	2340
ACCCTGATTT	CTACATCAAT	ATTTGTGAGC	CACTAAATCC	CATGCACGGA	GTGCCCTGTC	2400
CTGCCGAGGC	GCTGTGTGCG	AAAGTTCCTA	TTGATGGTCC	CCCATAGAT	ATCGGCCGGG	2460
TAGCAGGACC	ACCAATACTC	AATCCAATAG	CAAATGAGAT	TTACTTGAAT	TTTGAAAGCA	2520

GTACTCCTTG	CCAGGAATTC	AGTTGTAAAT	AAAATTGAAC	CTGCTCAACA	GCTGAGGGAG	2580
ACTAGAAATG	ATGGGTCCAT	ATCCTGGTGC	ATTGTCATAC	AATTCAAACA	ATGGTGCAGC	2640
TACCAGCTTG	TAATTTTTAG	GGACTGCAAA	CAAGGCTTTT	TCTTGAAGCT	GAACCAGAAA	2700
CAACTTCTTA	TGTTCTTAG	GCTTTGTAAT	ATGTGCAGGA	ATATATGGAT	ACTGAGGAGG	2760
TTCAAAATTT	GGTCTCCACC	AGTTACCAAT	GCAATCGTCA	ATGACCCAGT	CTTGCAAAAC	2820
TCCATCCTGA	CGACCCAGTA	TCTCTGTCAT	TAAGCGTTTT	AGTCTTCAA	CTTCATCTTC	2880
TCCTGGGTTA	AGTTCACCAC	CAGGTAGTTT	GAAGAAAGTT	GTTCCAGCT	GCAGCAGTAA	2940
CACATGGGGT	AGCCGGTGCT	CATGTACAAT	CAGAACCCCT	TCTACAGTCC	TCCTCATTC	3000
AATTTTATCA	AATTCTTCCC	TCATGCGCTG	AAATCTGGCT	GCAACAGAGC	TGTCCTTCTC	3060
GTAGAGGGGC	TCITTTGTAC	CAAAAGTATA	ATTGTAAGA	GGGTACAGGT	TGATGGTGG	3120
CTCCAGGGTG	AGGGGCTTCG	TCTGCTGGAT	GTACTTGTG	CCGAACTGAG	TGACCCCCCG	3180
GGGCCAGCCG	GTCTGCGAGC	GATTGGGCGG	TACCACAGAC	ATGCTGGCGA	GCTCCGGCGC	3240
TGACGGCGAG	CAGAAAGTGG	CAGGCAGGGT	AGACTTTCCC	CGTGGGGGAA	GCCTCGTGCC	3300
GAATTC						3306

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4218 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GAATTCGGCA	CGAGAATGGA	TCAACCTCAA	CAACACGTTA	AAGCTAGACG	AAAGAAGTAA	60
TACACAGTGT	ATGAGTCTCA	CATGAAATAC	CCGGATGTAA	ATCCAAAGAA	ACAGGAAGCA	120
GATTGGTGGT	TGCCAGGGAC	AAGGGCGGTG	GGAGGAGAAA	ATGGAGAGTA	ACGGGACTTT	180
ACTTTTGGAG	TGATGAGAAT	GTTTTGGAGC	TAGATAGAAG	TGGTGGTTGT	ACACCATTGT	240
GGATGTACTA	CCACTTAATT	GTTCACTTAA	AAAGTTAATT	TATGTGAATT	GCATCTTAAT	300
TAAAAACAAG	GATAACATTC	CAACTCCTGG	ACATTATCCT	TCCTTTCCAT	TTGATGTCAG	360
GCCCGTGTTA	GAATTCTCAT	CCGGTTTGGT	CACTGCACTT	AAGATGTGGA	GAAATTAGGA	420
CGCACAGTTA	AGAGGAAGGA	TAACACTGAT	TAAGGTAGTG	CTTTTCTAGG	TTTCCCCCTAA	480
ACAATTTAAC	AGATGGATAG	TGGCACCAC	TACGAGATGG	AAAAACCAGC	GGAAGGAAGA	540
TTTGGGGGAG	AAGTTAAGTT	TGCTTTGGGC	CTGTGTTTTG	CAACCTGAGT	GTAAGAGACA	600
TATGTTAAGT	CTTCAGTGGC	GAAACACTAA	AACTAGAAAT	GGATCAGAAT	TTTATCTTTG	660
GATGTGACTT	CTCAAGGATG	GTCTTGTAC	TTCAGTGCCT	GGTCAAATGA	CAAGATGGGC	720
AATCTTTTCC	TGAAGGTCCA	AGCACCTGAA	CGTGGCAGGG	TGACCCGATT	CCGATTTGCT	780
TAGACAATAT	CTAGTTCATG	CCTATTGTCC	CTCATGTAAT	TAATATCACT	CTCAAAATGT	840
CTCATTITGT	GCAATAAATT	CTGCAACGTG	ATGGCGGAC	TCTCGCGGCC	CGAGCGGCCG	900
GACCTTGTCT	TCGAGGAAGA	GGACCTCCCC	TATGAGGAGG	AAATCATGCG	GAACCAATTC	960
TCTGTCAAAT	GCTGGCTTCA	CTACATCGAG	TTCAAACAGG	GCGCCCCGAA	GCCCAGGCTC	1020
AATCAGCTAT	ACGAGCGGGC	ACTCAAGCTG	CTGCCCTGCA	GCTACAAACT	CTGGTACCGA	1080
TACCTGAAGG	CGCGTCGGGC	ACAGGTGAAG	CATCGCTGTG	TGACCGACCC	TGCCTATGAA	1140
GATGTCAACA	ACTGTCTATG	GAGGGCCTTT	GTGTTTCATG	ACAAGATGCC	TCGTCTGTGG	1200
CTAGATTACT	GCCAGTTTCT	CATGGACCAG	GGGCGCGTCA	CACACACCCG	CCGCACCTTC	1260
GACCGTGCCC	TCCGGGCACT	GCCCCATCAG	CAGCACTCTC	GAATTTGGCC	CCTGTATCTG	1320
CGCTTCTCTG	GCTCACACCC	ACTGCCTGAG	ACAGCTGTGC	GAGGCTATCG	GCGCTTCTCT	1380
AAGCTGAGTC	CTGAGAGTGC	AGAGGAGTAC	ATTGAGTACC	TCAAGTCAAG	TGACCGGCTG	1440
GATGAGGCCG	CCCAGCGCCT	GGCCACCGTG	GTGAACGACG	AGCGTTTCGT	GTCTAAGGCC	1500
GGCAAGTCCA	ACTACCAGCT	GTGGCACGAG	CTGTGCGACC	TCATCTCCCA	GAATCCGGAC	1560
AAGGTACAGT	CCCTCAATGT	GGACGCCATC	ATCCGCGGGG	GCCTCACCCG	CTTCACCGAC	1620
CAGCTGGGCA	AGCTCTGGTG	TTCTCTCGCC	GACTACTACA	TCCGCAGCGG	CCATTTTCGAG	1680
AAGGCTCGGG	ACGTGTACGA	GGAGGCCATC	CGGACAGTGA	TGACCGTGCG	GGACTTCACA	1740
CAGGTGTTTT	ACAGCTACGC	CCAGTTCGAG	GAGAGCATGA	TGCTGCAAAA	GATGGAGACC	1800
GCCTCGGAGC	TGGGGCGCGA	GGAGGAGGAT	GATGTGGACC	TGGAGCTGCG	CCTGGCCCCG	1860
TTCCAGCAGC	TCATCAGCCG	GCGGCCCTTG	CTCCTCAACA	CGCTCTTGCT	GCGCCAAAAC	1920
CCACACCACG	TGCACGAGTG	GCACAAGCGT	GTGCCCCCTG	ACCAGGGCCG	CCCCCGGGAG	1980
ATCATCAACA	CCTACACAGA	GGCTGTGCGA	ACGGTGGACC	CCTTCAAGGC	CACAGGCAAG	2040
CCCCCACTC	TGTGGGTGGC	GTTTGCCAAG	TTTATGAGG	ACAACGGACA	GCTGGACGAT	2100
GCCCGTGTCA	TCCTGGAGAA	GGCCACCAAG	GTGAACCTCA	AGCAGGTGGA	TGACCTGGCA	2160
AGCGTGTGGT	GTCAGTGCGG	AGAGCTGGAG	CTCCGACACG	AGAACTACGA	TGAGGCCTTG	2220
CGGCTGCTGC	GAAAGGCCAC	GGCGCTGCCT	GCCCCGCCGG	CCGAGTACTT	TGATGGTTCA	2280
GAGCCCGTGC	AGAACCCTGT	GTACAAGTCA	CTGAAGGTCT	GGTCCATGCT	CGCCGACCTG	2340
GAGGAGAGCC	TCGGCACCTT	CCAGTCCACC	AAGGCCGTGT	ACGACCCCAT	CCTGGACCTG	2400
CGTATCGCAA	CACCCAGAT	CGTCATCAAC	TATGCCATGT	TCCTGGAGGA	GCACAAGTAC	2460
TTCCAGGAGA	GCTTCAAGGC	GTACGAGCGC	GGCATCTCGC	TGTTCAAGTG	GCCCAACGTG	2520
TCCGACATCT	GGAGCACCTA	CCTGACCAAA	TTCATTGCCC	GCTATGGGGG	CCGCAAGCTG	2580
GAGCGGGCAC	GGGACCTGTT	TGAACAGGCT	CTGGACGGCT	GCCCCCAAAA	ATATGCCAAG	2640
ACCTTGTACC	TGCTGTACGC	ACAGCTGGAG	GAGGAGTGGG	GCCTGGCCCC	GCATGCCATG	2700
GCCGTGTACG	AGCGTGCCAC	CAGGGCCCTG	GAGCCCCGCC	AGCAGTATGA	CATGTTCAAC	2760

ATCTACATCA	AGCGGGCGGC	CGAGATCTAT	GGGGTCACCC	ACACCCGCGG	CATCTACCAG	2820
AAGGCCATTG	AGGTGCTGTC	GGACGAGCAC	GCGCCTGAGA	TGTGCCTGCG	GTTTGCAGAC	2880
ATGGAGTGCA	AGTCGGGGA	GATTGACCGC	GCCCGGGCCA	TCTACAGCTT	CTGCTCCCAG	2940
ATCTGTGACC	CCCGGACGAC	CGCGCGTTTC	TGGCAGACGT	GGAAGGACTT	TGAGGTCCGG	3000
CATGGCAATG	AGGACACCAT	CAAGGAAATG	CTGCGTATCC	GGCGCAGCGT	GCAGGCCACG	3060
TACAACACGC	AGGTCAACTT	CATGGCCTCG	CAGATGCTCA	AGGTCTCGGG	CAGTGCCACG	3120
GGCACCGTGT	CTGACCTGGC	CCCTGGGCAG	AGTGGCATGG	ACGACATGAA	GCTGCTGGAA	3180
CAGCGGGCAG	AGCAGCTGGC	GGCTGAGGCG	GAGCGTGACC	AGCCCTTGGC	CGCCACAGGC	3240
AAGATCCTGT	TCGTGAGGAG	TGACGCCTCC	CGGGAGGAGC	TGGCAGAGCT	GGCACAGCAG	3300
GTCACACCCG	AGGAGATCCA	GCTGGGCGAG	GACGAGGACG	AGGACGAGAT	GGACCTGGAG	3360
CCCAACGAGG	TTCGGCTGGA	GCAGCAGAGC	GTGCCAGCCG	CAGTGTGTTG	GAGCCTGAAG	3420
GAAGACTGAC	CCGTCCCCTC	GTGCCGAATT	CGGCACGAGC	AAGACCAGCC	CCCAGATCAT	3480
TTGCTCAAAA	GTTTTTCCTT	CGAAGTCACA	AATGTTTCAA	GGAATCTCAA	ATTTTACAAA	3540
GTTTGAAGTG	TGGCATTGG	TGGCCTGTGG	CTGTGTCCTC	TCTCTGTAGC	TGTTTTCTCC	3600
CTACATCCCT	GAAAGGAAGT	TGAGCCTGCT	CCTCCATCCG	CAGACCTCCC	TTTCCAGCGC	3660
CCAGGGCATC	GGGTGCTGTG	AGGGCAGCAT	GCTAGGTGTG	ACCGTGCTCC	TGGCCTCCAG	3720
GCCCGTGTCC	CTCTGTCTTC	TAGCCCACTA	AGGCCCTGGC	CCATTTGTGC	TAAACAGGCA	3780
GTCGGACCTA	GAAAGAGCAG	ACAATCTCTC	TGGGTCACCA	GTCTGGCTAG	GAGCTGGTCT	3840
CCTGACTGGG	ATCCAGGCCT	TCTCCCTGCG	CCATGTGAAT	TCCCAGGGGC	AGAGCCTGAA	3900
ATGTTGAACA	CAGCACTGGC	CAAAGAGATG	TCACCGTGGG	AACCGAGGCT	CTCTTCTCCT	3960
CCTGCCTGCT	TTCGTGGGTT	CAGAGTAGCT	GAGGCTTGTC	TGAGAGGAGT	TGGAGTGCTG	4020
GTTTTACCCC	TGGTGGTGT	GCTTTGCTTT	GAGGGCACTT	AGAAAGCCCA	GCCCAGCCCT	4080
TGCTCCTGCC	CTGCACACAG	CGGAGCGACT	TTTCTAGGTA	TGCTCTTGAT	TTCTGCAGAA	4140
GCAGCAGGTG	GCATGGAGCC	AAGAGGAAGT	GTGACTGAAA	CTGTCCACTC	ATAGCCCGGC	4200
TGCCGTATTG	AGAGGGCT					4218

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1187 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GAGCTCGCGC	GCCTGCAGGT	CGACACTAGT	GGATCCAAAG	AATTCGGCAC	GAGGGAAACT	60
CAACGGTGTA	CGAGTGGAGG	ACAGGGACAG	AGCCCTCTGT	GGTGGAACGA	CCCCACCTCG	120
AGGAGCTTCC	TGAGCAGGTG	GCAGAAGATG	CGATTGACTG	GGGCGACTTT	GGGGTAGAGG	180
CAGTGTCTGA	GGGGACTGAC	TCTGGCATCT	CTGCCGAGGC	TGCTGGAATC	GACTGGGGCA	240
TCTTCCCGGA	ATCAGATTCA	AAGGATCCTG	GAGGTGATGG	GATAGACTGG	GGAGACGATG	300
CTGTTGCTTT	GCAGATCACA	GTGCTGGAAG	CAGGAACCCA	GGCTCCAGAA	GGTGTGCCA	360
GGGGCCGAGA	TGCCCTGACA	CTGCTTGAAT	ACACTGAGAC	CCGGAATCAG	TTCCTTGATG	420
AGCTCATGGA	GCTTGAGATC	TTCTTAGCCC	AGAGAGCAGT	GGAGTTGAGT	GAGGAGGCAG	480
ATGTCCTGTC	TGTGAGCCAG	TTCCAGCTGG	CTCCAGCCAT	CCTGCAGGGC	CAGACCAAAG	540
AGAAGATGGT	TACCATGGTG	TCAGTGCTGG	AGGATCTGAT	TGGCAAGCTT	ACCAGTCTTC	600
AGCTGCAACA	CCTGTTTATG	ATCCTGGCCT	CACCAAGGTA	TGTGGACCGA	GTGACTGAAT	660
TCCTCCAGCA	AAAGCTGAAG	CAGTCCCAGC	TGCTGGCTTT	GAAGAAAGAG	CTGATGGTGC	720
AGAAGCAGCA	GGAGGCACCT	GAGGAGCAGG	CGGCTCTGGA	GCCTAAGCTG	GACCTGCTAC	780
TGGAGAAGAC	CAAGGAGCTG	CAGAAGCTGA	TTGAAGCTGA	CATCTCCAAG	AGGTACAGCG	840
GGCGCCCTGT	GAACCTGATG	GGAACCTCTC	TGTGACACCC	TCCGTGTTCT	TGCCGTGCCA	900
TCTTCTCCGC	TTTTGGGATG	AAGATGATAG	CCAGGGCTGT	TGTTTTGGGG	CCCTTCAAGG	960
CAAAGACCA	GGCTGACTGG	AAGATGGAAG	GCCACAGGAA	GGAAGCGGCA	CCTGATGGTG	1020
ATCTTGGCAC	TCTCCATGTT	CTCTACAAGA	AGCTGTGGTG	ATTGGCCCTG	TGGTCTATCA	1080
GGCGAAACCC	ACAGATTCTC	CTTCTAGTTA	GTATAGCGCA	AAAAGCTTCT	CGAGAGTACT	1140
TCTAGAGCGG	CCGCGGGCCC	ATCGATTTTC	CACCCGGGTG	GGGTACC		1187

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3306 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CCCTCACTAA	AGGGAACAAA	AGCTGGAGCT	CGCGCGCCTG	CAGGTCGACA	CTAGTGGATC	60
GAAAGTTCGT	TACGCCAAGC	TCGAAATTAA	CTCTGGGCTG	ACCCATAAAC	ATTTGTCTGA	120

TCTAGGATAT	AGTTGCGTTT	CTTGCGGGCA	GCAATCTGGA	TGAGGCGGTT	GAGGCACTGG	180
GTGGCCTGCT	GGATCAGGAC	ATCCCAGCGG	CCAGCATAGT	TCCGCTGCCG	GCGTAGGCC	240
ATCACCCGCA	TCTTATCCAT	GATGGCATTG	GTACCCAGGA	TGTTGTACTT	CTTGGGAAGG	300
TTGGAGGCTG	CATGTTTGAT	GGCCCATGTG	GTCTTGCCAG	CAGCAGGCAG	GCCCACCATC	360
ATCAGAACTC	CACATTCTGC	CTTGCTCTTT	GGTCCAACGG	TGCCCCGGAT	ACGCTCACTA	420
AGGGGAAGGT	GCTGGATGAA	GGTAAACCCC	GGGAGGACAG	AACAGTAGGG	CTCTGCTCTC	480
TGTCCGAAGT	TGAACCTCAC	TGCGCAATTC	TTCACCAGGA	CATGAGGATA	GAGGGCCTGA	540
CCCCCAAGG	CTTCCTTCTG	GATTCCGAAA	GCAATGCCCA	TCCACTTTCC	ATTCTTGGTA	600
AAAGACAGTT	CCACGTCTAT	TCCACATTCA	AAATCCGCAA	AGCAGCCAAT	CACCGGAGAG	660
CTCTGCGGTG	CTAGGAGAGC	GGCTGGGCCC	GCAGACTGGG	GGGAAAGCTC	CGCAGCCGCA	720
GTGGGCCCCA	GGATCAGGCC	CCGCGTGGCC	TGGAGAAGCC	CAGTCTGGGC	TGGAGCGGGA	780
GCTGGACAGT	GTGGCCTTGC	GTTCCGCCCC	GGGAGCGCTG	CGAGTGTGCG	GGCCTCGGGT	840
GGATTTGCTG	AGCACCAATA	CCTCAGGTTT	GCCAACCTGG	GGTTTTAGCT	CCCTTGGTTT	900
TAATCCCCTA	GGGGCGGGTG	GGGGCACGGG	AGGAAGGATG	GGCCAGCTGG	GTGCAATCCT	960
GCTGTAAAGC	AGCCATTCTC	TGATTTCTTA	GAATTAACCTA	AACGGTCGCG	CCGGAGGCCG	1020
CGGGGGCCGG	AGCGGAGCAG	CCGCGGCTGA	GGTTCCCGAG	TGGGCCGCTC	GGGGCTGCGC	1080
TCCGCCGCGC	GGACCCCGCG	CTCTGGCCCG	GCCGGCTCCG	GCCTCCGGGG	GGGCCGGGGC	1140
CGCCGGGACA	TGGTGCCAGT	CGCACCCCTT	CCCCGCCGCC	GCTGAGCTCG	CCGGCCGCGC	1200
CCGGGCTGGG	ACGTCCGAGC	GGGAAGATGT	TTTCCGCCCT	GAAGAAGCTG	GTGGGGTCCG	1260
ACCAGGCCCC	GGGCCGGGAC	AAGAATATCC	CCGCCGGGCT	GCAGTCCATG	AACCAGGCCG	1320
TGCAGAGGCG	CTTCGCCAAG	GGGGTGCACT	ACAACATGAA	GATAGTGATC	CGGGGAGACA	1380
GGAAACACGG	CAAGACAGCG	CTGTGGCACC	GCCTGCAGGG	CCGGCCGTTT	GTGGAGGAGT	1440
ACATCCCCAC	ACAGGAGATC	CAGGTCACCA	GCATCCACTG	GAGCTACAAG	ACCACGGATG	1500
ACATCGTGAA	GGTTGAAGTC	TGGGATGTAG	TAGACAAAGG	AAAATGCCAA	AAGCGAGGCG	1560
ACGGCTTAAA	GATGGAGAAC	GACCCCAAGG	AGNCGGAGTC	TGAAATGGCC	CTGGATGCTG	1620
AGTTCCTGGA	CGTGTAACAG	AACTGCAACG	GGGTGGTCAT	GATGTTTCGAC	ATTACCAAGC	1680
AGTGGACCTT	CAATTACATT	CTCCGGGAGC	TTCAAAAGT	GCCCACCCAC	GTGCCAGTGT	1740
GCGTGTCTGG	GAACTACCGG	GACATGGGCG	AGCACCAGAT	CATCCTGCCG	GACGACGTGC	1800
GTGACTTCAT	CGACAACCTG	GACAGACCTC	CAGGTTCTCT	CTACTTCCGC	TATGCTGAGT	1860
CTTCCATGAA	GAACAGCTTC	GGCCTAAAAGT	ACCTTCATAA	GTTCTTCAAT	ATCCCATTTT	1920
TGCAGCTTCA	GAGGGAGACG	CTGTTGCGGC	AGCTGGAGAC	GAACCAGCTG	GACATGGACG	1980
CCACGCTGGA	GGAGCTGTGC	GTGCAGCAGG	AGACGGAGGA	CCAGAACTAC	GGCATCTTCC	2040
TGGAGATGAT	GGAGGCTCGC	AGCCGTGGCC	ATGCGTCCCC	ACTGGCGGCC	AACGGGCAGA	2100
GCCCCATCCC	GGGCTCCCAG	TCACCAGTCC	TGCCGTGACC	CGCTGTGTCC	ACGGGGAGCT	2160
CCAGCCCGGG	CACACCCAG	CCCGCCCCAC	AGCTGCCCTT	CAATGCTGCC	CCACCATCCT	2220
CTGTGCCCCC	TGTACCAACC	TCAGAGGCC	TGCCCCAC	TGCGTGCCCC	TCAGCCCCCG	2280
CCCCACGGCG	CAGCATCATC	TCTAGGCTGT	TGGGACGTC	ACCTGCCACC	GAGGCAGCCC	2340
CTCCACCTCC	AGAGCCAGTC	CCGGCCGAC	AGGGCCAGC	AACGGTCCAG	AGTGTGGAGG	2400
ACTTTGTTC	TGACGACCGC	CTGGACCGCA	GCTTCCTGGA	AGACACAACC	CCGCCCAGGG	2460
ACGAGAAGAA	GGTGGGGGCC	AAGGTGCCCC	AGCAGGACAG	TGACAGTGAT	GGGGAGGCC	2520
TGGGCGGCAA	CCCGATGGTG	GCAGGGTTCC	AGGACGATGT	GGACCTCGAA	GACCAGCCAC	2580
GTGGGAGTCC	CCCGCTGCCT	GCAGGCCCGG	TCCCCAGTCA	AGACATCACT	CTTTCGAGTG	2640
AGGAGGAAGC	AGAAGTGGA	GCTCCACAA	AAGGCCCTGC	CCCAGCTCCC	CAGCAGTGCT	2700
CAGAGCCAGA	GACCAAGTGG	TCCTCCATAC	CAGCTTCGAA	GCCACGGAGG	GGGACAGCTC	2760
CCACGAGGAC	CGCAGCACCC	CCCTGGCCAG	GCGGTGTCTC	TGTTCCGACA	GGTCCGGAGA	2820
AGCGCAGCAG	CACCAAGGCC	CCTGCTGAGA	TGGAGCCGGG	GAAGGGTGAG	CAGGCCCTCT	2880
CGTCGGAGAG	TGACCCCGAG	GGACCCATTG	CTGCACAAAT	GCTGTCTTTC	GTCATGGATG	2940
ACCCCGACTT	TGAGAGCGAG	GGATCAGACA	CACAGCGCAG	GGCGGATGAC	TTTCCCCTGC	3000
GAGATGACCC	CTCCGATGTG	ACTGACGAGG	ATGAGGGCCC	TGCCGAGCCG	CCCCACCCC	3060
CCAAGCTCCC	TCTCCCGGCC	TTCAGACTGA	AGAATGACTC	GGACCTCTTC	GGGCTGGGGC	3120
TGGAGGAGGC	CGGACCCAAG	GAGAGCAGTG	AGGAAGGTAA	GGAGGGCAAA	ACCCCTCTA	3180
AGGAGAAGAA	AAAAAAACA	AAAAGCTTCT	CGAGAGTACT	TCTAGAGCGG	CCGCGGGCCC	3240
ATCGATTTC	CACCCGGGTG	GGGTACCAGG	TAAGTGATCC	CAATTCGCCC	TATAGTGAGT	3300
CGTATT						3306

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TGCGGGGCCA GAGTGGGCTG

20

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GCAGTCCTGG CCTGCGGATG

20

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTCGACAGGA GAATTGGTTC

20

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GCCTGGGTTT GGTGCGGGAC

20

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TGGTCGGGTG TTTGTGAGTG

20

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CCTCTCCGT CTCCTCAGTG

20

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GGATTGCTAG TCTCACAGAC

20

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TTAAGGGTGG CTGAAGGGAC

20

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ACCTTCCCTC CCTGTCACAG

20

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TGGTCGGGTG TTTGTGAGTG

20

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ACACCATTC AGAAATTCAG

20

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

AAACTGCAGG TGGCTGAGTC

20

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GTCCTAATGT TTTCAGGGAG

20

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

AAAACCTATG GTTACAATTC

20

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TCCTAGACAT GGTCAAGTG

20

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GATATAATTA GTTCTCCATC

20

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

ATGCCTGTTC CAGGCTGCAC

20

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

GGACGGCGAC CTCCACCCAC

20

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGGCTCCTCC GACGCCTGAG

20

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

AGTCTAGCCC TGGCCTTGAC

20

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GTCACCTGGGG ACTCCGGCAG

20

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CAGCTTTCCC TGGGCACATG

20

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CACAGCTGTC TCAAGCCCAG

20

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

ACTGTTCCCC CTACATGATG

20

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

ATCATATCCT CTTGCTGGTC

20

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GTTCCCAGAG CTTGTCTGTG

20

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

GTTTGGCAGA CTCATAGTTG

20

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

TAGCAGGGAG CCATGACCTG

20

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

CTTGCGGCCA GAAGCGAGAG

20

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

CCTCTCTCTC TCTCTCTCTC

20

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

TCCCCGCTGA TTCCGCCAAG

20

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

CTTTTGAAT TCGGCACGAG

20

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

CCCCTGGTCC GCACCAGTTC

20

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

GAGAAGGGTC GGGCGGCAG

20

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

AAATCACATC GCGTCAACAC

20

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

TAAGAGAGTC ATAGTTACTC

20

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GCTCTAGAAG TACTCTCGAG

20

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

ACTCTGGCCA TCAGGAGATC

20

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

CAGGCGTTGT AGATGTTCTG

20

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

AGTGGCAGGC AGAAGTAATG

20

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

GGTTGGAGAA CTGGATGTAG

20

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

CTATTCAGAT GCAACGCCAG

20

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

CCATGGCACA CAGAGCAGAC

20

(2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

GCTACCATGC AGAGACACAG

20

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

CAGGCTGACA AGAAAATCAG

20

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

GGCAGCATA GAGGAGAGAC

20

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

TGGGTGATGC CTTTGCTGAC

20

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

AAAACAAGAT CAAGTGATG

20

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

TTGCCACAT TGCTATGGTG

20

(2) INFORMATION FOR SEQ ID NO:60:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

GACCAAGATC AGAAGTAGAG

20

(2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

CCCCTGGGCC AATGATGTTG

20

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

TCTTCCACC ATAGCAATG

19

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

TGGTCTTGGT GACCAATGTG

20

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

ACACCTCGGT GACCCCTGTG

20

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

TCTCCAAGTT CGGCACAGTG

20

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

ACATGGGCTG CACTCAGGAC

20

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

GATCCTCTGA ACCTGCAGAG

20

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

GGAAATGAGG TGGGGCGATC

20

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

CTTTGCCTTG GACAAGGATG

20

(2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

GCACCTGCCA TTGGGGGTAG

20

(2) INFORMATION FOR SEQ ID NO:71:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

GGTGAAGCC ATTGACGGTG

20

(2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

TGCGTCTCTC GTCGCTGCTG

20

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

GCGGAACTC TGTGGTGCTG

20

(2) INFORMATION FOR SEQ ID NO:74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

AGGATTGCCT TCCTCTACTG

20

(2) INFORMATION FOR SEQ ID NO:75:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

TGTCTGTTTC ACCAGGGCAG

20

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

CCAGTGCCTC TATGCATGTC

20

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

AGGAAGCCCA CGCACACCAC

20

(2) INFORMATION FOR SEQ ID NO:78:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

CCCTTTGTTT CCTGATCTTC

20

(2) INFORMATION FOR SEQ ID NO:79:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

CGCTCGGGAT CCAGGTCATC

20

(2) INFORMATION FOR SEQ ID NO:80:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

TCGAGGTTCA GAGCGTAGTG

20

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

TCTTGATCT CTGGCACCTC

20

(2) INFORMATION FOR SEQ ID NO:82:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

CCATCAGAGT GAAGGAGGAG

20

(2) INFORMATION FOR SEQ ID NO:83:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

CCATCTTCCA CTGGTCAGAG

20

(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

CTCCTTCTCT TGGATCTCTG

20

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

TTACTTCAGC ACTGTTAGTC

20

(2) INFORMATION FOR SEQ ID NO:86:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

AGGGAGGTAG CTCAAAGCTC

20

(2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

TGGGTCCACA GTTCGCACAG

20

(2) INFORMATION FOR SEQ ID NO:88:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

CAACTCTGTG ATGGCTCCAG

20

(2) INFORMATION FOR SEQ ID NO:89:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

AGCAGGGTTC TGTCAAGAC

20

(2) INFORMATION FOR SEQ ID NO:90:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

CCATTGGGTG CTAGTCTCTC

20

(2) INFORMATION FOR SEQ ID NO:91:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

CAGCCATGCT GTCCCAGCAG

20

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

CTGGACCTGA GGTAGCGCTG

20

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

ATAACCAACC TGAGGCACTG

20

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

CCTGCAGGTC GACACTAGTG

20

(2) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

AATTGGAATG AGGAGGACTG

20

(2) INFORMATION FOR SEQ ID NO:96:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

GCTCTAGAAG TACTCTCGAG

20

(2) INFORMATION FOR SEQ ID NO:97:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

ATTGTATGAC AATGCACCAG

20

(2) INFORMATION FOR SEQ ID NO:98:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

TCCACAGAGG GCTTCATCAC

20

(2) INFORMATION FOR SEQ ID NO:99:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

CCTGACTGGC CTAAGCACAG

20

(2) INFORMATION FOR SEQ ID NO:100:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

AAGCCTCATA ACCACCACTG

20

(2) INFORMATION FOR SEQ ID NO:101:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

TGTCAACGGT GACAAGTGTG

20

(2) INFORMATION FOR SEQ ID NO:102:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

TTGTACACCA GCTGCAGGTC

20

(2) INFORMATION FOR SEQ ID NO:103:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

GGGTGTGGTG CAGATGAGTC

20

(2) INFORMATION FOR SEQ ID NO:104:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

ATCACACTCT TATAGCTCAG

20

(2) INFORMATION FOR SEQ ID NO:105:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

GTGGGAAGCT TTCCTCAGAC

20

(2) INFORMATION FOR SEQ ID NO:106:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

TGATGAACAT GGGCCTGGAG

20

(2) INFORMATION FOR SEQ ID NO:107:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

CATTGTGGAT GTACTACCAC

20

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

TGTGTTTTGC AACCTGAGTG

20

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

ATAGTGGCAC CACTTACGAG

20

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

AATTCTGCAA CGTGATGGCG

20

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

CACAAGATGC CTCGTCTGTG

20

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

AATCCGGACA AGGTACAGTC

20

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

GCACGAGTGG CACAAGCGTG

20

(2) INFORMATION FOR SEQ ID NO:114:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

GCAAGCGTGT GGTGTCAGTG

20

(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

TGTTTGAACA GGCTCTGGAC

20

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

CGGCATGGCA ATGAGGACAC

20

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

AGGACGAGAT GGACCTCCAG

20

(2) INFORMATION FOR SEQ ID NO:118:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

CCCTCTGTCC TCTAGCCCAC

20

(2) INFORMATION FOR SEQ ID NO:119:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

TCTTGAGGGG ACTGACTCTG

20

(2) INFORMATION FOR SEQ ID NO:120:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

TGAGTGAGGA GGCAGATGTC

20

(2) INFORMATION FOR SEQ ID NO:121:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

TGGCTTTGAA GAAAGAGCTG

20

(2) INFORMATION FOR SEQ ID NO:122:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

GCAAAAGACC AGGCTGACTG

20

(2) INFORMATION FOR SEQ ID NO:123:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

TGCAGCTCCT TGGTCTTCTC

20

(2) INFORMATION FOR SEQ ID NO:124:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

GATTCACAGT CCAAGGCTC

20

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

ATCTGGATGA GGCGGTGAG

20

(2) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

GGTCACTCTC CGACGAGGAG

20

(2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

GGATCAAAG TTCGTCTCTG

20

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

CGCTGTGTGT CTGATCCCTC

20

(2) INFORMATION FOR SEQ ID NO:129:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

ATGAAGGTAA ACCCGGGAG

20

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

TGGTCTCTGG CTCTGAGCAC

20

(2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

GCCTGGAGAA GCCCAGTCTG

20

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

CACACTCTGG ACCGTTGCTG

20

(2) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

AAAGCTCCGC AGCCGAGTG

20

(2) INFORMATION FOR SEQ ID NO:134:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

TCTCCAGGA AGCTGCGGTC

20

(2) INFORMATION FOR SEQ ID NO:135:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

GATGGTGGGG CAGCATTGAG

20

(2) INFORMATION FOR SEQ ID NO:136:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

GTCACCACTG GTGCCTGCAG

20

(2) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

ACCTCACGGT TGCCAACCTG

20

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

CGCAACAGCG TCTCCCTCTG

20

(2) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

AGTACCTTCA TAAGTTCTTC

20

(2) INFORMATION FOR SEQ ID NO:140:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

TCCCAGACTT CAACCTTCAC

20

(2) INFORMATION FOR SEQ ID NO:141:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

AAACATCTTC CCGGTCGGAC

20

(2) INFORMATION FOR SEQ ID NO:142:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

GCTGAGCACC TTTACCTCAC

20

(2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

GACGTCCGTC CGGGAAGATG

20

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

ACACAGGAGA TGCAGGTCAC

20

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

GAGTCTTCCA TGAAGAACAG

20

(2) INFORMATION FOR SEQ ID NO:146:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

GCAGTGAGGA AGGTAAGGAG

20

(2) INFORMATION FOR SEQ ID NO:147:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4047 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 378...1799
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

```

GGATCCAAAG GACGCCCCCG CCGACAGGAG AATTGGTTCC CGGCCCCGCG GCGATGCCCC 60
CCCGGTAGCT CGGGCCCGTG GTCGGGTGTT TGTGAGTGT TCTATGTGGG AGAAGGAGGA 120
GGAGGAGGAA GAAGAAGCAA CGATTGTCT TCTCGGCTGG TCTCCCCCG GCTCTACATG 180
TTCCCCGCAC TGAGGAGACG GAAGAGGAGC CGTAGCCGCC CCCCTCCCG GCCCGGATTA 240
TAGTCTCTCG CCACAGCGGC CTCGGCCTCC CTTGGATTG AGACGCCGAT TCGCCAGTG 300
TTTGGGAAAT GGAAGTAAT GACAGCTGGC ACCTGAAC TAAGTCTTTA TAGGCAACAC 360
CATTCCAGAA ATTCAGG ATG AAT GGG GAT ATG CCC CAT GTC CCC ATT ACT 410
                Met Asn Gly Asp Met Pro His Val Pro Ile Thr
                1             5             10

ACT CTT GCG GGG ATT GCT AGT CTC ACA GAC CTC CTG AAC CAG CTG CCT 458
Thr Leu Ala Gly Ile Ala Ser Leu Thr Asp Leu Leu Asn Gln Leu Pro
                15             20             25

CTT CCA TCT CCT TTA CCT GCT ACA ACT ACA AAG AGC CTT CTC TTT AAT 506
Leu Pro Ser Pro Leu Pro Ala Thr Thr Thr Lys Ser Leu Leu Phe Asn
                30             35             40

GCA CGA ATA GCA GAA GAG GTG AAC TGC CTT TTG GCT TGT AGG GAT GAC 554
Ala Arg Ile Ala Glu Glu Val Asn Cys Leu Leu Ala Cys Arg Asp Asp
                45             50             55

AAT TTG GTT TCA CAG CTT GTC CAT AGC CTC AAC CAG GTA TCA ACA GAT 602
Asn Leu Val Ser Gln Leu Val His Ser Leu Asn Gln Val Ser Thr Asp
                60             65             70             75

CAC ATA GAG TTG AAA GAT AAC CTT GGC AGT GAT GAC CCA GAA GGT GAC 650
His Ile Glu Leu Lys Asp Asn Leu Gly Ser Asp Asp Pro Glu Gly Asp
                80             85             90

ATA CCA GTC TTG TTG CAG GCC GTC CTG GCA AGG AGT CCT AAT GTT TTC 698
Ile Pro Val Leu Leu Gln Ala Val Leu Ala Arg Ser Pro Asn Val Phe
                95             100             105

AGG GAG AAA AGC ATG CAG AAC AGA TAT GTA CAA AGT GGA ATG ATG ATG 746
Arg Glu Lys Ser Met Gln Asn Arg Tyr Val Gln Ser Gly Met Met Met
                110             115             120

TCT CAG TAT AAA CTT TCT CAG AAT TCC ATG CAC AGT AGT CCT GCA TCT 794
Ser Gln Tyr Lys Leu Ser Gln Asn Ser Met His Ser Ser Pro Ala Ser
                125             130             135

TCC AAT TAT CAA CAA ACC ACT ATC TCA CAT AGC CCC TCC AGC CGG TTT 842
Ser Asn Tyr Gln Gln Thr Thr Ile Ser His Ser Pro Ser Ser Arg Phe
                140             145             150             155

GTG CCA CCA CAG ACA AGC TCT GGG AAC AGA TTT ATG CCA CAG CAA AAT 890
Val Pro Pro Gln Thr Ser Ser Gly Asn Arg Phe Met Pro Gln Gln Asn
                160             165             170

AGC CCA GTG CCT AGT CCA TAC GCC CCA CAA AGC CCT GCA GGA TAC ATG 938
Ser Pro Val Pro Ser Pro Tyr Ala Pro Gln Ser Pro Ala Gly Tyr Met
                175             180             185

CCA TAT TCC CAT CCT TCA AGT TAC ACA ACA CAT CCA CAG ATG CAA CAA 986
Pro Tyr Ser His Pro Ser Ser Tyr Thr Thr His Pro Gln Met Gln Gln
                190             195             200

```

GCA TCG GTA TCA AGT CCC ATT GTT GCA GGT GGT TTG AGA AAC ATA CAT 1034
 Ala Ser Val Ser Ser Pro Ile Val Ala Gly Gly Leu Arg Asn Ile His
 205 210 215

GAT AAT AAA GTT TCT GGT CCG TTG TCT GGC AAT TCA GCT AAT CAT CAT 1082
 Asp Asn Lys Val Ser Gly Pro Leu Ser Gly Asn Ser Ala Asn His His
 220 225 230 235

GCT GAT AAT CCT AGA CAT GGT TCA AGT GAG GAC TAC CTA CAC ATG GTG 1130
 Ala Asp Asn Pro Arg His Gly Ser Ser Glu Asp Tyr Leu His Met Val
 240 245 250

CAC AGG CTA AGT AGT GAC GAT GGA GAT TCT TCA ACA ATG AGG AAT GCT 1178
 His Arg Leu Ser Ser Asp Asp Gly Asp Ser Ser Thr Met Arg Asn Ala
 255 260 265

GCA TCT TTT CCC TTG AGA TCT CCA CAG CCA GTA TGC TCC CCT GCT GGA 1226
 Ala Ser Phe Pro Leu Arg Ser Pro Gln Pro Val Cys Ser Pro Ala Gly
 270 275 280

AGT GAA GGA ACT CCT AAA GGC TCA AGA CCA CCT TTA ATC CTA CAA TCT 1274
 Ser Glu Gly Thr Pro Lys Gly Ser Arg Pro Pro Leu Ile Leu Gln Ser
 285 290 295

CAG TCT CTA CCT TGT TCA TCA CCT CGA GAT GTT CCA CCA GAT ATC TTG 1322
 Gln Ser Leu Pro Cys Ser Ser Pro Arg Asp Val Pro Pro Asp Ile Leu
 300 305 310 315

CTA GAT TCT CCA GAA AGA AAA CAA AAG AAG CAG AAG AAA ATG AAA TTA 1370
 Leu Asp Ser Pro Glu Arg Lys Gln Lys Lys Gln Lys Lys Met Lys Leu
 320 325 330

GGC AAG GAT GAA AAA GAG CAG AGT GAG AAA GCG GCA ATG TAT GAT ATA 1418
 Gly Lys Asp Glu Lys Glu Gln Ser Glu Lys Ala Ala Met Tyr Asp Ile
 335 340 345

ATT AGT TCT CCA TCC AAG GAC TCT ACT AAA CTT ACA TTA AGA CTT TCT 1466
 Ile Ser Ser Pro Ser Lys Asp Ser Thr Lys Leu Thr Leu Arg Leu Ser
 350 355 360

CGT GTA AGG TCT TCA GAC ATG GAC CAG CAA GAG GAT ATG ATT TCT GGT 1514
 Arg Val Arg Ser Ser Asp Met Asp Gln Gln Glu Asp Met Ile Ser Gly
 365 370 375

GTG GAA AAT AGC AAT GTT TCA GAA AAT GAT ATT CCT TTT AAT GTG CAG 1562
 Val Glu Asn Ser Asn Val Ser Glu Asn Asp Ile Pro Phe Asn Val Gln
 380 385 390 395

TAC CCA GGA CAG ACT TCA AAA ACA CCC ATT ACT CCA CAA GAT ATA AAC 1610
 Tyr Pro Gly Gln Thr Ser Lys Thr Pro Ile Thr Pro Gln Asp Ile Asn
 400 405 410

CGC CCA CTA AAT GCT GCT CAA TGT TTG TCG CAG CAA GAA CAA ACA GCA 1658
 Arg Pro Leu Asn Ala Ala Gln Cys Leu Ser Gln Gln Glu Gln Thr Ala
 415 420 425

TTC CTT CCA GCA AAT CAA GTG CCT GTT TTA CAA CAG AAC ACT TCA GTT 1706
 Phe Leu Pro Ala Asn Gln Val Pro Val Leu Gln Gln Asn Thr Ser Val
 430 435 440

GCT GCA AAA CAA CCC CAG ACC AAT AGT CAC AAA ACC TTG GTG CAG CCT 1754
 Ala Ala Lys Gln Pro Gln Thr Asn Ser His Lys Thr Leu Val Gln Pro
 445 450 455

GGA ACA GGC ATA GAG GTC TCA GCA GAG CTG CCC AAG GAC AAG ACC TAAGA 1804
 Gly Thr Gly Ile Glu Val Ser Ala Glu Leu Pro Lys Asp Lys Thr
 460 465 470

TCCAGCAGGG AACTATGTAG TCACCCCGAG AGGCCAGCT CTCTCCGTGA GCTCTGGGCC 1864
 TAGGGTGGGG GTGGTTGTTG GTTCTGCGCG CACTGTTCCC CCTACATGAT GGGTCCATCC 1924
 CAGTTGGCTT CTCTCACTCG CTTCCTCTG TGGAGAAGCC TGTCCAGGTG TCACTGCCCTC 1984
 CAGGAAGCTG TCTCTGATTT CTCCAGTTGA ACAGTGAGAT TTGCCACACC TCACATGCAT 2044
 CGCTCTTGTC CCTGGAATTG TAACCATAGG TTTTCCTGTC TCCTGGAGGA CAAGGATGAG 2104

GGCCTTCCAC TTGAGTCTCC CTGGTGGAGC CCAGCTCCTG ACATACCTGG TAAAAGTTCT 2164
 CAAGAGAAGA ACATGGAGGA GGAATGTGGA TAACAACCCCT GGCTGCCTGT GTGTTCCAAG 2224
 CTAGGAAGAT GTAATGTCCC CACAAACGGG GTAAATGGCT TGCCTGCGTC ACAGCTGTCT 2284
 CAAGCCAGG CCCTGGGCGC CAGCCCAAGC CCAAGGACTA GGTCCAGAGC CACACAGCGC 2344
 CAGGCCACAT CCGCCTCACC TGGGACCCTT TGTGGGGTAC AGTCTCCGGC CCCACCCAGA 2404
 CCTCCTGAAG GAGAGACCCC ATGGCAAGGA CTCAGCCACC TGCAGTTTCA TAAGCCCCCA 2464
 GTGGGTTCCT AGGCATGAAG ACCACCGGTT AGAGGCTGAA CTGGCAGGAA CCTGTCTCCA 2524
 GCCCCTTCTC ACCCCAGCCG GGCCCTGCCT CAGAGGCAGC ACCCAGGACG TGGCCATGAC 2584
 CCGTGGACTC CACTCAATCC CTCTTCTCCA GGAGCCATGC AAAGTGTCTAG CCAGCCAGGC 2644
 CCTCGGAAGG CAGTCATCAC CTCTTAAGGC ATTGTGGGTG TCGTCTCTGC AACTGCCAGG 2704
 TGCAGCACAC GACCCGTGTC CGGTGTTTGA TAGCAGGGAG CCATGACCTG GCAACGATTC 2764
 CACGCTCAAA GGGGCACCCG GGGGGCCCTG GGTGGGGCGG GATCAGCTTT CCTGGGCAC 2824
 ATCTGCCTCA TTCCAGATCT CCAGGGCTCA TGTCTGTGAC AGGGAGGGAA GGCTCTGCC 2884
 TGGCCTTCCG TCAGCTCTGC CAGTGCAGGC TGGGCAGCCT GGGCTTTAGA GCTGGCTTCT 2944
 GCCCACACTT TCTCCGTGAA AGGAAAACAA CTATGAGTCT GCCAAACGCA TCTCAGATGC 3004
 GTTTTAAAAA ATTCTGGTCC CCGCTCTCTG TCCCATCATC CGCCTCGGGG ACTTCCTCTC 3064
 TCCGTGGTTC TCACCCATA CTCTGTCACT GCCACATTTT CACCTGGGCC TGGCCTTTGT 3124
 CTCACCTGAA AACTCCTGAA AATCTTGAAA TGGATTCTA GGTCACTGGG GACTCCGGCA 3184
 GCACATTCGG CTTCAGAATA AAGGGCGCCC GCGGTCCCCC AGCACCTCCC CAAGCCACAC 3244
 CCCTAGCTTC CCTCCCTATC CTGCGAGCCT GAGGGTCCCT TCAGCCACCC TTAAGTCCCC 3304
 ACCTGGGCTC CTGCCCCGCC CTGGCTAGC AGCGCCTTCT CCACCGGGGC CCCCTCTGCT 3364
 CACAGAGCCC CCTCACCTCC CTGGGGATGA GGGGCCAGGC CATGACCCTG AAAGTCTAGC 3424
 CCTGGCCTTG ACCTCCAGG AGCGCCCTCC CCGCCCTCTC CCGGCCCGG CCCGTCCTC 3484
 TGCTGCTGGC CTCTGGGTG TGGCCCGCAG ACTGAGCTGC GCTTGGGGT CCTGGCGGCC 3544
 TGGGCCGTCC CGCACCGAAC CAGGCGGTG GGAGCCCGGC GGGGAGGCG GAGGTCTCTC 3604
 TGGGGGTCC TCCGACGCT GAGGGCGCTG CTTCCTCCG GCGGCCCGG GTTCTGCGG 3664
 AGCCGGGGC TCCGCTCTCG GGTGACCCG TGAGACCCCG GGGGAGGCCG CTGGGAGGC 3724
 GCGGGCTCTG CTCCCGGGT CCAAACGCAC TGGCTGCCCC TCAGGAGGGA CGGCGACCTC 3784
 CACCACGGC GCTGGCGCCC GCACGGCCG TCCTCCCGT CCCGAGCCT GGACGCTCC 3844
 CGAGGCCCG CCGCCGGGCC CCACGCGCG CCCCATCCG AGGCCAGGAC TGCCTCCCG 3904
 GAGCTGGGG CCCCAGCCT GGAGGAGCCG GCCCAGACG CCTCCACAG CCTCCCGAG 3964
 CCACTCTGGC CCCGAGCCC CCGCCTGGT CGAGTGGGG TCTCTGGCC CGGCCTTTCC 4024
 CGGGGAAGGA AAGCAAAAG CTT 4047

(2) INFORMATION FOR SEQ ID NO:148:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 474 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

Met Asn Gly Asp Met Pro His Val Pro Ile Thr Thr Leu Ala Gly Ile
 1 5 10 15
 Ala Ser Leu Thr Asp Leu Leu Asn Gln Leu Pro Leu Pro Ser Pro Leu
 20 25 30
 Pro Ala Thr Thr Thr Lys Ser Leu Leu Phe Asn Ala Arg Ile Ala Glu
 35 40 45
 Glu Val Asn Cys Leu Leu Ala Cys Arg Asp Asp Asn Leu Val Ser Gln
 50 55 60
 Leu Val His Ser Leu Asn Gln Val Ser Thr Asp His Ile Glu Leu Lys
 65 70 75 80
 Asp Asn Leu Gly Ser Asp Asp Pro Glu Gly Asp Ile Pro Val Leu Leu
 85 90 95
 Gln Ala Val Leu Ala Arg Ser Pro Asn Val Phe Arg Glu Lys Ser Met
 100 105 110
 Gln Asn Arg Tyr Val Gln Ser Gly Met Met Met Ser Gln Tyr Lys Leu
 115 120 125
 Ser Gln Asn Ser Met His Ser Ser Pro Ala Ser Ser Asn Tyr Gln Gln
 130 135 140
 Thr Thr Ile Ser His Ser Pro Ser Ser Arg Phe Val Pro Pro Gln Thr
 145 150 155 160
 Ser Ser Gly Asn Arg Phe Met Pro Gln Gln Asn Ser Pro Val Pro Ser
 165 170 175
 Pro Tyr Ala Pro Gln Ser Pro Ala Gly Tyr Met Pro Tyr Ser His Pro
 180 185 190
 Ser Ser Tyr Thr Thr His Pro Gln Met Gln Gln Ala Ser Val Ser Ser
 195 200 205

Pro Ile Val Ala Gly Gly Leu Arg Asn Ile His Asp Asn Lys Val Ser
 210 215 220
 Gly Pro Leu Ser Gly Asn Ser Ala Asn His His Ala Asp Asn Pro Arg
 225 230 235 240
 His Gly Ser Ser Glu Asp Tyr Leu His Met Val His Arg Leu Ser Ser
 245 250 255
 Asp Asp Gly Asp Ser Ser Thr Met Arg Asn Ala Ala Ser Phe Pro Leu
 260 265 270
 Arg Ser Pro Gln Pro Val Cys Ser Pro Ala Gly Ser Glu Gly Thr Pro
 275 280 285
 Lys Gly Ser Arg Pro Pro Leu Ile Leu Gln Ser Gln Ser Leu Pro Cys
 290 295 300
 Ser Ser Pro Arg Asp Val Pro Pro Asp Ile Leu Leu Asp Ser Pro Glu
 305 310 315 320
 Arg Lys Gln Lys Lys Gln Lys Lys Met Lys Leu Gly Lys Asp Glu Lys
 325 330 335
 Glu Gln Ser Glu Lys Ala Ala Met Tyr Asp Ile Ile Ser Ser Pro Ser
 340 345 350
 Lys Asp Ser Thr Lys Leu Thr Leu Arg Leu Ser Arg Val Arg Ser Ser
 355 360 365
 Asp Met Asp Gln Gln Glu Asp Met Ile Ser Gly Val Glu Asn Ser Asn
 370 375 380
 Val Ser Glu Asn Asp Ile Pro Phe Asn Val Gln Tyr Pro Gly Gln Thr
 385 390 395 400
 Ser Lys Thr Pro Ile Thr Pro Gln Asp Ile Asn Arg Pro Leu Asn Ala
 405 410 415
 Ala Gln Cys Leu Ser Gln Gln Glu Gln Thr Ala Phe Leu Pro Ala Asn
 420 425 430
 Gln Val Pro Val Leu Gln Gln Asn Thr Ser Val Ala Ala Lys Gln Pro
 435 440 445
 Gln Thr Asn Ser His Lys Thr Leu Val Gln Pro Gly Thr Gly Ile Glu
 450 455 460
 Val Ser Ala Glu Leu Pro Lys Asp Lys Thr
 465 470

(2) INFORMATION FOR SEQ ID NO:149:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2998 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Genomic DNA

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 26...799
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

AAGCTTTTGG AATTCGGCAC GAGAT GCT ACA CAG GCT ATA TTT GAA ATA CTG 52
 Ala Thr Gln Ala Ile Phe Glu Ile Leu
 1 5
 GAG AAA TCC TGG TTG CCC CAG AAT TGT ACA CTG GTT GAT ATG AAG ATT 100
 Glu Lys Ser Trp Leu Pro Gln Asn Cys Thr Leu Val Asp Met Lys Ile
 10 15 20 25
 GAA TTT GGT GTT GAT GTA ACC ACC AAA GAA ATT GTT CTT GCT GAT GTT 148
 Glu Phe Gly Val Asp Val Thr Thr Lys Glu Ile Val Leu Ala Asp Val
 30 35 40
 ATT GAC AAT GAT TCC TGG AGA CTC TGG CCA TCA GGA GAT CGA AGC CAA 196
 Ile Asp Asn Asp Ser Trp Arg Leu Trp Pro Ser Gly Asp Arg Ser Gln
 45 50 55
 CAG AAA GAC AAA CAG TCT TAT CGG GAC CTC AAA GAA GTA ACT CCT GAA 244
 Gln Lys Asp Lys Gln Ser Tyr Arg Asp Leu Lys Glu Val Thr Pro Glu
 60 65 70
 GGG CTC CAA ATG GTA AAG AAA AAC TTT GAG TGG GTT GCA GAG AGA GTA 292

[illegible]

```

GCTGCCCTTT GGGGAAGTCA CCAACCTCCT GATGCTGAAG GGGAAAAACC AGGCCTTCAT 2446
CGAGATGAAC ACGGAGGAGG CTGCCAATAC CATGGTGAAC TACTACACCT CGGTGACCCC 2506
TGTGCTGCCG GGGCAGCCCA TCTACATCCA GTTCTCCAAC CACAAGGAGC TGAAGACCGA 2566
CAGCTCTCCC AACCAGGCGC GGGCCCAGGC GGCCCTGCAG GCGGTGAACT CGGTCCAGTC 2626
GGGGAACCTG GCCTTGGCTG CCTCGGCGGC GGCCGTGGAT GCAGGGATGG CGATGGCCGG 2686
GCAGAGCCCC GTGCTCAGGA TCATCGTGA GAACCTCTTC TACCCTGTGA CCCTGGATGT 2746
GCTGCACCAG ATTTTCTCCA AGTTCGGCAC AGTGTGAAG ATCATCACCT TCACCAAGAA 2806
CAACCAAGTC CAGGCCCTGC TGCAGTATGC GGACCCCGTG AGCGCCGAGC ACGCCAAGCT 2866
GTGCGTGGAC GGGCAGAACA TCTACAACGC CTGCTGCACG CTGCGCATCG ACTTTTCCAA 2926
GCTCACCAGC CTCACGTCA AGTACAACAA TGACAAGAGC CGTGACTACC TCGTGCCGAA 2986
TTCTTTGGAT CC

```

(2) INFORMATION FOR SEQ ID NO:150:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 258 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

```

Ala Thr Gln Ala Ile Phe Glu Ile Leu Glu Lys Ser Trp Leu Pro Gln
 1           5           10           15
Asn Cys Thr Leu Val Asp Met Lys Ile Glu Phe Gly Val Asp Val Thr
 20           25           30
Thr Lys Glu Ile Val Leu Ala Asp Val Ile Asp Asn Asp Ser Trp Arg
 35           40           45
Leu Trp Pro Ser Gly Asp Arg Ser Gln Gln Lys Asp Lys Gln Ser Tyr
 50           55           60
Arg Asp Leu Lys Glu Val Thr Pro Glu Gly Leu Gln Met Val Lys Lys
 65           70           75           80
Asn Phe Glu Trp Val Ala Glu Arg Val Glu Leu Leu Leu Lys Ser Glu
 85           90           95
Ser Gln Cys Arg Val Val Val Leu Met Gly Ser Thr Ser Asp Leu Gly
100           105           110
His Cys Glu Lys Ile Lys Lys Ala Cys Gly Asn Phe Gly Ile Pro Cys
115           120           125
Glu Leu Arg Val Thr Ser Ala His Lys Gly Pro Asp Glu Thr Leu Arg
130           135           140
Ile Lys Ala Glu Tyr Glu Gly Asp Gly Ile Pro Thr Val Phe Val Ala
145           150           155           160
Val Ala Gly Arg Ser Asn Gly Leu Gly Pro Val Met Ser Gly Asn Thr
165           170           175
Ala Tyr Pro Val Ile Ser Cys Pro Pro Leu Thr Pro Asp Trp Gly Val
180           185           190
Gln Asp Val Trp Ser Ser Leu Arg Leu Pro Ser Gly Leu Gly Cys Ser
195           200           205
Thr Val Leu Ser Pro Glu Gly Ser Ala Gln Phe Ala Ala Gln Ile Phe
210           215           220
Gly Leu Ser Asn His Leu Val Trp Ser Lys Leu Arg Ala Ser Ile Leu
225           230           235           240
Asn Thr Trp Ile Ser Leu Lys Gln Ala Asp Lys Lys Ile Arg Glu Cys
245           250           255
Asn Leu

```

(2) INFORMATION FOR SEQ ID NO:151:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1038 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

```

Ile Gln Arg Phe Gly Thr Ser Gly His Ile Met Asn Leu Gln Ala Gln
 1           5           10           15

```

Pro Lys Ala Gln Asn Lys Arg Lys Arg Cys Leu Phe Gly Gly Gln Glu
 20 25 30
 Pro Ala Pro Lys Glu Gln Pro Pro Pro Leu Gln Pro Pro Gln Gln Ser
 35 40 45
 Ile Arg Val Lys Glu Glu Gln Tyr Leu Gly His Glu Gly Pro Gly Gly
 50 55 60
 Ala Val Ser Thr Ser Gln Pro Val Glu Leu Pro Pro Pro Ser Ser Leu
 65 70 75 80
 Ala Leu Leu Asn Ser Val Val Tyr Gly Pro Glu Arg Thr Ser Ala Ala
 85 90 95
 Met Leu Ser Gln Gln Val Ala Ser Val Lys Trp Pro Asn Ser Val Met
 100 105 110
 Ala Pro Gly Arg Gly Pro Glu Arg Gly Gly Gly Gly Val Ser Asp
 115 120 125
 Ser Ser Trp Gln Gln Gln Pro Gly Gln Pro Pro Pro His Ser Thr Trp
 130 135 140
 Asn Cys His Ser Leu Ser Leu Tyr Ser Ala Thr Lys Gly Ser Pro His
 145 150 155 160
 Pro Gly Val Gly Val Pro Thr Tyr Tyr Asn His Pro Glu Ala Leu Lys
 165 170 175
 Arg Glu Lys Ala Gly Gly Pro Gln Leu Asp Arg Tyr Val Arg Pro Met
 180 185 190
 Met Pro Gln Lys Val Gln Leu Glu Val Gly Arg Pro Gln Ala Pro Leu
 195 200 205
 Asn Ser Phe His Ala Ala Lys Lys Pro Pro Asn Gln Ser Leu Pro Leu
 210 215 220
 Gln Pro Phe Gln Leu Ala Phe Gly His Gln Val Asn Arg Gln Val Phe
 225 230 235 240
 Arg Gln Gly Pro Pro Pro Asn Pro Val Ala Ala Phe Pro Pro Gln
 245 250 255
 Lys Gln Gln Gln Gln Gln Gln Pro Gln Gln Gln Gln Gln Gln Gln
 260 265 270
 Ala Ala Leu Pro Gln Met Pro Leu Phe Glu Asn Phe Tyr Ser Met Pro
 275 280 285
 Gln Gln Pro Ser Gln Gln Pro Gln Asp Phe Gly Leu Gln Pro Ala Gly
 290 295 300
 Pro Leu Gly Gln Ser His Leu Ala His His Ser Met Ala Pro Tyr Pro
 305 310 315 320
 Phe Pro Pro Asn Pro Asp Met Asn Pro Glu Leu Arg Lys Ala Leu Leu
 325 330 335
 Gln Asp Ser Ala Pro Gln Pro Ala Leu Pro Gln Val Gln Ile Pro Phe
 340 345 350
 Pro Arg Arg Ser Arg Arg Leu Ser Lys Glu Gly Ile Leu Pro Pro Ser
 355 360 365
 Ala Leu Asp Gly Ala Gly Thr Gln Pro Gly Gln Glu Ala Thr Gly Asn
 370 375 380
 Leu Phe Leu His His Trp Pro Leu Gln Gln Pro Pro Pro Gly Ser Leu
 385 390 395 400
 Gly Gln Pro His Pro Glu Ala Leu Gly Phe Pro Leu Glu Leu Arg Glu
 405 410 415
 Ser Gln Leu Leu Pro Asp Gly Glu Arg Leu Ala Pro Asn Gly Arg Glu
 420 425 430
 Arg Glu Ala Pro Ala Met Gly Ser Glu Glu Gly Met Arg Ala Val Ser
 435 440 445
 Thr Gly Asp Cys Gly Gln Val Leu Arg Gly Gly Val Ile Gln Ser Thr
 450 455 460
 Arg Arg Arg Arg Ala Ser Gln Glu Ala Asn Leu Leu Thr Leu Ala
 465 470 475 480
 Gln Lys Ala Val Glu Leu Ala Ser Leu Gln Asn Ala Lys Asp Gly Ser
 485 490 495
 Gly Ser Glu Glu Lys Arg Lys Ser Val Leu Ala Ser Thr Thr Lys Cys
 500 505 510
 Gly Val Glu Phe Ser Glu Pro Ser Leu Ala Thr Lys Arg Ala Arg Glu
 515 520 525
 Asp Ser Gly Met Val Pro Leu Ile Ile Pro Val Ser Val Pro Val Arg
 530 535 540
 Thr Val Asp Pro Thr Glu Ala Ala Gln Ala Gly Gly Leu Asp Glu Asp
 545 550 555 560
 Gly Lys Gly Leu Glu Gln Asn Pro Ala Glu His Lys Pro Ser Val Ile
 565 570 575
 Val Thr Arg Arg Arg Ser Thr Arg Ile Pro Gly Thr Asp Ala Gln Ala
 580 585 590
 Gln Ala Glu Asp Met Asn Val Lys Leu Glu Gly Glu Pro Ser Val Arg

```

      595              600              605
Lys Pro Lys Gln Arg Pro Arg Pro Glu Pro Leu Ile Ile Pro Thr Lys
  610              615              620
Ala Gly Thr Phe Ile Ala Pro Pro Val Tyr Ser Asn Ile Thr Pro Tyr
  625              630              635              640
Gln Ser His Leu Arg Ser Pro Val Arg Leu Ala Asp His Pro Ser Glu
      645              650              655
Arg Ser Phe Glu Leu Pro Pro Tyr Thr Pro Pro Pro Ile Leu Ser Pro
      660              665              670
Val Arg Glu Gly Ser Gly Leu Tyr Phe Asn Ala Ile Ile Ser Thr Ser
      675              680              685
Thr Ile Pro Ala Pro Pro Pro Ile Thr Pro Lys Ser Ala His Arg Thr
      690              695              700
Leu Leu Arg Thr Asn Ser Ala Glu Val Thr Pro Pro Val Leu Ser Val
  705              710              715              720
Met Gly Glu Ala Thr Pro Val Ser Ile Glu Pro Arg Ile Asn Val Gly
      725              730              735
Ser Arg Phe Gln Ala Glu Ile Pro Leu Met Arg Asp Arg Ala Leu Ala
      740              745              750
Ala Ala Asp Pro His Lys Ala Asp Leu Val Trp Gln Pro Trp Glu Asp
      755              760              765
Leu Glu Ser Ser Arg Glu Lys Gln Arg Gln Val Glu Asp Leu Leu Thr
      770              775              780
Ala Ala Cys Ser Ser Ile Phe Pro Gly Ala Gly Thr Asn Gln Glu Leu
  785              790              795              800
Ala Leu His Cys Leu His Glu Ser Arg Gly Asp Ile Leu Glu Thr Leu
      805              810              815
Asn Lys Leu Leu Lys Lys Pro Leu Arg Pro His Asn His Pro Leu
      820              825              830
Ala Thr Tyr His Tyr Thr Gly Ser Asp Gln Trp Lys Met Ala Glu Arg
      835              840              845
Lys Leu Phe Asn Lys Gly Ile Ala Ile Tyr Lys Lys Asp Phe Phe Leu
      850              855              860
Val Gln Lys Leu Ile Gln Thr Lys Thr Val Ala Gln Cys Val Glu Phe
  865              870              875              880
Tyr Tyr Thr Tyr Lys Lys Gln Val Lys Ile Gly Arg Asn Gly Thr Leu
      885              890              895
Thr Phe Gly Asp Val Asp Thr Ser Asp Glu Lys Ser Ala Gln Glu Glu
      900              905              910
Val Glu Val Asp Ile Lys Thr Ser Gln Lys Phe Pro Arg Val Pro Leu
      915              920              925
Pro Arg Arg Glu Ser Pro Ser Glu Glu Arg Leu Glu Pro Lys Arg Glu
      930              935              940
Val Lys Glu Pro Arg Lys Glu Gly Glu Glu Val Pro Glu Ile Gln
  945              950              955              960
Glu Lys Glu Glu Gln Glu Glu Gly Arg Glu Arg Ser Arg Arg Ala Ala
      965              970              975
Ala Val Lys Ala Thr Gln Thr Leu Gln Ala Asn Glu Ser Ala Ser Asp
      980              985              990
Ile Leu Ile Leu Arg Ser His Glu Ser Asn Ala Pro Gly Ser Ala Gly
      995              1000              1005
Gly Gln Ala Ser Glu Lys Pro Arg Glu Gly Thr Gly Lys Ser Arg Arg
  1010              1015              1020
Ala Leu Pro Phe Ser Glu Lys Lys Lys Lys Lys Gln Lys Ala
  1025              1030              1035

```

(2) INFORMATION FOR SEQ ID NO:152:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 849 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

```

Ile Arg His Glu Val Ser Phe Leu Trp Asn Thr Glu Ala Ala Cys Pro
  1              5              10              15
Ile Gln Thr Thr Thr Asp Thr Asp Gln Ala Cys Ser Ile Arg Asp Pro
      20              25              30
Asn Ser Gly Phe Val Phe Asn Leu Asn Pro Leu Asn Ser Ser Gln Gly
      35              40              45

```

Tyr Asn Val Ser Gly Ile Gly Lys Ile Phe Met Phe Asn Val Cys Gly
 50 55 60
 Thr Met Pro Val Cys Gly Thr Ile Leu Gly Lys Pro Ala Ser Gly Cys
 65 70 75 80
 Glu Ala Glu Thr Gln Thr Glu Glu Leu Lys Asn Trp Lys Pro Ala Arg
 85 90 95
 Pro Val Gly Ile Glu Lys Ser Leu Gln Leu Ser Thr Glu Gly Phe Ile
 100 105 110
 Thr Leu Thr Tyr Lys Gly Pro Leu Ser Ala Lys Gly Thr Ala Asp Ala
 115 120 125
 Phe Ile Val Arg Phe Val Cys Asn Asp Asp Val Tyr Ser Gly Pro Leu
 130 135 140
 Lys Phe Leu His Gln Asp Ile Asp Ser Gly Gln Gly Ile Arg Asn Thr
 145 150 155 160
 Tyr Phe Glu Phe Glu Thr Ala Leu Ala Cys Val Pro Ser Pro Val Asp
 165 170 175
 Cys Gln Val Thr Asp Leu Ala Gly Asn Glu Tyr Asp Leu Thr Gly Leu
 180 185 190
 Ser Thr Val Arg Lys Pro Trp Thr Ala Val Asp Thr Ser Val Asp Gly
 195 200 205
 Arg Lys Arg Thr Phe Tyr Leu Ser Val Cys Asn Pro Leu Pro Tyr Ile
 210 215 220
 Pro Gly Cys Gln Gly Ser Ala Val Gly Ser Cys Leu Val Ser Glu Gly
 225 230 235 240
 Asn Ser Trp Asn Leu Gly Val Val Gln Met Ser Pro Gln Ala Ala Ala
 245 250 255
 Asn Gly Ser Leu Ser Ile Met Tyr Val Asn Gly Asp Lys Cys Gly Asn
 260 265 270
 Gln Arg Phe Ser Thr Arg Ile Thr Phe Glu Cys Ala Gln Ile Ser Gly
 275 280 285
 Ser Pro Ala Phe Gln Leu Gln Asp Gly Cys Glu Tyr Val Phe Ile Trp
 290 295 300
 Arg Thr Val Glu Ala Cys Pro Val Val Arg Val Glu Gly Asp Asn Cys
 305 310 315 320
 Glu Val Lys Asp Pro Arg His Gly Asn Leu Tyr Asp Leu Lys Pro Leu
 325 330 335
 Gly Leu Asn Asp Thr Ile Val Ser Ala Gly Glu Tyr Thr Tyr Tyr Phe
 340 345 350
 Arg Val Cys Gly Lys Leu Ser Ser Asp Val Cys Pro Thr Ser Asp Lys
 355 360 365
 Ser Lys Val Val Ser Ser Cys Gln Glu Lys Arg Glu Pro Gln Gly Phe
 370 375 380
 His Lys Val Ala Gly Leu Leu Thr Gln Lys Leu Thr Tyr Glu Asn Gly
 385 390 395 400
 Leu Leu Lys Met Asn Phe Thr Gly Gly Asp Thr Cys His Lys Val Tyr
 405 410 415
 Gln Arg Ser Thr Ala Ile Phe Phe Tyr Cys Asp Arg Gly Thr Gln Arg
 420 425 430
 Pro Val Phe Leu Lys Glu Thr Ser Asp Cys Ser Tyr Leu Phe Glu Trp
 435 440 445
 Arg Thr Gln Tyr Ala Cys Pro Pro Phe Asp Leu Thr Glu Cys Ser Phe
 450 455 460
 Lys Asp Gly Ala Gly Asn Ser Phe Asp Leu Ser Ser Leu Ser Arg Tyr
 465 470 475 480
 Ser Asp Asn Trp Glu Ala Ile Thr Gly Thr Gly Asp Pro Glu His Tyr
 485 490 495
 Leu Ile Asn Val Cys Lys Ser Leu Ala Pro Gln Ala Gly Thr Glu Pro
 500 505 510
 Cys Pro Pro Glu Ala Ala Ala Cys Leu Leu Gly Gly Ser Lys Pro Val
 515 520 525
 Asn Leu Gly Arg Val Arg Asp Gly Pro Gln Trp Arg Asp Gly Ile Ile
 530 535 540
 Val Leu Lys Tyr Val Asp Gly Asp Leu Cys Pro Asp Gly Ile Arg Lys
 545 550 555 560
 Lys Ser Thr Thr Ile Arg Phe Thr Cys Ser Glu Ser Gln Val Asn Ser
 565 570 575
 Arg Pro Met Phe Ile Ser Ala Val Glu Asp Cys Glu Tyr Thr Phe Ala
 580 585 590
 Trp Pro Thr Ala Thr Ala Cys Pro Met Lys Ser Asn Glu His Asp Asp
 595 600 605
 Cys Gln Val Thr Asn Pro Ser Thr Gly His Leu Phe Asp Leu Ser Ser
 610 615 620
 Leu Ser Gly Arg Ala Gly Phe Thr Ala Ala Tyr Ser Glu Lys Gly Leu

```

625          630          635          640
Val Tyr Met Ser Ile Cys Gly Glu Asn Glu Asn Cys Pro Pro Gly Val
          645          650          655
Gly Ala Cys Phe Gly Gln Thr Arg Ile Ser Val Gly Lys Ala Asn Lys
          660          665          670
Arg Leu Arg Tyr Val Asp Gln Val Leu Gln Leu Val Tyr Lys Asp Gly
          675          680          685
Ser Pro Cys Pro Ser Lys Ser Gly Leu Ser Tyr Lys Ser Val Ile Ser
          690          695          700
Phe Val Cys Arg Pro Glu Ala Gly Pro Thr Asn Arg Pro Met Leu Ile
705          710          715          720
Ser Leu Asp Lys Gln Thr Cys Thr Leu Phe Ser Trp His Thr Pro
          725          730          735
Leu Ala Cys Glu Gln Ala Thr Glu Cys Ser Val Arg Asn Gly Ser Ser
          740          745          750
Ile Val Asp Leu Ser Pro Leu Ile His Arg Thr Gly Gly Tyr Glu Ala
          755          760          765
Tyr Asp Glu Ser Glu Asp Asp Ala Ser Asp Thr Asn Pro Asp Phe Tyr
          770          775          780
Ile Asn Ile Cys Gln Pro Leu Asn Pro Met His Gly Val Pro Cys Pro
785          790          795          800
Ala Gly Ala Ala Val Cys Lys Val Pro Ile Asp Gly Pro Pro Ile Asp
          805          810          815
Ile Gly Arg Val Ala Gly Pro Pro Ile Leu Asn Pro Ile Ala Asn Glu
          820          825          830
Ile Tyr Leu Asn Phe Glu Ser Ser Thr Pro Cys Gln Glu Phe Ser Cys
          835          840          845
Lys

```

(2) INFORMATION FOR SEQ ID NO:153:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 852 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

```

Met Ala Arg Leu Ser Arg Pro Glu Arg Pro Asp Leu Val Phe Glu Glu
 1          5          10          15
Glu Asp Leu Pro Tyr Glu Glu Glu Ile Met Arg Asn Gln Phe Ser Val
          20          25          30
Lys Cys Trp Leu His Tyr Ile Glu Phe Lys Gln Gly Ala Pro Lys Pro
          35          40          45
Arg Leu Asn Gln Leu Tyr Glu Arg Ala Leu Lys Leu Leu Pro Cys Ser
          50          55          60
Tyr Lys Leu Trp Tyr Arg Tyr Leu Lys Ala Arg Arg Ala Gln Val Lys
65          70          75          80
His Arg Cys Val Thr Asp Pro Ala Tyr Glu Asp Val Asn Asn Cys His
          85          90          95
Glu Arg Ala Phe Val Phe Met His Lys Met Pro Arg Leu Trp Leu Asp
          100          105          110
Tyr Cys Gln Phe Leu Met Asp Gln Gly Arg Val Thr His Thr Arg Arg
          115          120          125
Thr Phe Asp Arg Ala Leu Arg Ala Leu Pro Ile Thr Gln His Ser Arg
          130          135          140
Ile Trp Pro Leu Tyr Leu Arg Phe Leu Arg Ser His Pro Leu Pro Glu
145          150          155          160
Thr Ala Val Arg Gly Tyr Arg Arg Phe Leu Lys Leu Ser Pro Glu Ser
          165          170          175
Ala Glu Glu Tyr Ile Glu Tyr Leu Lys Ser Ser Asp Arg Leu Asp Glu
          180          185          190
Ala Ala Gln Arg Leu Ala Thr Val Val Asn Asp Glu Arg Phe Val Ser
          195          200          205
Lys Ala Gly Lys Ser Asn Tyr Gln Leu Trp His Glu Leu Cys Asp Leu
210          215          220
Ile Ser Gln Asn Pro Asp Lys Val Gln Ser Leu Asn Val Asp Ala Ile
225          230          235          240
Ile Arg Gly Gly Leu Thr Arg Phe Thr Asp Gln Leu Gly Lys Leu Trp
          245          250          255

```

Cys Ser Leu Ala Asp Tyr Tyr Ile Arg Ser Gly His Phe Glu Lys Ala
 260 265 270
 Arg Asp Val Tyr Glu Glu Ala Ile Arg Thr Val Met Thr Val Arg Asp
 275 280 285
 Phe Thr Gln Val Phe Asp Ser Tyr Ala Gln Phe Glu Glu Ser Met Ile
 290 295 300
 Ala Ala Lys Met Glu Thr Ala Ser Glu Leu Gly Arg Glu Glu Glu Asp
 305 310 315 320
 Asp Val Asp Leu Glu Leu Arg Leu Ala Arg Phe Glu Gln Leu Ile Ser
 325 330 335
 Arg Arg Pro Leu Leu Leu Asn Ser Val Leu Leu Arg Gln Asn Pro His
 340 345 350
 His Val His Glu Trp His Lys Arg Val Ala Leu His Gln Gly Arg Pro
 355 360 365
 Arg Glu Ile Ile Asn Thr Tyr Thr Glu Ala Val Gln Thr Val Asp Pro
 370 375 380
 Phe Lys Ala Thr Gly Lys Pro His Thr Leu Trp Val Ala Phe Ala Lys
 385 390 395 400
 Phe Tyr Glu Asp Asn Gly Gln Leu Asp Asp Ala Arg Val Ile Leu Glu
 405 410 415
 Lys Ala Thr Lys Val Asn Phe Lys Gln Val Asp Asp Leu Ala Ser Val
 420 425 430
 Trp Cys Gln Cys Gly Glu Leu Glu Leu Arg His Glu Asn Tyr Asp Glu
 435 440 445
 Ala Leu Arg Leu Leu Arg Lys Ala Thr Ala Leu Pro Ala Arg Arg Ala
 450 455 460
 Glu Tyr Phe Asp Gly Ser Glu Pro Val Gln Asn Arg Val Tyr Lys Ser
 465 470 475 480
 Leu Lys Val Trp Ser Met Leu Ala Asp Leu Glu Glu Ser Leu Gly Thr
 485 490 495
 Phe Gln Ser Thr Lys Ala Val Tyr Asp Arg Ile Leu Asp Leu Arg Ile
 500 505 510
 Ala Thr Pro Gln Ile Val Ile Asn Tyr Ala Met Phe Leu Glu Glu His
 515 520 525
 Lys Tyr Phe Glu Glu Ser Phe Lys Ala Tyr Glu Arg Gly Ile Ser Leu
 530 535 540
 Phe Lys Trp Pro Asn Val Ser Asp Ile Trp Ser Thr Tyr Leu Thr Lys
 545 550 555 560
 Phe Ile Ala Arg Tyr Gly Gly Arg Lys Leu Glu Arg Ala Arg Asp Leu
 565 570 575
 Phe Glu Gln Ala Leu Asp Gly Cys Pro Lys Tyr Ala Lys Thr Leu
 580 585 590
 Tyr Leu Leu Tyr Ala Gln Leu Glu Glu Glu Trp Gly Leu Ala Arg His
 595 600 605
 Ala Met Ala Val Tyr Glu Arg Ala Thr Arg Ala Val Glu Pro Ala Gln
 610 615 620
 Gln Tyr Asp Met Phe Asn Ile Tyr Ile Lys Arg Ala Ala Glu Ile Tyr
 625 630 635 640
 Gly Val Thr His Thr Arg Gly Ile Tyr Gln Lys Ala Ile Glu Val Leu
 645 650 655
 Ser Asp Glu His Ala Arg Glu Met Cys Leu Arg Phe Ala Asp Met Glu
 660 665 670
 Cys Lys Leu Gly Glu Ile Asp Arg Ala Arg Ala Ile Tyr Ser Phe Cys
 675 680 685
 Ser Gln Ile Cys Asp Pro Arg Thr Thr Gly Ala Phe Trp Gln Thr Trp
 690 695 700
 Lys Asp Phe Glu Val Arg His Gly Asn Glu Asp Thr Ile Lys Glu Met
 705 710 715 720
 Leu Arg Ile Arg Arg Ser Val Gln Ala Thr Tyr Asn Thr Gln Val Asn
 725 730 735
 Phe Met Ala Ser Gln Met Leu Lys Val Ser Gly Ser Ala Thr Gly Thr
 740 745 750
 Val Ser Asp Leu Ala Pro Gly Gln Ser Gly Met Asp Asp Met Lys Leu
 755 760 765
 Leu Glu Gln Arg Ala Glu Gln Leu Ala Ala Glu Ala Glu Arg Asp Gln
 770 775 780
 Pro Leu Arg Ala Gln Ser Lys Ile Leu Phe Val Arg Ser Asp Ala Ser
 785 790 795 800
 Arg Glu Glu Leu Ala Glu Leu Ala Gln Gln Val Asn Pro Glu Glu Ile
 805 810 815
 Gln Leu Gly Glu Asp Glu Asp Glu Asp Glu Met Asp Leu Glu Pro Asn
 820 825 830
 Glu Val Arg Leu Glu Gln Gln Ser Val Pro Ala Ala Val Phe Gly Ser

835
Leu Lys Glu Asp
850

840

845

(2) INFORMATION FOR SEQ ID NO:154:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 693 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

```

Met Phe Ser Ala Leu Lys Lys Leu Val Gly Ser Asp Gln Ala Pro Gly
 1           5           10           15
Arg Asp Lys Asn Ile Pro Ala Gly Leu Gln Ser Met Asn Gln Ala Leu
 20           25           30
Gln Arg Arg Phe Ala Lys Gly Val Gln Tyr Asn Met Lys Ile Val Ile
 35           40           45
Arg Gly Asp Arg Asn Thr Gly Lys Thr Ala Leu Trp His Arg Leu Gln
 50           55           60
Gly Arg Pro Phe Val Glu Tyr Ile Pro Thr Gln Glu Ile Gln Val
 65           70           75           80
Thr Ser Ile His Trp Ser Tyr Lys Thr Thr Asp Asp Ile Val Lys Val
 85           90           95
Glu Val Trp Asp Val Val Asp Lys Gly Lys Cys Lys Lys Arg Gly Asp
100           105           110
Gly Leu Lys Met Glu Asn Asp Pro Gln Glu Xaa Glu Ser Glu Met Ala
115           120           125
Leu Asp Ala Glu Phe Leu Asp Val Tyr Lys Asn Cys Asn Gly Val Val
130           135           140
Met Met Phe Asp Ile Thr Lys Gln Trp Thr Phe Asn Tyr Ile Leu Arg
145           150           155           160
Glu Leu Pro Lys Val Pro Thr His Val Pro Val Cys Val Leu Gly Asn
165           170           175
Tyr Arg Asp Met Gly Glu His Arg Val Ile Leu Pro Asp Asp Val Arg
180           185           190
Asp Phe Ile Asp Asn Leu Asp Arg Pro Pro Gly Ser Ser Tyr Phe Arg
195           200           205
Tyr Ala Glu Ser Ser Met Lys Asn Ser Phe Gly Leu Lys Tyr Leu His
210           215           220
Lys Phe Phe Asn Ile Pro Phe Leu Gln Leu Gln Arg Glu Thr Leu Leu
225           230           235           240
Arg Gln Leu Glu Thr Asn Gln Leu Asp Met Asp Ala Thr Leu Glu Glu
245           250           255
Leu Ser Val Gln Gln Glu Thr Glu Asp Gln Asn Tyr Gly Ile Phe Leu
260           265           270
Glu Met Met Glu Ala Arg Ser Arg Gly His Ala Ser Pro Leu Ala Ala
275           280           285
Asn Gly Gln Ser Pro Ser Pro Gly Ser Gln Ser Pro Val Leu Pro Ala
290           295           300
Pro Ala Val Ser Thr Gly Ser Ser Ser Pro Gly Thr Pro Gln Pro Ala
305           310           315           320
Pro Gln Leu Pro Leu Asn Ala Ala Pro Pro Ser Ser Val Pro Pro Val
325           330           335
Pro Pro Ser Glu Ala Leu Pro Pro Pro Ala Cys Pro Ser Ala Pro Ala
340           345           350
Pro Arg Arg Ser Ile Ile Ser Arg Leu Phe Gly Thr Ser Pro Ala Thr
355           360           365
Glu Ala Ala Pro Pro Pro Pro Glu Pro Val Pro Ala Ala Gln Gly Pro
370           375           380
Ala Thr Val Gln Ser Val Glu Asp Phe Val Pro Asp Asp Arg Leu Asp
385           390           395           400
Arg Ser Phe Leu Glu Asp Thr Thr Pro Ala Arg Asp Glu Lys Lys Val
405           410           415
Gly Ala Lys Ala Ala Gln Gln Asp Ser Asp Ser Asp Gly Glu Ala Leu
420           425           430
Gly Gly Asn Pro Met Val Ala Gly Phe Gln Asp Asp Val Asp Leu Glu
435           440           445
Asp Gln Pro Arg Gly Ser Pro Pro Leu Pro Ala Gly Pro Val Pro Ser
450           455           460

```

Gln Asp Ile Thr Leu Ser Ser Glu Glu Glu Ala Glu Val Ala Ala Pro
 465 470 475 480
 Thr Lys Gly Pro Ala Pro Ala Pro Gln Gln Cys Ser Glu Pro Glu Thr
 485 490 495
 Lys Trp Ser Ser Ile Pro Ala Ser Lys Pro Arg Arg Gly Thr Ala Pro
 500 505 510
 Thr Arg Thr Ala Ala Pro Pro Trp Pro Gly Gly Val Ser Val Arg Thr
 515 520 525
 Gly Pro Glu Lys Arg Ser Ser Thr Arg Pro Pro Ala Glu Met Glu Pro
 530 535 540
 Gly Lys Gly Glu Gln Ala Ser Ser Ser Glu Ser Asp Pro Glu Gly Pro
 545 550 555 560
 Ile Ala Ala Gln Met Leu Ser Phe Val Met Asp Asp Pro Asp Phe Glu
 565 570 575
 Ser Glu Gly Ser Asp Thr Gln Arg Arg Ala Asp Asp Phe Pro Val Arg
 580 585 590
 Asp Asp Pro Ser Asp Val Thr Asp Glu Asp Glu Gly Pro Ala Glu Pro
 595 600 605
 Pro Pro Pro Pro Lys Leu Pro Leu Pro Ala Phe Arg Leu Lys Asn Asp
 610 615 620
 Ser Asp Leu Phe Gly Leu Gly Leu Glu Glu Ala Gly Pro Lys Glu Ser
 625 630 635 640
 Ser Glu Glu Gly Lys Glu Gly Lys Thr Pro Ser Lys Glu Lys Lys Lys
 645 650 655
 Lys Thr Lys Ser Phe Ser Arg Val Leu Leu Glu Arg Pro Arg Ala His
 660 665 670
 Arg Phe Ser Thr Arg Val Gly Tyr Gln Val Ser Val Pro Asn Ser Pro
 675 680 685
 Tyr Ser Glu Ser Tyr
 690



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/57, 15/12, C07K 14/47, (Continued on the following page)	A3	(11) International Publication Number: WO 99/58559 (43) International Publication Date: 18 November 1999 (18.11.99)
(21) International Application Number: PCT/US99/10793 (22) International Filing Date: 14 May 1999 (14.05.99) (30) Priority Data: 09/081,385 14 May 1998 (14.05.98) US (71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GATANAGA, Tetsuya [JP/US]; 77 Wellesley, Irvine, CA 92612 (US). GRANGER, Gale, A. [US/US]; 31562 Santa Rosa, Laguna Beach, CA 92651 (US). (74) Agents: CAMPBELL, Cathryn et al.; Campbell and Flores, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 20 January 2000 (20.01.00)
(54) Title: FACTORS AFFECTING TUMOR NECROSIS FACTOR RECEPTOR RELEASING ENZYME ACTIVITY (57) Abstract The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are method for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.		

C12N 9/64, 15/11, C07K 16/18, 16/40, C12Q 1/68, G01N 33/68, 33/573, C12Q 1/37, A61K 38/17, 38/48, 48/00, 39/395.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 99/10793

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/57 C12N15/12 C07K14/47 C12N9/64 C12N15/11
 C07K16/18 C07K16/40 C12Q1/68 G01N33/68 G01N33/573
 C12Q1/37 A61K38/17 A61K38/48 A61K48/00 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL/GENBANK DATABASES Accession no AJ003355 Sequence reference HSJ003355 13 October 1997 SZULZEWSKY I ET AL: "An integrated transcript map for the whole human chromosome 21" XP002121991 the whole document	3-5
X	EMBL/GENBANK DATABASES Accession no AA779203 Sequence reference AA779203 6 February 1998 HILLIER L ETAL: "WashU-NCI human EST project" XP002122454 the whole document	3-5

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date, or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

18 November 1999

Date of mailing of the international search report

03/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Van der Schaal, C

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EMBL/GENBANK DATABASES Accession no U52222 Sequence reference HS5252210 26 April 1996 KANOH H AND EXTON J: "Human afarpatin 2, a putative target protein of ADP-ribosilation" XP002122455 the whole document</p>	1,7,9-17
X	<p>MINET M AND LACROUTE F: "Cloning and sequencing of a human cDNA coding for a multifunctional polypeptide of the purine pathway by complememntation of the ade2-101 mutant in Saccharomyces cerevisiae" CURRENT GENETICS, vol. 18, 1990, pages 287-291, XP002122452 figure 3</p>	1,7,9-17
X	<p>GONZALEZ I ET AL: "Variation among human 28S ribosomal genes" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 82, November 1985 (1985-11), pages 7666-7670, XP002122453 WASHINGTON US figure 3</p>	1
X	<p>EMBL/GENBANK DATABASES Accession no T33896 Sequence reference HS89620 14 January 1995 ADAMS M ET AL: "Initial assessment of human gene diversity and expression patters based upon 52" XP002122456 the whole document</p>	3-5
P,X	<p>EMBL/GENBANK DATABASES Accession no AI002979 Sequence reference AI002979 11 June 1998 HILLIER L ET AL: "WashU-NCI human EST project" XP002122457 figure W</p>	3-5
X	<p>EMBL/GENBANK DATABASES Accession no AA806165 Sequence reference AA806165 16 February 1998 "National Cancer Insitiute, Cancer Genome Anatomy Project" XP002122458 the whole document</p>	3-5
	-/-	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>OSHIMA A ET AL: "The human cation-independent mannose 6-phosphate receptor" JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 263, no. 5, 15 February 1988 (1988-02-15), pages 2553-2562, XP002121990 MD US see figure 2 amino acids 912-1750</p>	1,7,9-17
X	<p>EMBL/GENBANK DATABASES Accession no C06247 Sequence reference HSC2476 25 August 1996 TAKEDA J: "EST" XP002122459 the whole document</p>	3-5
X	<p>EMBL/GENBANK DATABASES Accession no AA707194 Sequence reference AA707194 5 January 1998 HILLIER L ET AL: "WashU-NCI human EST Project" XP002122460 the whole document</p>	3-5
X	<p>EMBL/GENBANK DATABASES Accession no AA599596 Sequence reference AA599596 29 September 1997 HILLIER L ET AL: "WashU-NCI human ESR project" XP002122461 the whole document</p>	3-5
X	<p>KATSURA K ET AL: "IDENTIFICATION OF THE PROTEOLYTIC ENZYME WHICH CLEAVES HUMAN P75 TNF RECEPTOR IN VITRO" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 222, no. 738, 15 May 1996 (1996-05-15), pages 298-302, XP002058218 ISSN: 0006-291X page 299, paragraphs 2,3</p>	25
A	<p>EP 0 657 536 A (YEDA RES & DEV) 14 June 1995 (1995-06-14) cited in the application</p>	

-/-

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 99/10793

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PORTEU F ET AL: "HUMAN NEUTROPHIL ELASTASE RELEASES A LIGAND-BINDING FRAGMENT FROM THE 75-KDA TUMOR NECROSIS FACTOR (TNF) RECEPTOR" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 28, 5 October 1991 (1991-10-05), pages 18846-18853, XP000229747 ISSN: 0021-9258	
P,X	WO 98 20140 A (GRANGER GALE A ;UNIV CALIFORNIA (US); GATANAGA TETSUYA (US)) 14 May 1998 (1998-05-14) cited in the application the whole document	1,7, 9-17, 19-23, 25-32

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 10793

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 21-23 and 30-32 are (partially)
directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/10793

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0657536	A	14-06-1995	AU 679559 B	03-07-1997
			AU 7574294 A	04-05-1995
			CA 2133872 A	13-04-1995
			JP 7194376 A	01-08-1995
			US 5665859 A	09-09-1997
			US 5766917 A	16-06-1998
			ZA 9407962 A	21-11-1995
WO 9820140	A	14-05-1998	AU 5162198 A	29-05-1998
			EP 0938548 A	01-09-1999
			NO 992187 A	01-07-1999



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/57, 15/12, C07K 14/47, (Continued on the following page)	A3	(11) International Publication Number: WO 99/58559 (43) International Publication Date: 18 November 1999 (18.11.99)
(21) International Application Number: PCT/US99/10793 (22) International Filing Date: 14 May 1999 (14.05.99) (30) Priority Data: 09/081,385 14 May 1998 (14.05.98) US (71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GATANAGA, Tetsuya [JP/US]; 77 Wellesley, Irvine, CA 92612 (US). GRANGER, Gale, A. [US/US]; 31562 Santa Rosa, Laguna Beach, CA 92651 (US). (74) Agents: CAMPBELL, Cathryn et al.; Campbell and Flores, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i> (88) Date of publication of the international search report: 20 January 2000 (20.01.00) Date of publication of the amended claims: 16 March 2000 (16.03.00)
(54) Title: FACTORS AFFECTING TUMOR NECROSIS FACTOR RECEPTOR RELEASING ENZYME ACTIVITY (57) Abstract <p>The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are method for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.</p>		

C12N 9/64, 15/11, C07K 16/18, 16/40, C12Q 1/68, G01N 33/68, 33/573, C12Q 1/37, A61K 38/17, 38/48, 48/00, 39/395

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

AMENDED CLAIMS

[received by the International Bureau on 2 February 2000 (02.02.00);
original claims 33-35 added; remaining claims unchanged (1 page)]

disease selected from the group consisting of heart failure, cachexia, inflammation, endotoxic shock, arthritis, multiple sclerosis, and sepsis.

30. A method of treating cancer in a subject, comprising increasing signal transduction from TNF into cells at the site of the cancer in the subject according to claim 22 or 23.
31. A method of treating a disease selected from the group consisting of heart failure, cachexia, inflammation, endotoxic shock, arthritis, multiple sclerosis, and sepsis, comprising decreasing signal transduction from TNF into cells at the site of the disease in the subject according to claim 21 or 23.
32. The method of claim 31, comprising administering to the subject an effective amount of the polypeptide of any of claims 7-8 or 11-12.
33. The polynucleotide according to any of claims 1-5, wherein said nucleotide sequence is not contained in any of the sequences of the following GenBank Accession Nos: AJ003355, AA806165; AI002979; T33896; U52522; AA779203; C06247; AA707194; AA599596; 5453538; U13369; and J03528.
34. The polypeptide according to any of claims 7-10, the sequence of which is not completely encoded by a polynucleotide sequence contained in any of the sequences of the following GenBank Accession Nos: AJ003355, AA806165; AI002979; T33896; U52522; AA779203; C06247; AA707194; AA599596; 5453538; U13369; and J03528.
35. The polynucleotide according to claim 15, the sequence of which is not contained in any of the sequences of the following GenBank Accession Nos: AJ003355, AA806165; AI002979; T33896; U52522; AA779203; C06247; AA707194; AA599596; 5453538; U13369; and J03528.